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Abstract
Diseases which affect the central nervous system present a huge burden to sufferers
and caregivers. In tandem with longevity, prevalences of age-related
neurodegenerative diseases are increasing. However, despite the evident necessity
for pharmaceutical interventions, there has been a distinct lack of drug
development to combat these disorders. This is largely attributed to high financial
costs of using rodent models. Thus the validation of a more cost-effective in vivo
system would facilitate pharmaceutical screening. The work presented in this
thesis addresses this issue by assessing the utility of zebrafish in two costly areas of
translational neurobiology – lead identification and safety pharmacology.
An aversive classical conditioning assay was developed and automated as a
behavioural screening method. This robust assay allows fast assessment of
cognition and cognitive decline. The effect of neurotoxin treatment on aversive
learning was then assessed using this assay, demonstrating its efficacy as a
screening tool for neurodegeneration research.
Subsequently, a transgenic zebrafish line - expressing a mutated form of the
Alzheimer’s-associated human amyloid precursor protein - was assessed,
demonstrating an age-related cognitive impairment. Additionally new genetic
zebrafish lines were generated, which over-express genes (both endogenous and
transgenic) related to Alzheimer’s-like pathologies. Whilst these were not assessed
within this thesis, they present promising tools for possible future investigations.
Regarding safety pharmacology, regulatory bodies require all CNS-penetrant
drugs be assessed for abuse potential. Zebrafish display reward responses to several
common drugs of abuse (e.g. amphetamine, cocaine, morphine). Thus, the latter
sections of this thesis evaluated the utility of zebrafish for assessing human abuse
potential. A CPP paradigm was utilised to test a range of drugs, with the
sensitivity and specificity of zebrafish compared to previous reports using rodent.
Additionally, the development of a zebrafish drug discrimination assay was
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consequences of PIN1 signalling (i.e. inhibition of Aβ aggregation
and dephosphorylation of tau). (Yellow text on red background,
neurodegenerative effect; white text on blue background,
neuroprotective effect; ˆrg, up-regulation; 2o α > β, protein
secondary structure change from α helix to β sheet) . . . . . . . . . . 109
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4.5 Stability of housekeeping genes. qPCR data were entered into
the online RefFinder tool. The results demonstrate that rpl13α was
the most stably expressed gene. . . . . . . . . . . . . . . . . . . . . . 113
4.6 Effects of AlCl3 treatment on gene expression. qPCR
expression analyses (‘fragment number ’) were calculated and
normalised to rpl13α expression. No significant effect was found for
appb (p=0.33) or bace1 (p=0.098) expression (by one-tailed t-test).
The increase in pin1 expression failed to reach significance (p=0.06;
by two-tailed t-test) (n=12). Data plotted as mean ± SEM. . . . . . 115
4.7 Prolonged effects of aluminium exposure on gene
regulation. Animals were exposed to AlCl3 (100µM) or saline for
three hours, then placed in a ‘recovery tank’ and sacrificed at the
times specified. No effect was found for appb expression
(F3,20=0.266, p=0.849). A significant effect was found for bace1
expression (F3,19=5.595, p=0.006). The pin1 up-regulation failed to
reach significance (F3,19=2.925, p=0.06), although a significant
up-regulation was found post-hoc at 30-minutes following exposure
(n=24). ***, p<0.001; by one-way ANOVA, then one-sided (appb
and bace1 ) or two-sided (pin1 ) Dunnett’s test. Data plotted as
mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
4.8 Dose-dependent effects of AlCl3 on gene expression at one-
hour following exposure. (A & D) The up-regulation of appb failed
to reach significance (F1,22=4.237, p=0.052). (B & E) A significant
up-regulation of bace1 was found (F1,22=4.745, p=0.041). (C & F) No
effect was found for pin1 expression (F1,19=1.114, p=0.305) (n=23).
By simple linear regression. Data plotted as raw values (A-C) and
mean ± SEM (D-F). . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.9 Dose-dependent effect of AlCl3 on dapk1 expression at one
hour post exposure. A significant up-regulation was found
(F1,20=5.162, p=0.035). By simple linear regression. Data plotted as
raw values (A) and mean ± SEM (B). . . . . . . . . . . . . . . . . . 118
4.10 Neurodegeneration following AlCl3 treatment. FluoroJade
®
B staining was conducted on 10µm sections of zebrafish
telencephalon. Increased staining is apparent in the AlCl3-treated
brains (B) compared to saline-treated brains (A). (Larger images
are included in Appendices; Section 9.1.) Approximate positions of
brain sections are indicated on the right-hand side (both A & B),
with focal region indicated in the coronal (top) graphics (images
from Wulliman et al. 2012). . . . . . . . . . . . . . . . . . . . . . . . 119
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4.11 AlCl3 dose-response curve. Analysis by linear mixed effects
model found significant effects for ‘AlCl3 concentration’
(F3,23.379=6.673, p=0.002) and ‘trial ’ (baseline vs. probe)
(F1,28.622=24.329, p<0.0005). A significant interaction (AlCl3
concentration * trial) was also found (F3,23.623=5.3, p=0.006).
Post-hoc analyses found that, at low concentrations of AlCl3
(≤50µM), significant aversion of the CS was observed in the probe
trial. However this effect was not seen at the highest dose (100µM)
(n=29). **, p<0.01; ***, p<0.001; by two-tailed t-test with
Bonferroni correction applied. Data plotted as mean ± SEM. . . . . . 120
4.12 Effects of dapk1 signalling on pin1 neuroprotective
signalling. dapk1 phosphorylates pin1 to inactivate it. This would
inhibit the neuroprotective signalling of pin1 (inhibition of Aβ
aggregation and dephosphorylation of tau). dapk1 is activated by
CaN (via dephosphorylation), which itself is activated by Ca2+,
found to accumulate in cells following Al treatment. . . . . . . . . . . 123
5.1 Classification of APP mutations. Mutations located around the
β- and α-cleavage sites are regarded as Class I mutations. The are
the Swedish (double), Flemish, Arctic, and Iowa mutations.
Mutations located around the γ-cleavage site are regarded as Class
II mutations. These are the Austrian, French, Florida, London, and
Australian mutations. (Image from Wiley et al. 2005). . . . . . . . . 127
5.2 Detection of hAPP expression in transgenic fish. cDNA from
Tg(HuC:hAPP;ins:eGFP) (homozygous vs wild-type) fish was
amplified by PCR, using primers specific for hAPP and HuC. The
hAPP gene fragment was only detected in the homozygous fish,
demonstrating it’s transgenic expression. The relatively similar
expression of HuC (semi-quantitative) serves as a control. . . . . . . . 142
5.3 Performance of 6.5-MPF transgenic hAPP zebrafish in
classical aversion learning. Transgenic hAPP-expressing fish
were assayed using a classical aversion paradigm. Both wild-type
lines, but not the hAPP-expressing line, significantly avoided the CS
in the probe trials. Significant effects were found for genotype
(F(2,78.271)=5.278, p=0.007) and trial (‘baseline’ vs ‘probe’)
(F(1,78.353)=58.114, p<0.0005). A significant genotype*trial
interaction was detected (F(2,78.009)=4.661, p=0.012; (n=81).
Linear mixed effects model; ***, p<0.001; by two-tailed t-test with
Bonferroni correction applied. Data plotted as mean ± SEM. . . . . . 143
5.4 Pilot - performance of 3.5-MPF transgenic hAPP zebrafish
in classical aversion learning. Transgenic hAPP-expressing fish
were assayed using a classical aversion paradigm. All three genotypes
significantly avoided the CS in the probe trials (n=11). *, p<0.05;
**, p<0.01; by two-tailed t-test with Bonferroni correction applied.
Data plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . 144
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5.5 Transgenic hAPP expression induces an age-related effect
on cognition. Zebrafish - both wild-type and transgenically
expressing hAPP - were assessed for their performance in the
classical aversion assay at three ages. At 3-MPF, all three
genotypes significantly avoided the CS in the probe trials. However
in older fish (6.5-MPF and 14.5-MPF) hAPP expression inhibited
learning. Significant effects were found for genotype
(F(2,150.368)=8.113, p<0.0005) and trial (F(1,148.041)=159.398,
p<0.0005). No significant effect was found for age
(F(2,149.576)=2.375, p=0.096). However significant interactions
were found for genotype*age (F(4,149.525)=4.675, p=0.001) and
genotype*trial*age (F(4,147.190)=2.503), p=0.045. Pairwise
comparison of the genotypes found that hAPP was significantly
different from TU (p=0.002) and hAPP-WT (p<0.0005). No
significant difference was found between TU and hAPP-WT
(p=0.824) (n=155). Linear mixed effects model; *, p<0.05; **,
p<0.01; ***, p<0.001; by two-tailed t-test with Bonferroni
correction applied. Data plotted as mean ± SEM. . . . . . . . . . . . 145
5.6 Effect of transgenic hAPP expression on pin1 expression.
The expression of pin1 was assessed by qPCR in two wild-type lines
(TU and hAPP-WT) against transgenic hAPP fish, at 3.5-MPF (A)
and 14.5-MPF (B). No significant difference was detected at either age
- 3.5-MPF (F(2,10)=1.618, p=0.246); and 14.5-MPF (F(2,10)=0.993,
p=0.404) (n=15). By one-way ANOVA. Data plotted as mean ± SEM.146
5.7 Neurodegeneration in transgenic hAPPLON/SWE line.
FluoroJade® B staining was conducted on 10µm sections of
zebrafish telencephalon. Increased staining is apparent in brains in
transgenic hAPPLON/SWE-expressing brain (B) compared to
wild-type brains (A). (Larger images are included in Appendices;
Section 9.3). Approximate positions of brain sections are indicated
on the right-hand side (both A & B) (images from Wulliman et al.
2012). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
5.8 Expression of transgenes in embryos following injection.
Zebrafish embryos were injected with expression plasmid and
transposase mRNA (0.02ng of each in Danieau Buffer) at the
one-cell stage. Un-injected controls show kaede expression, but no
mCherry-FP (A & B). Injected embryos show expression of both
kaede and mCherry-FP (as a marker of transgene expression) (C & D).149
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6.1 Pathways involved in reward signalling. (A) The
mesocorticolimbic system is made up of two sets of DAergic
projections, originating in the VTA; the mesolimbic system (green)
projects to the NAcc, whilst the mesocortical pathway (purple)
projects to the PFC. DAergic projections from the VTA have also
been found to extend to the DRN (yellow). Additionally, the
nigrostriatal pathway (red) extends from the substantia nigra (SNc)
to the striatum. (B) Serotonergic pathways project from the DRN
to the VTA (purple), NAcc (yellow) and PFC (green); and from the
MRN to the PFC (blue). (Images adapted from Arias-Carrión et al.
2010) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
6.2 Neuroanatomical structures hypothesised to be orthologous
with mammalian reward signalling structures. The PTN (A,
in yellow), Vd (B, in red) and Dc (B, in green) have been paralleled
(to some extent) with the mammalian VTA, NAcc and PFC
(respectively). Locations of coronal sections are shown saggitally in
(C-D). (Image adapted from Wulliman et al. 2012.) . . . . . . . . . . 165
6.3 CPP assay tank. All stages of CPP experimentation were
conducted in opaque rectangular tanks (20cm x 15cm x 30cm;
WxHxL) containing 2.5L aquarium water. Basal and
post-conditioning (probe) preferences for each stimulus was assessed
by giving free access to the entire tank. During conditioning
sessions, a divider was inserted in the centre of the tank (indicated
here by a vertical line through centre of tank), restricting access to
one of the two stimulus-presenting arenas. . . . . . . . . . . . . . . . 169
6.4 CPP assay validation. The conditioning of zebrafish with
fentanyl (as an US) resulted in a quadratic regression. No effect was
found in the linear term (F1,129=1.698, p=0.195); however a
significant preference change for the CS-presenting arena was found
in the quadratic term (F1,129=5.233, p=0.024) (n=130). By one-way
ANOVA, then one-sided Dunnett’s test; *, p<0.05. Data plotted as
mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
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6.5 Neuroprotective drugs with conserved reinforcing
properties in zebrafish. Six neuroprotective drugs - reported to exert
reinforcing effects in humans - were found to induce significant CPP in
zebrafish. Caffeine produced a quadratic dose-response curve, with no effect in
the linear term (F1,86=0.153, p=0.696); however a significant effect was found in
the quadratic term (F1,86=5.497, p=0.002) (n=89). Ethanol produced a
quadratic dose-response curve, with effects for both the linear term
(F1,42=8.006, p=0.007) and the quadratic term (F1,42=8.007, p0.007) (n=45).
Fentanyl treatment produced a quadratic dose-response curve, with no effect
found for the linear term (F1,129=1.698, p=0.195); however a significant effect
was found for the quadratic term (F1,129=5.233, p=0.024) (n=130). Morphine
produced a linear dose-response curve (F1,37=8.704, p=0.006) (n=39). The
quadratic dose-response curve for nicotine failed to reach significance in the
linear term (F1,47=1.279, p=0.264); however there was a significant effect in the
quadratic term (F1,47=11,516, p=0.001) (n=50). PCP treatment produced a
significant linear dose-reponse curve (F1,77=5.01, p=0.028) (n=78). By
polynomial one-way ANOVA, then one-sided Dunnett’s test; *, p<0.05; **,
p<0.01. Data plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . 173
6.6 Neuroprotective drugs without reinforcing properties in
zebrafish. Four neuroprotective drugs - reported to exert
reinforcing effects in humans - failed to induce significant CPP in
zebrafish. All of these drugs produced linear dose-response curves
which failed to reach significance. Bupropion (F1,81=0.587, p=0.446)
(n=83). Ketamine (F1,75=2.272, p=0.136) (n=76). Procaine
(F1,79=0.017, p=0.896) (n=137). THC (F1,82=1.115, p=0.294)
(n=83). By one-way ANOVA. Data plotted as mean ± SEM. . . . . . 174
6.7 Neuroprotective drugs with no reinforcing properties. Two
drugs which are not reinforcing in humans were included in the
study as negative controls. Neither of these induced significant CPP
in zebrafish. Atomoxetine produce a quadratic dose-response curve
which failed to reach significance in both the linear (F1,84=0.746,
p=0.39) and quadratic terms (F1,84=2.566, p=0.113) (n=88).
Similarly, the quadratic dose-response curve for naloxone failed to
reach significance in both term - linear (F1,55=0.037, p=0.848);
quadratic (F1,55=0.202, p=0.655) (n=56). By linear regression.
Data plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . 175
6.8 Locomotion assessment of drugs which failed to induce CPP
in zebrafish. Neuroprotective drugs which exert reinforcing effects
on humans, but failed to induce zebrafish CPP, were assessed for their
affects on locomotion. Bupropion (F4,279=9.904, p<0.0005), ketamine
(F4,305=3.74, p<0.0005), procaine (F4,297=2.517, p=0.042) and THC
(F4,240=11.588, p<0.0005) all induced significant effects on distance
travelled (n=50 per drug). By linear mixed effects model; *, p<0.05;
**, p<0.01; ***, p<0.001. Data plotted as mean ± SEM. . . . . . . 176
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6.9 Locomotion assessment of CPP ‘negative controls’.
Neuroprotective drugs which have no reported reinforcing affects on
humans (and were found to have no affect on zebrafish CPP, above)
were assessed for their affects on locomotor activity. Both of these
drugs caused significant changes in distance travelled. Atomoxetine
(F4,231=10.642, p<0.0005). Naloxone (F4,253=9.758, p<0.0005)
(n=50 per drug). By linear mixed effects model; *, p<0.05; **,
p<0.01; ***, p<0.001. Data plotted as mean ± SEM. . . . . . . . . . 177
7.1 Shock titration. The number of electric shocks delivered (paired
with CS exposure) was titrated to establish the most effective
conditioning parameters, when probe trials were conducted at 24
hours. A main effect was found for the number of shocks delivered
(F2,21.670=16.535, p<0.0005). No main effect was found for trial
(F1,21.562=1.953, p=0.176); however there was a significant trial *
number of shocks interaction (F2,21.317=16.827, p<0.0005). Post-hoc
analyses of baselines vs probes for each condition failed to find
significant differences at any number of shocks (by paired one-tailed
t-test with Bonferroni correction applied). Data plotted as mean ±
SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
7.2 Increased habituation. Zebrafish were exposed to the stimlui (as
per baseline trials) on two separate days prior to conditioning. (A)
When probe trials were conducted immediately following
conditioning, a significant main effect was found for number of
shocks (F2,7.806=9.491, p=0.008). Pairwise comparisons found
9-shocks to be significantly different from 18-shocks (p=0.043). (B)
However, when probe trials were conducted 24 hours after
conditioning, no significant main effect was found for number of
shocks (F2,11=3.509, p=0.066) *, p<0.05; **, p<0.01; (by paired
one-tailed t-test with Bonferroni correction applied). Data plotted
as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
7.3 Length of recall. Zebrafish were assessed for their aversion of the
CS at set time following conditioning. A significant effect was found
for trial (F4,41=4.693, p=0.003). Pairwise comparisons found that
baseline was only significantly different from Probe 0-hours ; ***,
p<0.0005. Data plotted as mean ± SEM. . . . . . . . . . . . . . . . . 190
7.4 Assessment of pilot ‘escape’ fear conditioning assay. (A)
The mean CS preferences were not significantly different between
baselines and probes (F1,8=0.835, p=0.388). The preferences were
not significantly different on Day 1 from Day 2 (F1,8=0.094,
p=0.768). No trial * day interaction was found (F1,8=0.02,
p=0.890). (B) CS preferences were plotted against time, indicating
that aversive behaviour may extinguish in the first 1.5 minutes of
probe trial. Data plotted as mean ± SEM. . . . . . . . . . . . . . . . 192
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7.5 Analyses using 1.5-minute probes. (A) Comparison of the initial
1.5-minutes of probes (for each day) found a main effect was found
for day (F1,14.807=5.074, p=0.04). (B) Assessment of the full data set
found no main effects; neither for trial (F1,8.569=0.269, p=0.617) nor
day (F1,9.77=4.399, p=0.063). No trial * day interaction was found
(F1,8.769=1.91, p=0.201). Data plotted as mean ± SEM. . . . . . . . 193
7.6 Qualitative manipulation of baseline (habituation) and
‘dark-out ’ periods. Two fish (per group) were assessed for their
CS-aversion following different periods of habituation (‘baseline’)
and ‘dark-out ’ (between conditioning and probe). (A) Ten minutes
of habituation may have produced learning in one of the fish
(Subject #01), however this appears to extinguish rapidly over the
course of the probe trial. (B) By increasing the habituation time to
thirty minutes, the fish appear to avoid the CS for the entirety of
the probe trial. (C) Increasing the ‘dark’ period (between
conditioning and probe) from 1-minute to 30-minutes appears to
inhibit CS aversion. Data plotted as raw preference scores. . . . . . . 194
7.7 Quantitative manipulation of baseline (habituation) and
‘dark-out ’ periods. (A) Following ten minutes of baseline and one
minute ‘dark-out’, no main effect was found for trial
(F1,313.902=1.673, p0.197). (B) Following thirty minutes of baseline
and one minute of ‘dark-out’, a main effect was found for trial
(F1,433.116=32.095, p<0.0005). (C) Following thirty minutes baseline
and 30 minutes ‘dark-out’, a significant main effect was found for
trial (F1,450.873=21.478, p<). (D) Direct comparison of these
parameters found significant main effects for trial (F1,19=5.454,
p=0.031) and length of baseline (i.e. 10 vs 30 minutes) (F1,19=4.958,
p=0.038). No significant effect was found for length of ‘dark-out’
(F1,19=3.281, p=0.086). By linear mixed effects model ; *, p<0.0005.
Data plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . 195
7.8 Increased number of discrete trials. Fish were exposed to the
either 30 trials (30x 60seconds) or 90 trials (90x 20seconds). No
significant effect was found for number of discrete trials
(F1,9.322=0.338, p=0.575). No number of discrete trials * trial
interaction was found (F1,9.753=1.433, p=0.26). A significant main
effect was found for trial (F1,15.729=55.488, p<0.0005). By linear
mixed effects model, then one-tailed paired samples t-test with
Bonferonni correction applied; **, p<0.01; ***, p<0.001 Data
plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . 196
7.9 Titration of ‘dark-out period. The ‘dark-out ’ period between
conditioning and probe trial was titrated to investigate the length
of time for which aversion is observable. A main effect was found
for trial (F1,20.681=10.619, p=0.004). No main effect was found for
the ‘dark-out ’ period (F4,18.891=1.821, p=0.167); however a significant
trial * dark-out interaction was found (F4,18.834=6.234, p=0.002). By
linear mixed effects model, then one-tailed paired samples t-test with
Bonferroni correction applied; *, p<0.05. Data plotted as mean ± SEM196
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7.10 Manipulating the frequency of US delivery. During
conditioning, zebrafish were exposed to US (9V electric shock)
whilst swimming inside the ‘zone’ presenting the CS (following the
two seconds escape time at the start of each discrete trial). Shocks
were delivered at a frequency of 1-, 2- or 5-shocks per second (as
labelled). No main effect was found for shock frequency
(F2,47=0.219, p=0.804). A significant main effect was found for trial
(F1,47=45.255, p<0.0005). No shock frequency * trial interaction
was found (F2,47=1.389, p=0.259). By linear mixed effects model,
then one-tailed paired samples t-test with Bonferroni correction
applied; **, p<0.01; ***, p<0.001. Data plotted as mean ± SEM. . . 197
7.11 Repeated conditioning sessions pilot. Zebrafish were exposed
to four conditioning sessions (one per day, on four consecutive days),
then probed one day following the final conditioning session. No
significant effect was found for trial (F1,12=0.383, p=0.548). Data
plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . 198
7.12 Manipulation of habituation exposure. Subjects were exposed
to either a blank screen or the conditioning stimuli during the
habituation period. No significant effects were found for trial
(F1,13=0.588, p=0.457) or habituation exposure (F1,13=4.051,
p=0.065). No trial * habituation exposure interaction was found
(F1,13=0.005, p=0.946). By linear mixed effects model. Data plotted
as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
7.13 Voltage titration. Zebrafish were conditioned on four consecutive
days, using 2V, 5V, or 9V US. No main effects were found for trial
(F1,19.539=0.074, p=0.789) or voltage (F2,12.711=0.662, p=0.533). No
trial * voltage interaction was found (F2,12.352=1.023, p=0.388). Data
plotted as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . 199
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7.1 Neuroprotective drugs which are discriminated from saline.
Previous research has found that the following neuroprotective
drugs induce state-dependent learning in mammals. The
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ADAM, a disintegrin and metalloproteinase
ADD, attention deficit disorder
ADHD, attention deficit hyperactivity disorder
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Al, aluminium
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CHAPTER 1. GENERAL INTRODUCTION
1.1 The necessity for new therapeutics to treat
Alzheimer’s-like diseases
The failure of current Alzheimer’s-like diseases therapies to effectively treat these
diseases has become evident in recent years, particularly due to the increased
longevity seen in western societies. It is argued in this thesis that much of this
failure results from the variety of molecular dysregulations which result in similar
pathologies, commonly termed ‘Alzheimer’s disease’. However, treating these
distinct pathologies as a single disease results in a generic approach, unspecific to
the array of molecular dysregulations which may be aetiological in these
conditions. Thus, a review of the prevalences, various mechanisms of molecular
dysregulations and currently available treatments are presented and evaluated.
1.1.1 Prevalence of Alzheimer’s-like diseases
Diseases affecting the central nervous system (CNS) are a growing concern within
modern medicine. The World Health Organisation reported that neurological
conditions present the highest burden (‘disability-adjusted life years ’ - a measure of
the number of years lost due to illness) of all disorders, including various infectious
diseases (WHO 2006). Indeed, recent years have seen increases in the prevalence of
many chronic neurological conditions, including Alzheimer’s-like diseases (AD),
attention deficit disorder (ADD), cerebral palsy, Huntinton’s disease (HD),
multiple sclerosis (MS), schizophrenia, and unipolar depression (Andersen et al.
2011; Barnett et al. 2003; Bray et al. 2006; Brookmeyer et al. 2007; Evans et al.
2013; Ferri et al. 2006; Vincer et al. 2006; Visser et al. 2010). Further, with
increasing longevity, increases in the prevalences of age-related neurological
conditions are becoming particularly evident, with the impact of on society ever
more prominent (Joseph et al. 1998).
Many age-related CNS disorders include a neurodegenerative component, due
to the lower cellular regeneration in comparison with other organs of the body.
These complex diseases are characterised by aberrant apoptosis of CNS neurons.
Depending on the regions affected, this may result in lasting impairment to a range
of abilities, including cognitive, motor, sensory, olfactory and social functioning (e.g.
Draganski et al. 2013; Wickremaratchi et al. 2011; Nolano et al. 2008; Mesholam
et al. 1998; Zahn et al. 2009). These subsequently have devastating effects on quality
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of life for both sufferers and carers (Janardhan and Bakshi 2002; Schrag et al. 2000;
Aoun et al. 2010). The vast array of different molecular dysregulations that may
lead to these disorders present extremely complex challenges for medical researchers
to investigate. Indeed, even within the umbrella-term of ’Alzheimer’s-like diseases ’,
a range of potential molecular candidates have been proposed to be aetiological in
disease pathologies.
1.1.2 Complexity and diversity of the pathogenesis of
Alzheimer’s-like diseases
AD are the most prominent neurodegenerative disorders and the second most
common of all neurological disorders (following cerebrovascular disease) (WHO
2006). Research indicates that the global instances of AD in 2006 was between 24
and 27 million, with cases doubling every 20 years and expected to treble by 2050
(Brookmeyer et al. 2007; Ferri et al. 2006).
Commonly, AD are divided into two catagories - early-onset (EOAD) and
late-onset (LOAD); divisions characterised by the age at which symptoms begin to
present (commonly, before or after 60-65 years; e.g. Bertram and Tanzi 2008;
Filley et al. 1986). EOAD are estimated to account for less than 6% of total AD
(Zhu et al. 2015). Despite this, research has paid more attention to this
subdivision, with a greater understanding of the genetic components of EOAD
than that of LOAD.
Mechanisms of neurodegeneration and variety of possible aetiologies
Both divisions of AD are characterised by extracellular amyloid plaques (formed
by aggregates of Aβ peptides) and neurofibrillary tangles (NFT; resulting from
hyperphosphorylation of tau proteins, causing an instability of microtubules) (see
Figure 1.1; Krstic and Knuesel 2013; Schmechel et al. 1993; Schoonenboom et al.
2004; Small and Duff 2008).
‘Amyloid cascade’ hypotheses (see Figure 1.2) have been heavily implicated in
EOAD; whereby dysregulated amyloid peptide production is considered
aetiological and tau hyperphosphorylation a down-stream consequence (albeit with
its own destructive consequences) (e.g. Haass and Selkoe 2007; Hardy et al. 1998;
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Figure 1.1: Hallmarks of Alzheimer’s-like diseases. The two most prominent
pathologies of AD are the extracellular aggregation of Aβ peptides, resulting
in amyloid plaque deposition (yellow circles) and the hyperphosphorylation of
tau, resulting in neurofibrillarly tangles (white circles). (Image adapted from
Association® 2017.)
Jin et al. 2011; Small and Duff 2008). A range of mutations within the amyloid
precursor protein (APP) gene has been associated with dysregulated cleavage of
Aβ peptides, resulting in extracellular aggregation and subsequent plaque
formation (discussed in greater depth in Chapter 5, Section 5.1.1). However
amyloid cascade hypotheses are somewhat limited in their explanation of certain
findings.
For example, humans may develop both amyloid plaques and NFT in the absence
of dementia (e.g. Mann et al. 1987b; Perry 1980; Sparks et al. 1993; Sparks et
al. 1995; Tomlinson et al. 1968). The transgenic expression of mutated human
APP (hAPP) in rodents fails to produce NFT, requiring an additional transgenic
expression of mutant tau to achieve both of the characteristic hallmarks of AD (e.g.
Lewis et al. 2001; Schwab et al. 2004; see Armstrong 2006; Reitz 2012). Interestingly,
mutations to PS1 (part of the γ-secretase complex, which cleaves the Aβ peptides
from APP) have been shown to induce tau phosphorylation, possibly by increasing
its interaction with GSK3β (Pigino et al. 2001; Takashima et al. 1998). This suggests
that amyloid and tau pathologies may share a common mechanism, but that it is
up-stream of amyloid dysregulation.
Ari Sudwarts 28
CHAPTER 1. GENERAL INTRODUCTION
A
B
Figure 1.2: Amyloid cascade hypothesis. Amyloid cascade hypotheses regard
dysregulation of amyloid metabolism as aetiological in AD. (A) APP metabolism
by BACE1 and γ-secretase results in the cleavage of Aβ peptides, the length
of which is determined by the site of γ-secretase action. (B) These theories
suggest that increased Aβ peptides (particularly the Aβ42 species) result in amyloid
plaque formation, initiating a ‘cascade’ of neurodegenerative responses, resulting
in tau hyperphosphorylation, and ultimately the classic features of an Alzheimer’s
pathology (i.e. amyloid plaques and NFT). (Images adapted from Karran et al.
2011; Haass and Selkoe 2007; A & B, respectively.)
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Additionally, a direct link between amyloid and tau suggests plaques and NFT
would be distributed in the same brain regions; a supposition found not to occur in
AD patients’ brains (Armstrong et al. 1993; Armstrong 2006). Further, it has been
reported that NFT can actually precede amyloid plaque formation (e.g.
Duyckaerts 2004; Price et al. 1991b). Whilst this in itself does not disprove
amyloid cascade hypotheses - it is possible that low levels of amyloid aggregation
(undetectable as plaques in histological staining) trigger tau hyperphosphorylation
to a greater level - the combination of these issues suggest that amyloid cascade
hypotheses are insufficient to holistically explain the pathogenesis of AD (at least
not as a single disease).
In addition to APP, mutations in the presenilin genes have been strongly
associated with the pathogenesis of EOAD (e.g. Bertram and Tanzi 2008). These
genes (PS1 and PS2) code for the catalytic subunits of the γ-secretase complex,
facilitating its cleavage of APP (mechanism and mutations discussed in greater
depth in Chapter 5, Section 5.1.1). As indicated above, PS1 mutations have been
shown to increase tau phosphorylation (e.g. Takashima et al. 1998). A far greater
number of AD-related mutations have been associated with PS1 than APP,
demonstrating that function-altering mutations to APP-metabolising enzymes may
have a greater impact than mutations to APP itself (MDB 2017; Alzforum 2017;
Bertram and Tanzi 2008). In this regard, hypotheses which regard presenilin
mutations as aetiological to (many types of) AD may be a viable alternative to
amyloid cascaded hypotheses, suggesting that the dysregulation of up-stream
(APP-metabolising) proteins results in amyloid plaque formation and tau
hyperphosphorylation as down-stream consequences.
Whilst this perhaps provides a more inclusive aetiological understanding of AD,
it is still impossible to regard them as a single disease (i.e. with a single molecular
cause) as presenilin mutations do not explain the diseases of those patients without
these SNPs. Indeed, it is not even sufficient to explain the cause of AD which do not
result from amyloid mutations, as mutations to other up-stream genes have been
associated with the induction of both pathological hallmarks (i.e. amyloid and tau).
In this regard, the involvement of two proteins - a neuroprotective enzyme (PIN1)
and it’s inhibitor (DAPK1) - may provide an explanation for some of the diseases
grouped under AD.
PIN1 has been demonstrated to exert multiple neuroprotective functions in
relation to AD pathologies. It induces a conformational change in APP, resulting
in decreased Aβ cleavage (Pastorino et al. 2006). In the presence of Aβ42 peptides
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PIN1 is activated (dephosphorylated at Ser16), resulting in dephosphorylation of
tau, as well as APP (which may inhibit β-site APP cleaving enzyme 1, BACE1,
processing of APP and the subsequent Aβ secretion) (Bulbarelli et al. 2009; Lee
et al. 2003; Maudsley and Mattson 2006). PIN1 also catalyses the isomerisation
from cis to trans in both APP and tau, leading to dephosphorylation (Driver et al.
2014; Lu et al. 2003). Additionally, PIN1 has been demonstrated to inhibit
GSK3β, believed to mediate amyloid-driven phosphorylation of tau (Ma et al.
2012; see Hooper et al. 2008; Kremer et al. 2011; Salcedo-Tello et al. 2011).
These effects on the key proteins associated with AD pathologies suggests that
homeostatic dysregulation to PIN1 signalling may play a pivotal role in the
pathogenesis of some manifestations of AD. The evidence for PIN1 mutations in
AD patients is unclear, however sequence variants have been reported to be
associated with disease in some patients (Maruszak et al. 2009). Thus, in
combination with other known genetic factors (i.e. presenilin and APP mutations,
ApoE ε4) PIN1 signalling may contribute to providing a more holistic
understanding of the genetic basis for disease aetiologies (without regarding
environmental factors).
Additionally, PIN1 is inactivated (via phosphorylation) by DAPK1 (Bialik and
Kimchi 2011; Lee et al. 2011). A study by Kim and colleagues found that DAPK1
is up-regulated (at a protein level) in the hippocampi of LOAD patients, and that
its expression caused tau phosphorylation in vitro (Kim et al. 2014). However
another clinical study failed to find a significant up-regulation in the frontal
cortices (FC), reporting high expression in controls as well as AD patients
(Hainsworth et al. 2010). Again, these conflicting findings may be explained by the
presence of DAPK1 dysregulation (over-expression) in combination with other
AD-related genetic factors; however the evidence for these combinations of genetic
risk-factors hypothesis is lacking.
Other than its inactivation of PIN1, DAPK1 signalling includes other
mechanisms of neurodegeneration. DAPK1 interacts with NMDA-R’s in rodent
models of cerebral ischaemia, facilitating excitotoxicity; it’s inhibition in these
models is reported to facilitate regeneration and rescue (Tu et al. 2010; Won et al.
2014; Won and Hong 2016). Further, the excitotoxic interaction between DAPK1
and NMDA-R may somewhat explain the efficacy of memantine (a NMDA-R
antagonist) in treating AD. With regard to gene variants, intronic SNPs in DAPK1
have been reported in LOAD patients, suggesting that a regulatory (rather than
functional) dysregulation may be present (Li et al. 2006; Wu et al. 2011b).
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LOAD are far more common than EOAD, with the apolipoprotein E (ApoE) ε4
allele consistently associated with late-onset disease manifestations (Bertram and
Tanzi 2008). The involvement of this gene will be discussed in greater detail in
Chapter 5 (Section 5.1.1). However, of interest, ApoE ε4 has been reported to
modulate PIN1 and PS1, as well as SIRT1 (reported to be neuroprotective against
Aβ toxicity) (Lattanzio et al. 2014). Additionally, it has been reported that the
presence of ε4 allele alone is insufficient to describe the pathogenesis of LOAD, with
mutations in the ApoE regulatory region possibly offering a more holistic explanation
(Bullido et al. 1998; Morris et al. 2010a).
Neurotransmitter systems’ sensitivities
It must be noted that the neurotransmitter systems appear to have differential
sensitivities to AD pathologies. Cholinergic neurons are particularly vulnerable to
amyloid toxicity, with serotonergic and glutamatergic (GLUergic) cells also
showing high sensitivity; the dopaminergic (DAergic) and γ-Amynobutyric acid
(GABA)ergic systems appear better preserved (Bowen et al. 1983; Martorana and
Koch 2014; Nitsch 1996; Procter et al. 1988). Providing an in-depth description of
the mechanisms of these degenerations would be somewhat of a digression from the
theme of this thesis. However, in order to further emphasise the molecular
variabilities of AD, a general description follows:
Cholinergic signalling is involved in a range of cognitive abilities; amongst
these, attentional and memory functions are a prominent dysfunction in
age-related dementias (Blokland 1995; Furey et al. 2000; Hasselmo 1999; Hasselmo
2006; Himmelheber et al. 2000; Klinkenberg et al. 2011; Perry 1980). Decreased
acetylcholine (ACh) synthesis has been reported in various cortical regions of
post-mortem AD brains, including the temporal lobes (Richter et al. 1980; Rossor
et al. 1982). Additionally, acetylcholinesterase (AChE) activity has been shown to
increase Aβ aggregation (Eubanks et al. 2006). Cholinergic functioning decreases
(in the limbic system) during ‘normal’ aging, which likely contributes to the
age-related manner of AD impairments (see Albuquerque et al. 2009). The
mechanisms of cholinergic vulnerability appears to relate to the nAChR α7 & α4
subunits (see Figure 1.3). The number of neurons expressing α7 (at a protein
level) in the temporal cortices has been reported to decrease by around 50% in AD
patients (Banerjee et al. 2000). Decreases in total protein expression of both α4
and α7 have been reported in the hippocampi of AD patient (35% and 36%,
respectively; see Guan et al. 2000). Interestingly, reductions in protein expression
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Figure 1.3: Nicotinic receptors in Alzheimer’s-like diseases. α4/β2-nAChRs
facilitate pre-synaptic Ca2+ influx on GABAergic neurons, thus inhibiting synaptic
transmission and LTP. This action is facilitated by high concentrations of Aβ
peptides. α7-nAChRs facilitate Ca2+ influx at pre-synpatic excitatory neurons, as
well as post-synaptically. Both of these actions are inhibited by high concentrations
of Aβ peptides, whilst the pre-synaptic effect is facilitated by low concentrations.
have not been associated with changes in mRNA levels, demonstrating that these
do not derive from transcriptional down-regulation (Wevers et al. 1999). Another
study confirmed this finding with regard to the α4 subunit, but reported an
increase in α7 mRNA (Hellström-Lindahl et al. 1999). It is possible that this
finding may be explained by feedback from a reduction in protein load, however
research to support this hypothesis is lacking. Behaviourally, this manifests
primarily as cognitive deficits in memory functioning in AD patients (Coyle et al.
1983). Interestingly, nAChR α7 dysregulation has been implicated in traumatic
brain injury (TBI), a condition which also includes amyloid deposition, as well as
ApoE ε4 activity (Chu et al. 2005; D’Andrea and Nagele 2006; Hartman et al.
2002; Kelso et al. 2006; Parri et al. 2011; Pierce et al. 1996; Smith et al. 2003;
Verbois et al. 2000; Verbois et al. 2003).
nAChR α4 subunits commonly form hetermeric receptor complexes with nAChR
β2 subunits (the most common nAChR formation). These receptors are expressed
pre-synaptically on GABAergic neurons, facilitating their (inhibitory) signalling;
an action facilitated by high (nM) concentrations of Aβ (Jürgensen and Ferreira
2010). Aβ peptides directly interact with the α7-nAChR (a homomeric receptor
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which only contains the nAChR α7 subunit), inihibiting its activity (including its
facilitation of Ca2+ influx at synaptosomes) (Lee and Wang 2003; Spencer et al. 2006;
Wang et al. 2000a). Interestingly, the concentration of extracellular Aβ affects its
modulation of α7-nAChR-mediated Ca2+ influx; low (pM) concentrations appear
to facilitate pre-synaptic influx (and subsequently synaptic transmission), whilst
higher (nM) concentrations inhibit post-synaptic influx (and subsequently long-term
potentiation, LTP) (see Jürgensen and Ferreira 2010). Additionally, Aβ42 has been
shown to bind α7-nAChRs with a greater affinity than Aβ40, demonstrating one
mechanism by which the longer peptide may facilitate neurotoxicity to a greater
level than the shorter species (Lee and Wang 2003). Additionally, extracellular
Aβ42 has been proposed to bind α7-nAChRs (expressed on the surface of neurons),
and endocytosed to dysrupt intracellular mechanisms (D’Andrea and Nagele 2006).
Serotonergic pathways also play a role in memory functions, as well as anxiety
and depression; dysfunctions which have been reported in clinical AD (Bowen et al.
1983; Chen et al. 1996; Cross et al. 1986; Devanand et al. 1996; Ferretti et al. 2001;
Kepe et al. 2006; Meltzer et al. 1998; Palmer et al. 1987; Reinikainen et al. 1988; Teri
et al. 1999; Wragg and Jeste 1989). An isoform of the 5-hydroxytryptamine (5-HT)4
receptor has been reported to regulate APP metabolism, reducing Aβ cleavage (Cho
and Hu 2007; Lezoualc’h and Robert 2003). Whilst the exact nature of serotonergic
dysregulation in AD is still unclear, this link between amyloid pathogenesis and
depressive mood suggests it may present an important area of research for the welfare
of patients.
Glutamatergic signals are excitatory, affect synaptic plasticity, and are involved
in aspects of memory (Bashir et al. 1993; Bortolotto and Collingridge 1993; Liu et al.
2004; Malenka and Nicoll 1993; McEntee and Crook 1993; Nakanishi 1994; Tsien
et al. 1996). Dysregulation in AD has been implicated in excitotoxicity, with an
NMDA-R antagonist (memantine) prescribed as a treatment (Danysz and Parsons
2003; Hynd et al. 2004; Koutsilieri and Riederer 2007; Lipton 2006; Liu et al. 2007b).
Interestingly, decreased glutamate, as well as aspartate, has been reported in the
caudate nucleus of post-mortem AD brains, suggesting an impairment to decision
making and reward-based association learning (Balleine et al. 2007; Haruno and
Kawato 2006; Seidl et al. 2001). Further, Aβ inhibits NMDA-R functioning and
causes loss of synapses (Shankar et al. 2007; Snyder et al. 2005).
Dopamine (DA) pathways facilitate reward signalling and fine motor control
(Ikemoto 2007; Nestler and Carlezon 2006; Salamone 1992; Volkow et al. 1998;
Wooten and Trugman 1989). DA irregularities have been reported in the ventral
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tegmental area (VTA) and nucleus accumbens (NAcc) of AD patients, perhaps
explaining dysfunctions observed in reward / motivational mechanisms (in
addition to 5-HT dysregulation) (Mann et al. 1987a; Mitchell et al. 2011; Murray
et al. 1995). nAChR α7 has been reported to mediate Aβ-induced DA secretion in
the pre-frontal cortex (PFC), whilst muscarinic receptors facilitate an inhibition of
NAcc DA, indicating a complex mechanism of indirect modulation (Preda et al.
2008; Trabace et al. 2007; Wu et al. 2007).
GABA functions as the primary inhibitory neurotransmitter of the developed
brain (e.g. Davies 2003). Decreased GABA has been reported in temporal and
occipital lobes, as well as the cerebellum of AD patients post-mortem (Rossor et al.
1982; Seidl et al. 2001). Receptor densities of both GABAA and GABAB are reduced
in the hippocampi of post-mortem AD brains (Chu et al. 1987). In a rodent model
of AD, reactive astrocytes (increased ‘activated’ astrocytes, a response to neuronal
death and hallmark of AD; attenuation is associated with functional recovery) have
been shown to synthesise GABA, with similar features reported in AD post-mortem
brains (Eddleston and Mucke 1993; Jo et al. 2014; Ramı́rez et al. 2005). Additionally,
Aβ40 has been shown to positively modulate GABAA α6 subunit (Zhan et al. 2014).
This suggests that a shift in BACE1 cleavage of APP - to produce Aβ42 peptides
(over Aβ40) - would result in a decrease in (inhibitory) GABA signalling, leading to
excitotoxicity.
1.1.3 Current therapies
Due to the underlying neurodegeneration in AD, it is logical that drug discovery
would focus on neuroprotection and neurogenesis. ‘Neuroprotection’ is regarded in
the current thesis as relating to mechanisms which attenuate dysregulated
molecular signalling without necessarily having a direct ‘anti-apoptotic’ action (i.e.
inhibiting caspase signalling). By protecting existing neurons, or possibly replacing
degenerating ones, the detrimental impacts of neurodgeneration may be somewhat
attenuated. However the discovery and development of drugs to facilitate these
phenomena have been distinctly lacking, with virtually all promising
disease-modifying candidates failing clinical screening (Becker and Greig 2008;
Becker and Greig 2010; Heemskerk et al. 2002; Schneider and Lahiri 2009). It is
likely that these failures result from a failure to genotype patients in clinical
development, often using a diagnosis of AD based on behavioural phenotypes (i.e.
not distinguishing between the underlying aetiologies of these diseases).
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In this regard, even attempting to treat the common mechanisms of
neurodegeneration (i.e. caspase signalling) may be futile, as there is evidence from
animal models that neuronal apoptosis occurs subsequent to cognitive impairment.
For example, impaired fear conditioning has been reported in a double-transgenic
mouse line (expressing hAPP/PS1) in the absence of neurodegeneration, with
minimal (<1%) amyloid aggregation in the amygdala (which governs fear
conditioning behaviour; see Section 3.1.2) (Knafo et al. 2009). Additionally,
transgenic mice (expressing hAPPSWE) show substantial amyloid deposition and
plaque formation in the absence of neuronal apoptosis (Stein and Johnson 2002).
Thus, the development of efficacious therapies appears to require pharmacological
targetting of the specific molecular dysregulations which occur in different forms of
AD. This approach has been overlooked in AD drug discovery, which has largely
focussed on commonalities in these distinct pathologies.
There are currently only four drugs prescribed for AD, with the most recent being
approved in 2003 (Cummings et al. 2014; Mangialasche et al. 2010). Of these current
treatments, the primary action of three - donepezil, galantamine and rivastigmine
- is the inhibition of cholinesterase, thereby prolonging the action of ACh (Ago et
al. 2011; Cacabelos 2007; Polinsky 1998; Villarroya et al. 2007; Wilkinson 1999).
These were developed in alignment with cholinergic hypotheses of AD (alluded to
above in Section 1.1.2) - that dysfunction in cholinergic pathways are a major factor
in AD (e.g. Coyle et al. 1983; Francis et al. 1999; Perry 1986; Shen 2004; Terry
and Buccafusco 2003). The other drug - memantine - is a NMDA-R antagonist
(Chen and Lipton 2005; Parsons et al. 2007). This was developed in light of the
aforementioned findings of NMDA-related excitotoxicity in AD (Danysz and Parsons
2003; Olney et al. 1997). However in addition to these primary pharmacological
targets, other (possibly beneficial) effects have been reported:
Donepezil is also a Sigma-1 receptor (σ1; previously an orphan receptor,
subsequently found to bind the endogenous hallucinogen N,N -dimethyltryptamine;
Fontanilla et al. 2009) agonist, which is reported to protect against Aβ peptide
toxicity, and may offer some level of neuroprotection against excitotoxicity,
oxidative stress, ER stress, mitochondrial dysfunction and Ca2+ dysregulation
(Griesmaier et al. 2012; Hayashi and Su 2007; Marrazzo et al. 2005; Maurice et al.
2006; Nguyen et al. 2015; Svensson and Nordberg 1998). The protection against
Aβ toxicity has been shown to be indirectly mediated by α7-nAChR, but not
α4β2-nAChR (Arias et al. 2005). Donepezil has also been shown to inhibit GSK3β
(indirectly, via protein kinase B), thus inhibiting tau phosphorylation (Hamano
et al. 2013; Noh et al. 2013). Additionally, donepezil is a direct agonist of the
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muscarinic M1 receptor, suggesting an additional facilitation of memory functions,
as well as modulation of axiogenic mechanisms (Roldán et al. 1997; Snape et al.
1999; Wall et al. 2001).
Galantamine , in addition to inhibition of AChE, exerts some level of
butyrylcholinesterase (BChE) inhibition (Harvey 1995; Walsh et al. 2011).
Inhibition of this non-specific cholinesterase has been shown to increase ACh,
reduce Aβ peptide cleavage, and improve cognition (performance in maze
assessment) and long-term potentiation in a transgenic mouse model (expressing
hAPPSWE + PS1) (Greig et al. 2005). Galantamine has been reported to directly
bind nicotinic (although not muscarinic) receptors (α3β4, α4β2, α6β4), inducing a
positive allosteric modulation (Samochocki et al. 2003). This has been shown to
induce an increase in sAPPα (indicating an increase in α-secretase cleavage, in the
‘non-amyloidogenic’ processing pathway; see Chapter 4, Section 4.1.2) (Lenzken
et al. 2007). In vitro, it has been found to protect against Aβ toxicity,
mitochondrial dysfunction and ER stress (Arias et al. 2004; Liu et al. 2010). As
with donepezil, galantamine’s protection against Aβ toxicity has been shown to be
mediated by α7-nAChR, but not α4β2-nAChR (Arias et al. 2005). In comparison
with donepezil, galantamine has been reported to exert greater long-term
preservation of cognitive function (Wilcock et al. 2003).
Rivastigmine is less selective for AChE (over BChE) than donepezil and
galantamine (Eskander et al. 2005; Farlow 2003; Ogura et al. 2000). Findings from
AD post-mortem brains demonstrate greater BChE expression than AChE in
amyloid plaques, indicating that targetting this enzyme may be more efficacious in
the pathologies of AD (Eskander et al. 2005). Further, it has been found that
AChE decreases with AD progression, whilst BChE increases (possibly as a
compensatory mechanism for AChE), or else is unaffected (see Farlow 2003; Lane
et al. 2006; Nordberg et al. 2013). Thus, drugs which specifically inhibit AChE
may be less efficacious than BChE inhibition in later stages of the diseases. With
regard to amyloid, rivastigmine has been shown to decrease Aβ production and
increase sAPPα, indicating a shift from β- to α-secretase cleavage (Bailey et al.
2011; Ray et al. 2012; Yang et al. 2013). However, the neuroprotective effects of
rivastigmine against Aβ are not mediated by α7-nAChR, in contrast to both
donepezil and galantamine (Arias et al. 2005). Interestingly, via its affects on
nAChRs, rivastigmine has been shown to somewhat attenuate 5-HT dysregulation
following brain injury at a distant site (Islam et al. 2014).
Memantine (the NMDA-R antagonist) has been reported to protect neurons
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Table 1.1: Pharmacology of current ‘Alzheimer’s disease’ drugs. The
primary pharmacological actions of the four current AD treatments are listed,
as are known secondary secondary actions. The involvement of α7-nAChR in
neuroprotective signalling is indicated.



















Memantine NMDA-R (antagonist) α7-nAChR antagonist Yes
against glutamate excitotoxicity (Danysz and Parsons 2003; Lipton 2006; Tanović
and Alfaro 2005). Interestingly, the mechanism of this excitotoxicity relates to the
cellular location of NMDA activity. Indeed, activity at synapses has been shown to
facilitate neuronal survival, whereas extrasynaptic NMDA transmission induces
mitochondrial dysfunction and neurodegeneration (Hardingham et al. 2002;
Hardingham and Bading 2010; Papadia and Hardingham 2007). In this regard,
extrasynaptic NMDA-R are activated by glutamate, secreted from astrocytes in
response to Aβ (a detrimental mechanism mediated by α7-nAChR; however
memantine antagonises this receptor) (Banerjee et al. 2005; Talantova et al. 2013).
The effect of Aβ on extrasynaptic NMDA-R impairs long-term potentiation and
induces synaptic loss (Li et al. 2011; Rönicke et al. 2011). Interestingly,
extrasynaptic NMDA-R activity has been shown to increase Aβ production,
apparently forming a positive feedback loop, causing neurodegeneration (Bordji
et al. 2010). Memantine (and its derivitive, nitromemantine) have been found to
protect against Aβ-induced excitotoxicity, showing higher selectivity for
extrasynaptic over synaptic receptors (Talantova et al. 2013; Xia et al. 2010).
Despite these potentially neuroprotective actions, the ability of these drugs to
reduce atrophy is far from sufficient to halt disease progression. Indeed, despite a
reduction (compared with untreated control subjects), donepezil patients still
present a substantial level of hippocampal degeneration (Hashimoto et al. 2005).
Another study found that, despite cognitive benefits, donepezil had no effect on
disability progression or institutionalisation (Group 2004). A meta-analysis found
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no effect for any of the cholinesterase inhibitors on disease progression (Ito et al.
2010). Additionally, methodological flaws in clinical studies have been highlighted,
suggesting that positive findings for cholinesterase inhibition may be somewhat
erroneously acclaimed (Kaduszkiewicz et al. 2005). Similarly, one study found that
memantine reduced the rate of neurodegeneration specifically in the right
hippocampus (although neither left hippocampus nor total brain showed any
effect) (Weiner et al. 2011). However a longer-term (one-year) study failed to find
significant effects on either total brain or hippocampal atrophy (Wilkinson et al.
2012).
Thus, the current AD therapies may provide some symptomatic / functional
benefits. However no convincing effect on halting the underlying neurodegeneration
has been consistently reported. In this light, it is clear that the discovery of new
pharmacological interventions is imperative to sufferers of AD.
1.2 Relationship to abuse potential
Amongst the myriad problems associated with drug discovery is the area of safety
pharmacology ; “a discipline which uses principles of pharmacology ...to generate
data to inform risk / benefit assessment” (Pugsley et al. 2008, p.1382). This is
especially pertinent to CNS-acting drugs, as the ability of compounds to affect
mood / emotional state may lead to abuse, having dire consequences for patients.
For example, a drug which facilitates signalling within the reward pathways
(mesocorticolimbic system) may prove to have high abuse potential (i.e. a high
likelihood that it will be abused by humans). Additionally, compounds may have
psychologically depressive effects on patients, thus diminishing quality of life in order
to extend length of life. In this light, there is a clear necessity to screen drugs which
cross the blood-brain barrier (BBB) for their abuse potential.
A range of drugs with neuroprotective efficacy (in relation to some form of CNS
insult) is abused in human society (discussed in Chapter 6, Section 6.1.2). With
specific regard to AD, the assessment of abuse potential is particularly pertinent
due to common comorbidity with depression and anxiety, which have been
proposed as early risk factors for AD development (Caraci et al. 2010; Kessing and
Andersen 2004; Ownby et al. 2006; Robert et al. 2002; Taft and Barkin 1990; Tune
1998). Indeed, the prescription of antidepressants is common in the treatment of
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AD; with improved outcomes being reported for combined treatment with AD
drugs (Thompson et al. 2007). However, the administration of a drug with
anxiogenic properties would likely compound the disease-induced depression.
Thus, the concept of altered mood in AD highlights the necessity to assess the
effects of novel drugs on this manner of psychological state.
1.2.1 Reinforcing and anxiolytic side-effects
Donepezil agonises σ1 receptor, exerting an anti-depressant effect on rodents
(Maurice et al. 2006). Indeed, the agonistic action of abused drugs (e.g. cocaine,
mephamphetamine) on σ1 receptor suggests that this pharmacological mechanism
may have significant abuse-related consequences (Narayanan et al. 2011; Nguyen
et al. 2005; Sharkey et al. 1988). Of concern, σ receptor agonists have been shown
to substitute cocaine in a rodent self administration assay (Hiranita et al. 2010).
This suggests that donepezil may substitute for cocaine, either in rodent
self-administration, or in human drug abusers. However, as yet, these specific
questions have not been addressed in the literature.
In addition to ‘reinforcing’ drugs (i.e. those which facilitate signalling in the
mesocorticolimbic system), anxiolytic drugs have a high tendency to be abused in
human society (although those which act on the 5-HT system may have lower
abuse potential; Wit and Griffiths 1991; Lader 1994). In this regard, donepezil,
rivastigmine and memantine have all been shown to exert anxiolytic properties,
with the cholinesterase inhibitors reported to be antidepressant (by reversal of
chronic stress-related behaviours) in rodents; an effect the authors linked to
increased cholinergic signalling (Papp et al. 2016). Indeed, another cholinesterase
inhibitor - an extract from Salvia officinalis (commonly termed garden sage) - has
also been reported to produce anxiolytic effects on humans (Kennedy et al. 2006).
Additionally, nicotine itself has been shown to produce much the same effect
(Brioni et al. 1993; Picciotto et al. 2002; Saĺın-Pascual et al. 1996; Tizabi et al.
1999). Importantly for the current thesis, the phenomenon of nicotine-induced
anxiolytic behaviour has been observed in zebrafish using ‘tank diving ’ assessment
(Levin et al. 2007).
The primary action of memantine, as mentioned above, is antagonism of
NMDA-Rs. Two drugs with this same primary pharmacological function are
ketamine and phencyclidine (PCP) - general anaesthetics with significant human
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abuse potential (Dotson et al. 1995; Pradhan 1985). Interestingly, both of these
drugs have been found to exert some level of neuroprotection (discussed in
Chapter 6, Section 6.1.2), suggesting two commonalities between NMDA-inhibiting
compounds (namely, neuroprotection and anxiolysis).
Interestingly, the administration of antidepressants to AD patients has been
associated with a reduction in cognitive decline (Mossello et al. 2008). This may
suggest that depression itself facilitates this loss of cognitive faculties; thus
inhibiting the depressive state somewhat attenuates the cognitive impairments.
Alternatively, it is possible that the antidepressant drugs exert some level of
pharmacological nootropic / neuroprotective effect. In this light, the
antidepressant (SSRI) citalopram has been shown to inhibit both AChE and
BChE; co-administration with galantamine has been reported to increase cognitive
preservation (Walsh et al. 2011).
1.2.2 High costs of drug development
Over a decade ago, the development of a new drug was estimated to cost over $802
million (USD); this figure has been rising, now believed to exceed $2.5 billion (Adams
and Brantner 2006; DiMasi et al. 2003). This is even higher for CNS-acting drugs,
causing many prominent pharmaceutical companies to reduce their endeavours in
these fields (Pankevich et al. 2014; Wegener and Rujescu 2013).
Much of these costs are incurred due to the number of identified leads which fail
in drug development (DiMasi et al. 2003). It has been estimated that 30% of drug
failures are due to their being ineffective, whilst an additional 30% are due to safety
concerns, demonstrating a clear necessity for improving pre-clinical safety screening
in an economical manner (Kola and Landis 2004). In this regard, the abilities of
zebrafish to perform basic cognitive tasks suggests that this organism may present
a useful, economical tool for pre-mammalian drug screening.
Larval zebrafish has been highlighted as a possible model for early toxicity
assessment (Redfern et al. 2008). However, in assessing some of the more complex
aspects of safety pharmacology, it seems that adult zebrafish may also present an
important candidate in this area of drug development.
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1.3 Current animal models
Within basic neurobiology, there is a tendency to utilise rodents to model human
diseases. This is largely due to the high level of neuroanatomical and genetic
conservation between these mammals and humans (estimated at 99.5% of
disease-related genes; Huang et al. 2004). Similarly, the ability to observe and
empirically measure complex behavioural outcomes in rodents has led to their
extensive utilisation.
1.3.1 Models of Alzheimer’s-like diseases
Following high-throughput in vitro identification of potential compounds, drug
discovery processes rely heavily on rodent models of disease (Hughes et al. 2011;
Van Dam and De Deyn 2006). Generally, the non-transgenic models of AD (i.e.
‘spontaneous’, chemically induced and lesioned models) may induce degeneration
anatomically related to AD and mimic cognitive deficits, however they lack
amyloid and tau hallmarks (see Van Dam and De Deyn 2006).
With regard to transgenic rodents, several strains have been generated to model
aspects of AD pathologies. The rodent models which do not express hAPP do
not show amyloid pathologies, as murine Aβ does not form plaques (Johnstone
et al. 1991; Van Dam and De Deyn 2006). By expressing mutant forms of hAPP,
pathologies including Aβ plaque formation and cognitive deficits have been modelled
(Games et al. 1995; Hsiao et al. 1996; Sturchler-Pierrat et al. 1997). However, these
lack NFT, casting doubt over the concept of amyloid as a single causative factor in
AD pathogenesis (as discussed above in Section 1.1.2).
The double-transgenic expression of hAPP with PS1 or tau develop increased
amyloid pathology (and tau pathology for the tau-expressing double-transgenic);
however the neuroanatomical distribution of AD hallmarks is inconsistent with
‘typical’ AD (Götz et al. 2004; McGowan et al. 2006; Van Dam and De Deyn
2006). Thus, in order to induce a more holistic representation of ‘typical ’ AD
pathology, triple transgenic expression has been required thus far (Janelsins et al.
2005; Oddo et al. 2003a; Oddo et al. 2003b; Rhein et al. 2009; Van Dam and
De Deyn 2006). Whilst the development of this model (expressing mutated
versions of hAPP, PS1 and tau) appears to represent the pathologies, the
requirement of three mutated transgenes leaves questions as to its relevance with
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the aetiology of the diseases.
In light of these difficulties with current AD models, it is clear that the generation
of new genetically manipulated lines is necessary. Indeed, the strong association
of amyloid and tau with these diseases, coupled with the insufficienct pathologies
caused by mis-expression of these genes, suggests that up-stream signalling proteins
may play a more aetiological role in some of these disease pathologies. In this regard,
the aforementioned functions of PIN1 and DAPK1 may present efficacious targets
for both basic and translational research.
Behavioural measures
In the assessment of behavioural outcomes, a range of rodent assays has been
designed and implemented to assess AD-related cognitive declines:
Maze tests involve training an animal to navigate to a specific location, assessing
visuo-spatial learning and memory retrieval competencies (e.g. Drapeau et al. 2003;
Morris 1984; Olton et al. 1977; Vorhees and Williams 2006). However these often
require multiple training session, reducing the throughput when used in screening.
Additionally, physical exertion is required in water mazes, possibly compromising
investigations aimed at neurotransmitter systems involved in motivation or motor
control.
Operant conditioning paradigms (e.g. ‘Skinner box ’) assess non-spatial memory
(e.g. Nelson et al. 1997; Tonkiss et al. 1988; Van Dam and De Deyn 2006). These
assays require multiple training sessions to an even greater extent than maze tests,
again reducing the throughput. Additionally, the utilisation of food reward may
affect investigations in which neuroanatomical structures involved in appetite or
motivation are affected, or where experimental intervention has an impact on the
size of an animal (as with hAPP transgenic mice; see Huitrón-Reséndiz et al. 2002).
Fear conditioning also assesses non-spatial learning, however the minimal
training (conditioning) required means that throughput is much higher than other
behavioural paradigms; thus it is more optimal for development as a screening
assay (e.g. Arvanitis et al. 2014; Van Dam and De Deyn 2006). However assays
typically involve measurement of ‘freezing’ behaviour, the assessment of which is
difficult in rodents (Van Dam and De Deyn 2006). Thus, the development of a
robust screening assay would require empirical measurement of an alternative
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index of learning (e.g. preference for a conditioned stimulus, CS).
1.3.2 Reward and addiction research
Addiction is a complex phenomenon, assessed by the extent to which drug seeking
behaviours become detrimental to the subject. It is defined as “behaviour
...employed in a pattern characterised by (1) recurrent failure to control behaviour
and (2) continuation of the behaviour despite significant negative consequences”
(Goodman 1990, p.1403). In this light, the assessment of ‘addiction’ is problematic
in model organisms.
Indeed, the ability to motivate an animal to change it’s drug-seeking behaviour
is only possible using an alternative (non-drug) reward; thus the perseverance of
drug-seeking would only be indicative of the relative strengths of the rewards (drug
vs non-drug). Some have attributed the persistence of operant responding in the
absence of drug delivery to ‘addiction’ (e.g. Deroche-Gamonet et al. 2004). However
there is a distinct lack of motivation to cease responding, other than the absence
of reward. Thus, it is difficult to associate this behaviour with the motivational
influences involved in human cessation.
With regard to negative consequences, it is possible to administer a negative
stimulus (e.g. an electric shock) in addition to drug delivery, following operant
responding (Deroche-Gamonet et al. 2004). However the ethical considerations of
administering punishment obviate the preference for developing assays in which this
is not required. Further, findings that relatively few rodents display this level of
persistent drug-seeking behaviour suggest a high number of animals are required to
model human addiction (Deroche-Gamonet et al. 2004). Thus, the utility of assays
which indicate ‘drug reinforcement’ (measured as drug consumption or drug-seeking
behaviour in the absence of negative consequences), rather than ‘addiction’ appear
to have higher efficacy in assessing the human abuse liability of novel compounds.
Indeed, short-term reinforcement appears a more sensitive index of human abuse
potential (which would often follow prolonged exposure) than attempting to induce
short-term addictive behaviour in model organisms.
The investigation of reward signalling and drug-seeking behaviours commonly
involves wild-type animals (e.g. Baker et al. 1998; Shi et al. 2004). However, rodents
carrying mutations - often to receptor targets of a drug - have been utilised to
Ari Sudwarts 44
CHAPTER 1. GENERAL INTRODUCTION
assess the genetic basis of reward and addiction (e.g. Caine et al. 2002; Changeux
2010; Chiamulera et al. 2001; Cunningham et al. 2000; Epping-Jordan et al. 1999).
Additionally, selective breeding has lead to the generation of rodent strains with
high sensitivity to reinforcing compounds (e.g. alcohol-prefering rats; see Bell et al.
2006; McBride et al. 2014; Vengeliene et al. 2003).
Behavioural measures
The assessment of reward and drug-seeking behaviours has commonly revolved
around two assays - self administration (SA) and conditioned place preference
(CPP). Additionally, drug discrimination has been used to assess abuse liability in
comparison to a drug with known abuse potential. These will be discussed in
greater detail later in this thesis (see Chapters 6 and 7). However brief
descriptions of typical paradigms are provided here:
Self administration assays involve the conditioned pairing of an operant
behavioural response (i.e. presses on a lever) with the administration of a drug,
typically delivered via a transcranial cannula (e.g. Ettenberg et al. 1982; Roberts
et al. 1996; Roberts et al. 1999; Shaham et al. 1993). The response rate (number
of drug administrations by lever presses in a given time) is then used as a measure
of the reinforcing properties of the drug.
CPP assays involve the pavlovian conditioning of a drug with a neutral
environmental stimulus (CS). Following conditioning, the animal’s preference for
the CS (in the absence of drug administration) is compared to basal preference, as
a measure of drug-seeking behaviour.
Drug discrimination utilises operant conditioning paradigms, in which the
animal receives a food reward following an operant behaviour (i.e. lever presses).
Multiple training sessions are required, whereby presses on one lever are reinforced
with food following drug administration, whilst presses on the alternative lever are
reinforced following saline administration. A novel compound may then be
administered and the animal placed in the conditioning chamber without any food
reinforcement. A significantly higher number of presses on the drug-paired lever
indicates that the novel drug is producing a ‘state’ similar to that of the trained
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drug. It thus indicates the specific pharmacology of a drug in relation to a drug
with known pharmacological actions.
1.4 Using zebrafish to refine current animal
models
The zebrafish (Danio rerio) has been utilised in molecular biological research for
a number of years. The sequencing of the zebrafish genome has facilitated it’s
utility in molecular genetic investigations, as well as other basic molecular biological
applications (Howe et al. 2013). Further, the organism is estimated to have conserved
orthologues of 70% of human genes, and 80% of disease-related genes (Howe et al.
2013; Howe et al. 2017). This high level of genetic conservation highlights the
potential efficacy of using zebrafish for both forward and reverse genetic screens, as
well as pharmacological target validation and lead identification studies.
Within the field of molecular neurobiology, the zebrafish is an unique organism.
The larvae remain transparent until approximately five days-post-fertilisation, and
pigmentation can be inhibited after this stage using phenylthiocarbamide (PTU).
This allows fluorescent tags to be fused to genes of interest, and imaged in vivo (e.g.
Higashijima et al. 2000; Lawson and Weinstein 2002; Parinov et al. 2004). Further,
an ‘albino’ (‘casper ’) mutant line has been developed, in which pigmentation is
inhibited throughout life, allowing fluorescent imaging in the adult fish (White et
al. 2008).
1.4.1 Neuroanatomical conservation and molecular
signalling
As a vertebrate organism, many neuroanatomical regions of the mammalian brain
have been reported to have orthologues in zebrafish. Whilst this will be discussed
in greater detail in subsequent chapters of this thesis, key conserved structures
(as relative to the current research) have been reported to include the amygdala
(medial zone of the dorsal telencephalic area, Dm), hippocampus (lateral zone of
the dorsal telencephalic area, Dl), VTA (posterior tuberal nucleus, PTN), NAcc
(dorsal nucleus of the ventral telencephalic area, Vd), and PFC (central zone of the
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dorsal telencephalic area, Dc) (see Figures 3.2 & 6.2) (Klee et al. 2012; Mueller et al.
2011; Parker et al. 2012b; Rink and Wullimann 2001; Rupp et al. 1996).
1.4.2 Current AD-related transgenic zebrafish
Despite the significant utility of hAPP expression in rodent models of AD,
transgenic zebrafish lines have paid more heed to tauopathies. The transgenic
expression of human mutated tau has been shown to present hyperphosphorylation
and neurodegeneration, whilst the inclusion of a fluorescent tag allows assessment
of tau expression in vivo (Paquet et al. 2009; Paquet et al. 2010). Other transgenic
mutant tau lines have been reported to present microtubule dysfunction
representative of NFT (Bai et al. 2007; Tomasiewicz et al. 2002). However there is,
as yet, no reports of a stable transgenic zebrafish amyloidogenic model.
With regard to the direction of the current research, despite the
aforementioned uncertainties about the aetiological role of amyloid, a significant
proportion of transgenic mice used in AD drug discovery present amyliodopathies.
Thus, in order for zebrafish to prove efficacious as a refinement on rodent models,
an observable amyloid-induced phenotype must be identified. Therefore, this thesis
will assess cognition in an already-established (but unpublished) transgenic
zebrafish (expressing hAPPLON/SWE; see Chapter 5). Subsequent to this, the
generation of new genetically manipulated zebrafish lines may be viewed as viable
alternatives to the development of rodent strains in translational neurobiology.
1.4.3 Behavioural competencies
Despite their long utilisation in molecular biological investigations, the extent to
which zebrafish are efficacious in behavioural research has only recently come to
light. For example, they reliably perform simple choice discrimination tasks, in
both appetitive and aversive conditioning paradigms (Bilotta et al. 2005; Valente
et al. 2012). They have also been demonstrated to be capable of more complex
behavioural tasks, including 5-choice discriminations, reversal learning and set-shift
discrimination (Parker et al. 2014; Parker et al. 2012a).
It has also been reported that zebrafish display drug-seeking behaviour in CPP
paradigms, suggesting their efficacy as a model for human drug reward (Collier et
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al. 2014; Mathur et al. 2011). Importantly, the conservation of neuronal structures
and pathways which govern many reward mechanisms have been demonstrated in
zebrafish (mentioned above and discussed in Chapter 6). Whilst this implies their
efficacy as a model in basic research, it also suggests their utility in industrial safety
pharmacological settings; by implementing zebrafish screens prior to rodent studies
it may be possible for pharmaceutical companies to reduce both financial and ethical
costs associated with drug discovery. However, the extent (i.e. drug range) to which
zebrafish respond to compounds abused in human society is currently unknown.
As mentioned above, anxiolytic / anxiogenic behaviours are observable in
zebrafish using ‘tank diving’ assays (e.g. Levin et al. 2007). Whilst this specific
assay is not pertinent to the current thesis, it demonstrates the conservation of
these behavioural phenomena, which are imperative to the experience of reward
and aversion.
1.5 General aims
The aims of this thesis are to investigate the utility of zebrafish in translational
neurobiology, as a refinement on rodent models currently used This will be
undertaken through the following objectives:
1. To develop an automated behavioural paradigm to assess classical aversion
learning in zebrafish
2. To assess neurotoxin (aluminium, Al) treatment as a model of
neurodegeneration in zebrafish, testing the hypothesis that classical aversion
will be impaired
3. To assess the effects of transgenic hAPP expression in zebrafiish, as a model
of AD-related molecular dysregulation, testing the hypothesis that classical
aversion will be impaired
4. To determine the utility of a zebrafish CPP paradigm as a model of human
reward pharmacology
5. To develop a zebrafish drug discrimination paradigm, testing the hypothesis
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2.1 Animal maintenance
Zebrafish (Danio rerio) of the Tubingen wild-type strain were used in all
experimentation, unless stated otherwise. All fish were housed on a circulating
aquarium system, at 28oC, using a 14-hour : 10-hour light:dark cycle. Fish were
fed a commercial, general-purpose pellet food in the morning, and live (hatched)
brine shrimp (artemia) in the afternoon.
Breeding was conducted by ‘pairing’ fish (typically one male with with female)
in breeding tanks (containing inserts with perforated floors) in the evening. The
following morning, after the room lights were switched on, the water in the breeding
tanks was changed and the fish were not fed until the afternoon. Eggs were collected
at approximately midday, placed in clean aquarium water, and incubated (in Petri
dishes) at 28oC until five days post fertilisation. Following this, fry were fed a
commercial fry food until ten days post fertilisation, then added to the circulating
aquarium system.
2.2 Total RNA extraction from zebrafish brain
tissue
Zebrafish were sacrificed by decapitation and brain tissue removed by dissection on a
dry Petri dish lid, using micro-dissection forceps. Immediately following dissection,
tissue was placed in a ‘freezer block’ (-20o) for transportation. If the samples were
not processed on the same same day, they were stored at -80oC until processing.
RNA was extracted from each brain individually, using a Trizol-chloroform
method. 500µl of Trizol (Ambion®, Thermo Fisher) was added to each brain and
homogenised by trituration through pipette tips, in descending sizes (P1000, then
P200, then P10). Following trituration, a further 500µl of Trizol was added, the
combined 1mL samples were mixed (by pipetting six times) and then incubated at
room temperature for 5 minutes.
200µl of chloroform was then added, and the sample agitated vigorously (by
shaking) for 15 seconds. Following agitation, the samples were incubated at room
temperature for 3 minutes, before centrifugation at ≥x17,000g for 15 minutes, at
4oC.
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The upper aqueous phase was then removed to a clean sample tube, mixed with
isopropanol (1:1, mixed by pipetting six times), and incubated on ice for 10 minutes.
The mixture was then centrifuged at ≥x17,000g for 30 minutes, at 4oC.
The resultant supernatant was discarded. The remaining pellet was washed with
70% ethanol and centrifuged at ≥x17,000g for 5 minutes, at 4oC.
The resultant supernatant was discarded. The remaining pellet was then air-
dried, re-suspended in 30µl ddH 2O, and incubated at 55oC for 10 minutes. Samples
were stored at -20oC short-term (up to 2 weeks) or at -80oC for longer-term storage.
2.3 Quantification of nucleic acids
Nucleic acid concentrations (both DNA and RNA) were determined using 2.5µl
drops on a Nanodrop 2000 (ThermoScientific), as per the manufacturer’s
recomendations. Absorbance was read at 260nm.
2.4 DNAse I treatment and cDNA synthesis
In order to remove any genomic DNA, the RNA extracts were treated with DNAse
I (New England Biolabs). Frozen RNA samples were thawed on ice. The following
reaction was then set up:
Total RNA x µl (1µg)
Protoscript II Reaction Mix (2x)1 6.5µl
DNAse I 0.1µl
ddH2O to 12.5µl
Total reaction volume 12.5µl
1Part of the New England Biolabs Protoscript II First Strand cDNA Synthesis Kit, which was
subsequently used to reverse-transcribe RNA into cDNA.
Ari Sudwarts 51
CHAPTER 2. GENERAL METHODOLOGY
The reaction mix was incubated at 37oC for 10 minutes, then at 75oC to heat-
inactivate the DNAse I enzyme.
The DNAse-treated RNA was then reverse transcribed using the Protoscript II
First Strand cDNA Synthesis Kit (New England Biolabs) in the following reaction:
(DNAse I-treated RNA) (12.5µl)
Protoscript II Reaction Mix (2x) 3.5µl
Protoscript II Enzyme Mix (10x) 2µl
Random Primer Mix 1µl
OligoDT Primer Mix 1µl
Total reaction volume 20µl
The reaction was incubated at 25oC for 5 minutes (to facilitate primer binding),
42oC for 60 minutes (temperature for enzymatic reaction), the enzyme was heat-
inactived 85oC for 5 minutes.
2.5 Agarose gel electrophoresis
Agarose was added to TAE buffer (40mM Tris, 20mM glacial acetic acid, 1mM
EDTA) at the specified concentrations (between 1% - 2%) and heated in a microwave
oven, on full power, until dissolved. peqGREEN dye (VWR International.; item
732-3196) was added to the solution as per the manufacturer’s instructions (5µl in
100mL) and mixed by gentle agitation. The solution was then poured into a mould,
a comb added, and allowed to set by cooling at room temperature.
The comb was then removed, the solidified gel was placed in an electrophoresis
tank, and immersed in TAE buffer (described above) to cover the wells. DNA /
RNA fragments were mixed with ‘Loading Dye’ (NEB; item B7025S) as per the
manufacturer’s instructions (1:6 dye:sample), and added to the wells of the gel. A
DNA ladder (NEB; item N3200S) was added in the same manner to a well. The lid
was then placed on the electrophoresis tank, and the nucleotide fragments separated
by running the tank at 120V for approximately 25 minutes. The gel was then imaged
on a ‘Fusion Solo S ’ imaging machine (Vilber Lourmat), using Vision Capt software.
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2.6 Preparation of LB-broth
LB-broth (Miller’s) was dissolved in ddH2O, as per the manufacturer’s instructions
(25g/L). The solution was autoclaved, then allowed to cool to room temperature
before antibiotics were added at 100µg/mL.
2.7 Preparation of agar plates
LB-agar was dissolved into ddH2O as per the manufacturer’s instructions (17.5g into
500mL). The solution was then autoclaved. Immediately following autoclaving, the
agar was placed in a water bath, pre-heated to 50oC.
Once the water bath temperature had returned to 50oC, the relevant antibiotic
was added to the agar at 100µg/mL. If blue/white screening was required, X-gal
and IPTG was also added to the agar (final concentrations of 40ng/µl & 0.1mM,
respectively). Plates were then poured immediately, using approximately 25mL agar
per sterile Petri dish.
Plates were left to set for at least 30 minutes before plating cells. If not used
immediately, plates were wrapped in parafilm and stored at 4oC for a maximum of
4 days.
2.8 Preparation of competent cells
All procedures described in this section were conducted using aseptic technique (i.e.
in the presence of a Bunsen burner flame).
One aliquot (50µl) of Top10 Competent Cells (Thermo Fisher) was thawed on
ice and then streaked onto a LB-agar plate, containing streptomycin. The plate was
then incubated up-side-down at 37oC, overnight, in a temperature-regulated room.
The following morning the plate was removed from the heated room and stored
at 4oC, wrapped in parafilm. Single (isolated) bacterial colonies were later selected
from the plate and cultured in 5mL LB-Broth containing streptomycin. Cultures
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were then incubated at 37oC in a shaking incubator, overnight, to generate ‘starter
cultures’.
The following morning, 1mL of the 5mL starter culture was added to 100mL
fresh LB-broth (containing streptomycin). The larger culture was then incubated at
37oC in a shaking incubator, for approximately 2 hours. The cells were then cooled
on ice for approximately 15 minutes.
The 100mL culture was divided into 2x 50mL Falcon tubes and centrifuged at
500rpm for 10 minutes, at 4oC. The supernatant was removed by decanting and the
pellets re-suspended in ice-cold TfbI (see below), at a combined volume of 50mL.
The re-suspended cells were inoculated on ice for approximately 15 minutes.
The cell suspension was centrifuged at 500rpm for 10 minutes, at 4oC, the
supernatant removed by decanting, and the cells were re-suspended in 4mL
ice-cold TfbII (see below). The cells were then aliquotted at 100µl and stored at
-80oC until use.
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2.9 Transformation and culturing of competent
cells
All procedures described in this section were conducted using aseptic technique (i.e.
in the presence of a Bunsen burner flame).
Competent cells were thawed on ice for at least 10 minutes, then aliquotted into
pre-chilled sample tubes at 50µl per transformation. 50-100ng of plasmid DNA was
added per transformation and mixed by ‘flicking’ the tube six times. The samples
were incubated on ice for 20 minutes, mixing again after approximately 10 minutes.
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Samples were ‘heat-shocked’ at 42oC for 60 seconds then incubated on ice for 2
minutes. 950µl LB-broth (without antibiotics) was added to the transformed cells
and the culture incubated at 37oC in a shaking incubator for 1 hour.
Cultures were then centrifuged at ≥x17,000g on a bench-top microcentrifuge
for 2 minutes. The supernatant was removed by decanting and the cell pellet re-
suspended in approximately 100µl LB-broth (without antibiotics). The re-suspended
cells were plated on LB-agar plates (prepared as described in Section 2.7) containing
100µg/mL antibiotic (usually ampicillin).
The cultured plates were left to dry for approximately 10 minutes and then
incubated up-side-down at 37oC, overnight.
The following day the plates were removed from incubation, wrapped in parafilm,
and stored at 4oC for the duration of the day. Individual (isolated) colonies were
then selected using a sterile P10 pipette tip and cultured in 5mL LB-broth containing
antibiotics at 100µg/mL (usually ampicillin). These cultures were then incubated
at 37oC, in a shaking incubator, overnight.
2.10 Generation of glycerol stocks of transformed
cells
All procedures described in this section were conducted using aseptic technique (i.e.
in the presence of a Bunsen burner flame).
Following transformation (as described in Section 2.9), the 5mL ‘Starter
cultures’ were removed from incubation. 500µl of each culture was added to 500µl
of autoclaved 60% glycerol, vortexed at maximum speed for approximately 10
seconds, then stored at -80oC.
2.11 Gel extraction
DNA was extracted from agarose gels (following electrophoresis) using the
QIAquick Gel Extraction kit (QIAGEN), as per the manufacturer’s instructions.
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All centrifugation steps were conducted on a bench-top microcentrifuge at
maximum speed (∼17,000xg), at room temperature.
Following electrophoresis through agarose gels, bands corresponding to the
correct gene fragment sizes were excised from the gels using a sharp scalpel. The
gel slices were weighed, and Buffer QG was then added at 3x v/w for 1% gels, or
6x v/w for 2% gels. The gels were dissolved in the buffer by incubating in a 50oC
waterbath for 10 minutes (vortexing occasionally).
DNA was then precipitated by adding isopropanol at 1x v/w gel volume mixed by
vortexing. The samples were then placed in QIAquick spin columns and centrifuged
for 60 seconds.
Flow-through was discarded by decanting, 500µl Buffer QG added to the spin
columns and then centrifuged for 60 seconds.
Flow-through was discarded by decanting, 750µl Buffer PE added to the columns
and then centrifuged for 60 seconds.
Flow-through was again discarded and the column re-centrifuged (dry) for 60
seconds.
The columns were then removed and added to a clean microcentrifuge tube. 30µl
ddH2O was added to the centre of each column, left to stand at room temperature
for 3 minutes, then centrifuged for 60 seconds.
2.12 Miniprep purification of plasmid cultures
Plasmid DNA from ‘Starter cultures’ (5mL) was purified using the Quicklyse
Miniprep kit (QIAGEN), as per the manufacturer’s instructions. All centrifugation
steps were conducted on a bench-top microcentrifuge at maximum speed
(∼17,000xg), at room temperature.
Following generation of glycerol stocks (as described in Section 2.10), 1.5mL of
each starter culture was added to a 2mL sample tube and centrifuged for 60 seconds.
Supernatant was removed by decanting and the cells re-suspended in 400µl ice-cold
Complete Lysis Solution by vortexing at maximum speed, for approximately 30
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seconds. Samples were incubated at room temperature for 3 minutes (to allow cell
lysis). The lysates were then added to QuickLyse spin columns and centrifuged for
60 seconds.
The column was washed with 400µl Buffer QLW (containing ethanol) and
centrifuged for 60 seconds. The flow-through was discarded and the column
re-centrifuged (dry) for 60 seconds.
The columns were then removed and added to a clean microcentrifuge tube. 30µl
ddH2O was added to the centre of each column, left to stand at room temperature
for 3 minutes, then centrifuged for 60 seconds.
2.13 Maxiprep purification of plasmid cultures
For applications that required large quantities of plamid DNA, 100µl of ‘Starter
cultuers’ (5mL) or 200µl glycerol stocks were inoculated into 100mL LB-broth and
cultured at 37oC, in a shaking incubator, overnight. Plasmid DNA was then purified
using the QIAfilter Maxi kit, as per the manufacturer’s instructions.
Cells were harvested by centrifugation at 6,000xg, at 4oC, for 15 minutes.
Supernatants were discarded by decanting and the cell pellets re-suspended in
10mL Buffer P1 by vortexing at maximum speed.
10mL Buffer P2 was then added to the cell suspension and the sample mixed
by vigorous inversion approximately 6 times. Mixed samples were then incubated
at room temperature for 5 minutes to lyse cells.
10mL Buffer P3 was added to the lysates, the samples mixed by vigorous
inversion approximately 6 times, and the samples added to the barrels of QIAfilter
Cartridges (with caps attached to the outlet nozzle). The samples were incubated
in the cartridges at room temperature for 10 minutes (without the plunger
inserted).
During the incubation period, QIAGEN-tip 500 tips were equilibrated by
application of 10mL Buffer QBT, and allowing the buffer to pass through the tip
by gravity flow.
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The caps were then removed from the QIAfilter Cartridges, the plungers inserted
into the cartridges, and the samples were filtered into the equilibrated QIAGEN-tip
500 tips. The samples were allowed to pass through the tips by gravity flow.
The tips were washed with 30mL Buffer QC (x2), which were allowed to pass
through the tip by gravity flow. DNA was then eluted from the tips by adding 15mL
Buffer QF and allowing it to pass through the tips, into a clean 15mL Falcon tube,
by gravity flow.
DNA was precipitated by addition of 10.5mL isopropanol to eluted DNA and
mixed by vortexing at maximum speed. Samples were then centrifuged at
>15,000xg, at 4oC, for 30 minutes.
The supernatant was discarded by decanting, the DNA pellet washed with 5mL
70% ethanol and centrifuged at >15,000xg for 10 minutes.
The supernatant was discarded and the DNA pellet allowed to air-dry for
approximately 10 minutes. DNA was then re-suspended in 100µl ddH2O.
2.14 PCR purification
Polymerase chain reaction (PCR) products were purified using the QIAquick PCR
Purification kit (QIAGEN), as per the manufacturer’s instructions. All
centrifugation steps were conducted on a bench-top microcentrifuge at maximum
speed (∼17,000xg), at room temperature.
Buffer PB was added to the PCR product at a ratio or 5:1 (buffer:sample - i.e.
125µl buffer to 25µl PCR product) and mixed by pipetting. Mixed samples were
added to QIAquick spin columns and centrifuged for 60 seconds.
Flow-through was discarded, 750µl Buffer PE added to the columns, and
centrigued for 60 seconds. Flow-through was again discarded and the columns
re-centrifuged (dry) for 60 seconds.
The columns were then removed and added to a clean microcentrifuge tube. 30µl
ddH2O was added to the centre of each column, left to stand at room temperature
for 3 minutes, then centrifuged for 60 seconds.
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2.15 Ethanol precipitation
DNA / RNA was purified by ethanol precipitation in the following manner. All
centrifugation steps were conducted on a bench-top microcentrifuge at maximum
speed (≥17,000xg), at 4oC.
Sodium acetate (3M, pH5.2) was added to nucleic acid at 1/10th volume (i.e. 1µl
sodium acetate to 9µl sample). The samples were mixed thoroughly by pipetting.
Pre-chilled ethanol was then added at 2.5x volume of mixed samples (i.e. 25µl
added to 10µl sample). The samples were mixed thoroughly by pipetting, then
incubated at -20oC for at least 20 minutes.
Following incubation, the samples were centrifuged at ≥x12,000g for 15 minutes.
Supernatants were discarded by decanting. The pellet was then washed by adding
70% ethanol and mixing by inversion (6x). Samples were centrifuged at ≥x12,000g
for 2 mins.
The supernatant was discarded by decanting. The pellet was allowed to air-dry,
then re-suspended in an appropriate volume of ddH2O or buffer.
2.16 Cloning into pGEM®-T Easy
PCR products with adenosine overhangs (i.e. from Taq polymerase) were cloned into
the pGEM-®-T Easy vector (Promega) - which contains complementary thymidine
overhangs - as per the manufacturer’s instructions. The following reactions were set
up:
Ligation buffer (2x) 5µl
pGEM®-T Easy vector (50ng) 1µl
PCR product (insert) xµl*
T4 DNA ligase 1µl
ddH2O (to 10µl)
Total 10µl
*(3:1 insert:plasmid molecular ratio)
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Table 2.2: Primer sequences used to generate in situ hybridisation
probes. All primer sequences were designed using the NCBI Primer Blast tool.
Annealing temperatures were initially calculated using the New England Biolabs






























Reactions were mixed by pipetting, then incubated at room temperature for 2
hours.
Ligated DNA (2µl) was then transformed into competent cells (as described in
Section 2.9), then plated on ampicillin plates using blue/white selection (as described
in Section 2.7).
2.17 Primer design for in situ hybridisation
probes
cDNA sequences were derived from the Ensembl project website (Flicek et al. 2014).
All primers (see table 2.2) were designed using the NCBI Primer Blast tool (Ye et
al. 2012) and purchased from Eurofins Genomics. Where possible, primers were
designed to amplify a sequence that includes an intron in genomic DNA.
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2.18 Generation of in situ hybridisation probes
from cDNA
Total RNA was extracted, DNAse-treated and reverse transcribed into cDNA, as
described in Sections 2.2 and 2.4. Gene fragments were then PCR-amplified from
cDNA (using the primers specified in Table 2.2, in the following reaction (reagents
from New England Biolabs):
Reaction mix:
Thermopol Buffer (10x) 2.5µl
dNTPs (10mM) 0.5µl
Forward primer (10µM) 0.5µl






Initial denaturation 95oC 30 seconds
Denature 95oC 30 seconds
x35 cyclesAnneal (variable) 1 minuteExtension 68oC 1.5 minutes
Final extension 68oC 5 minutes
Hold 4oC ∞
The resulting gene fragments were electrophoresed through a 1% agarose gel.
Bands of the correct size were extracted from the gel as described in Section 2.11.
Extracted gene fragments were then cloned into pGEM®-T Easy, transformed
into competent cells with blue/white screening, and cultured as described in Sections
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2.16, 2.9 and 2.7. Starter Cultures were Miniprepped as described in Section 2.12
(following glycerol stock generation, described in Section 2.10). Minipreps were
sequences (by Eurofin Genomics) to confirm insertion of the correct gene fragment
and to check orientation (5′ →3′) in pGEM®-T Easy.
The gene fragments were then amplified from the pGEM®-T Easy plasmid using
M13 primers (to include both the SP6 and the T7 polymerase sites), in the following
reaction (reagents from New England Biolabs):
Reaction mix:
Thermopol Buffer (10x) 10µl
dNTPs 2µl
M13 Forward primer 2µl






Initial denaturation 95oC 30 seconds
Denature 95oC 30 seconds
x35 cyclesAnneal 44
oC 1 minute
Extension 68oC 1.5 minutes
Final extension 68oC 5 minutes
Hold 4oC ∞
The linear fragments were PCR purified (as described in Section 2.14), and then
in vitro transcription of the riboprobes was set up in the following reactions (using
Roche SP6/T7 Transcription Kit):
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Transcription Buffer (10x) 1µl
Linear DNA template xµl (1µg)





*(Either SP6 polymerase or T7 polymerase,
depending on gene orientation.)
Samples were mixed by pipetting, then incubated at 37oC for 3 hours.
Riboprobes were purified by ethanol precipitation (as described in Section 2.15)
and re-suspended in 83.3µl buffer (containing 25% formamide and 5 x SSC Buffer
(75mM sodium citrate, 750mM NaCl)).
2.19 In situ hybridisation
In situ hybridisation was conducted as described previously (Carleton et al. 2014):
Tissue preparation
Zebrafish were sacrificed by decapitation. Whole brains were dissected on a dry
Petri dish lid, placed in OCT compound and immediately frozen on dry ice. Time
between sacrificing and freezing did not exceed 10 minutes. Tissue was stored at
-80oC until further processing.
Tissue was then cut in -30oC in 10µm sections and mounted onto charged
(‘Superfrost ’) slides (VWR). Slides were then stored at -20oC until further
processing.
Slides were fixed for exactly 5 minutes in 3% Fixation Buffer (3%
paraformaldehyde, 0.3% NaH2PO4*H2O, 1.6% NaHPO4, + 3 drops NaOH per
700mL). Slides were then dehydrated in an ascending ethanol series (70%, 95%,
100%) for 2 minutes each.
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If slides were not immediately processed further, they were stored at -80oC until
needed.
In situ probing
Slides were acetylated in freshly prepared Acetylation Solution (0.675%
triethanolamine, 0.15% acetic anhydride) at room temperature for 10 minutes.
Slides were then rinsed in 2 x SSPE Buffer (1.753% NaCl, 0.276% NaH2PO4*H2O,
0.074%, pH 7.4), twice. Sections were dehydrated in an ascending ethanol series
(70%, 95%, 100%) for 2 minutes each. They were then air-dried for ∼10 minutes.
120µl hybridisation solution (50% deionised formamide, 2 x SSPE Buffer, 2µg/µl
yeast tRNA, 250ng/mL riboprobe) was pipetted on to each slide. A strip of parafilm
placed on top and the slides incubated in a humidity chamber at 65oC overnight.
The following morning, slides were immersed in cold 2 x SSPE Buffer and the
parafilm peeled off using forceps. Samples were then washed in Post Hybridisation
Wash Buffer I (2 x SSPE Buffer, 50% formamide) at 65oC for 70 minutes (agitating
every ∼10 minutes), followed by two washes in Post Hybridisation Wash Buffer II
(0.1% SSPE Buffer) at 65oC for 30 minutes each (agitating every ∼10 minutes).
Slides were then placed in TNT Buffer (100mM Tris-HCl pH 7.5, 100mM NaCl,
0.3% Triton-X 100) for at least 10 minutes.
TNB Blocking Buffer (100mM Tris-HCl pH 7.5, 100mM NaCl, 0.36% Blocking
Reagent (Invitrogen)) was filtered through a 0.22µm syringe filter and 1% skimmed
milk added. 150µl was then pipetted on to each slide and parafilm placed on top.
The samples were incubated in a humidity chamber at room temperature, for 30
minutes.
Blocking Buffer was then discarded and 150µl anti-digoxigenin-AP antibody
(Roche) was added (1:500 in fresh TNB Blocking Buffer). Samples were incubated
with the antibody in a humidity chamber at room temperature, for 2 hours.
Antibody solution was then discarded and slides washed in TNM (100mM Tris-
HCl pH 9.5, 100mM NaCl, 5mM MgCl2), agitating, for 15 minutes, twice.
NBT/BCIP solution (Roche) was filtered using a 0.22µm syringe filter. The
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Table 2.3: Primers sequences used for qPCR. All sequences were designed































slides were incubated in filtered NBT/BCIP overnight, or until signal became
evident.
Slides were then washed in ddH2O for at least 1 hour, air-dried and cleared
in xylene. Coverslips were mounted using non-aqueous mounting media (either
Histomount DPX).
2.20 Primer design for qPCR
cDNA sequences were derived from the Ensembl project website (Flicek et al. 2014).
All primers (see table 2.3) were designed using the NCBI Primer Blast tool (Ye et
al. 2012) and purchased from Eurofins Genomics. Where possible, primers were
designed to amplify a sequence that includes an intron in genomic DNA.
2.21 qPCR primer optimisation
All quantitative polymerase chain reaction (qPCR) experiments were conducted
using absolute quantification (standard curve) methodology (e.g. Parker et al. 2016).
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In order to generate standard curves, qPCR primers were used to amplify the correct
fragments from cDNA (synthesised as per Section 2.4), in a standard PCR reaction:
Reaction mix:
Thermopol Buffer (10x) 2.5µl
dNTPs (10mM) 0.5µl
Forward primer (10µM) 0.5µl






Initial denaturation 95oC 30 seconds
Denature 95oC 30 seconds
x35 cyclesAnneal (variable) 1 minuteExtension 68oC 1.5 minutes
Final extension 68oC 5 minutes
Hold 4oC ∞
PCR products were run on 2% agarose gels and bands of the correct size were
extracted, as described in Section 2.11.
Following gel extraction, DNA concentration was determined as described in
Section 2.3. The total number of fragments was calculated using the Avogadro
constant, then diluted to an appropriate concentration (usually 1011). This sample
was then serially diluted to produce a standard curve of 106, 105, 104, 103, and 102
fragments per 2µl.
Initially, standard curves were set up for each gene, in the following manner:
Reaction mix:
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2 x SYBR Green I Mastermix (Bio-Rad) 5µl
Forward primer (10µM) 0.22µl
Reverse primer (10µM) 0.22µl
ddH2O 4.06µl
Total 9.5µl
The standard curve samples were loaded, in triplicates, directly into the bottom
of a 96-well plate, at 2µl per sample. In the same manner, 2µl of each test sample
cDNA (reverse-transcribed from 1µg RNA) was loaded in triplicate, directly into
the bottom of the wells. 9µl of the above reaction mix was then loaded (by reverse
pipetting) on the side of each well. An adhesive film strip was placed over the top
of the plate, and the plate centrifuged at full speed, at 4oC, for 2 minutes.
The plates was run through thermocycles on a Bio-Rad CFX Connect qPCR
machine, in the following protocol:
Thermocycles:
Initial denaturation 95oC 5 minutes
Denature 95oC 10 seconds

x45 cycles
Anneal (variable) 6 seconds
Extension 72oC 6 seconds
(plate read)
Denature 95oC 30 seconds
Melt curve x oC - 99oC* 30 seconds
Hold 4oC ∞
(*temperature increased in 0.5oC increments, from annealing temperature)
Annealing temperatures were optimised for each primer set. Temperatures that
produced a single product size, with Efficiency between 90%-110% and R2 of >0.98
were used for experiments qPCR trials.
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2.22 Total protein extraction from zebrafish brain
tissue
Zebrafish were sacrificed by decapitation. Full brain tissue was dissected out and
immediately stored at -20oC.
RIPA buffer (50mM Tris-HCl pH 7.6, 150mM NaCl, 1% IGEPAL-CA630, 0.5%
sodium desoxycholate, 0.1% SDS) containing cOmplete Protease Inhibitor Cocktail
(Roche), was added to frozen tissue (100µl/brain) and allowed to thaw on ice. Tissue
was homogenised in buffer using a small mechanical homogeniser, then sonicated
using a probe sonicator on full power, for 10 strokes.
The samples were centrifuged at 700 xg, at 4oC, for 5 minutes. Supernatants
were removed to a clean sample tube, 6x Laemmli Sample Buffer (recipe for final
working concentrations - 62.5mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01%
Bromophenol blue, 1.25% β-mercaptoethanol) added (1:6), and then boiled at 95oC,
for 10 minutes.
If not processed immediately, protein extracts were stored at -80oC until use.
2.23 Western blot antibody optimisation
10% Resolving gel:
H2O 1.9mL
30% acrylamide mix 1.7mL
1.5M Tris-HCl (pH 8.8) 1.3mL
10% SDS 0.05mL
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H2O 1.4mL
30% acrylamide mix 0.33mL
1M Tris-HCl (pH 6.8) 0.25mL
10% SDS 0.02mL
10% ammonium persulfate 0.02mL
TEMED 0.002mL
10% SDS-PAGE gels were cast (see above). Proteins were loaded and run
through the gel at 120V for, using running buffer (25mM Tris, 192mM glycine,
10% SDS), for 70 minutes, on ice.
Proteins were then blotted on to pure nitrocellulose membrane (Perkin Elmer)
using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad), at 10V, for 45 minutes.
Blots were blocked with 10% skimmed milk + 5% BSA in PBS-T (PBS + 0.02%
tween), at 4oC, overnight. Membranes were washed with PBS-T for 5 minutes
(x5), then probed with either chicken anti-Aβ (Abcam, ab17473) or rabbit anti-
APP C-terminal (Millipore, 171610), as specified, in 3% BSA (1:2,000), at room
temperature, for 2 hours. The antibody was removed (and stored with sodium azide
at 4oC) and the membranes washed with PBS-T for 5 minutes (x5). Normalisation
antibody (mouse anti-acetylated tubulin, Sigma T6793), was added in 3% BSA
(1:2,000) and incubated at room temperature, for 10 minutes.
Blots were washed with PBS-T for 5 minutes (x5). Infra-red fluorescent
secondary antibody (Abcam, ab175787 and ab175775) were diluted in 3% BSA
(1:10,000) and incubated at room temperature for 40 minutes. Membranes were
again washed with PBS-T for 5 minutes (x5), rinsed in ddH2O, and stored in
ddH2O. Blots were then imaged on an Odyssey CLx system (LI-COR).
Quantification was conducted using Image Studio Lite software (LI-COR).
2.24 TUNEL assay
The TUNEL assay (Millipore) was performed as per the manufacturer’s instructions,
except that nickel enhancement was used to increase signal:
Zebrafish were sacrificed by decapitation and whole brain tissue dissected out.
Tissue was immediately immersed in OCT Compound (Tissue-Tek) and frozen on
Ari Sudwarts 69
CHAPTER 2. GENERAL METHODOLOGY
dry ice. If not processed immediately, samples were then stored in OCT Compound
at -80oC.
Tissue was cut on a cryostat at -20oC in 10µm sections and mounted on charged
(‘Superfrost ’) slides. If not used immediately after sectioning, slides were stored at
-20oC.
Sections were fixed in 1% paraformaldehyde (in PBS, pH 7.4) at room
temperature for 10 minutes, then washed in PBS for 5 minutes (x2). They were
then post-fixed in pre-chilled ethanol: acetic acid (2:1) at -20oC, for 5 minutes.
Sections were again washed in PBS for 5 minutes (x2).
Following this, endogenous peroxidases were quenched with 3% hydrogen
peroxide (in PBS) at room temperature, for 5 minutes. Sections were again
washed in PBS for 5 minutes (x2).
Excess liquid was removed from the slides and Equilibration Buffer added for
∼3 minutes. Working concentration of TdT enzyme (in Reaction Buffer was added
to the slides, a plastic coverslip placed over the liquid, and incubated at 37oC, in a
humidified chamber, for 1 hour. Coverslips were then removed, excess liquid poured
off, and the slides immersed in working strenght Stop/Wash Buffer (agitating for
15 seconds, then incubating for 10 minutes, at room temperature).
Slides were washed with PBS for 1 minute (x3), Anti-Digoxigenin Peroxidase
Conjugate added to each slide and a plastic coverslip placed on top. Slides were
then incubated in a humidified chamber for 30 minutes, at room temperature.
Slides were washed with PBS for 2 minutes (x4), then incubated in
working-strength peroxidase substrate (0.05% 3,3′-diaminobenzidine, 0.05% nickel
ammonium sulfate, 0.015% H2O2, in PHB, pH 7.2) at room temperature, for up to
20 minutes.
Slides were washed in dH2O for 1 minute (x3), followed by a 5 minute incubation
in dH2O. They were then dipped in 100% n-butanol ten times (x2) and incubated
in 100% n-butanol for 30 seconds.
Finally, sections were dehydrated in 100% xylene for 2 minutes (x3), before
coverslips were mounted using DPX mounting media.
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2.25 Fluoro-Jade® B staining
Fluoro-Jade® B was purchased from Millipore. Staining protocol was as per
previously reported (see Laflamme et al. 2016):
Zebrafish were sacrificed by decapitation and whole brain tissue dissected out.
Tissue was immediately immersed in OCT Compound (Tissue-Tek) and frozen on
dry ice. If not processed immediately, samples were then stored in OCT Compound
at -80oC.
Tissue was cut on a cryostat at -20oC in 10µm sections and mounted on charged
(‘Superfrost ’) slides. If not used immediately after sectioning, slides were stored at
-20oC.
Sections were fixed in 4% paraformaldehyde (+50mM NaOH, in PBS) at room
temperature for 20 minutes, then washed in KPBS (22mM K2HPO4, 3.3mM
KH2PO4, 138.6mM NaCl) for 2 minutes. They were dehydrated in an ascending
ethanol series (50%, 70%, 100%) for 2 minutes each, then rehydration in a
descending ethanol series (70%, 50%) for 2 minutes each, and incubated in KPBS
for 2 minutes.
Slides were then incubated in 0.06% KMnO4 (in ddH2O) for 5 minutes at room
temperature, and rinsed in ddH2O for 1 min.
Sections were stained by incubation in 0.0004% Fluoro-Jade® B (+ DAPI, in
ddH2O) for 10 mins, rocking (agitating) at room temperature. They were then
rinsed in ddH2O for 1 minute (x3) and left to dry overnight.
The following day, slides were cleared in xylene for 2 minutes (x2), and coverslips
mounted using DPX.
2.26 Cloning into pCS2+
pCS2+ plasmid (Adgene) was transformed into competent cells and Maxiprepped
(as described in Sections 2.9 and 2.13). The resultant DNA was digested using
EcoRI restriction enzyme (New England Biolabs), in the following reaction (NB:
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desired genes - previously cloned into pGEM®-T Easy, as described in Section 2.16
- were digested in a parallel reaction):
Cutsmart®Buffer 5µl




Samples were mixed by pipetting and incubated at 37oC for ∼1 hour. The EcoRI
restriction enzyme was then heat-inactivated by incubation at 65oC for 20 minutes.
Linearised pCS2+ plasmid and gene sequences were electrophoresed through 1%
agarose gels, and extracted as described in Section 2.11. Genes were then inserted
into the linear pCS2+ by the following ligation reaction:
Reaction Buffer 2µl
Vector DNA xµl (50ng)
Gene insert xµl*
ddH2O (to 20µl)
T4 DNA Ligase 1µl
Total 20µl
*(3:1 insert:plasmid molecular ratio)
Samples were mixed by pipetting, then incubated at room temperature for 2
hours. Ligated gene fragments-pCS2+ were transformed into competent cells and
Maxiprepped as described in Sections 2.9 and 2.13, respectively.
2.27 Cloning into Tol2 expression vector
Following cloning into pCS2+ (as described in Section 2.26), gene-pCS2+ constructs
were sequenced (Eurofins Genomics) to confirm 5′ →3′ orientation. Gene fragments
were PCR-amplified off the plasmid, in the following reaction:
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Reaction mix:
Thermopol Buffer (10x) 2.5µl
dNTPs (10mM) 0.5µl
SP6 primer (forward) (10µM) 0.5µl






Initial denaturation 95oC 30 seconds
Denature 95oC 30 seconds
x35 cyclesAnneal 43
oC 1 minute
Extension 68oC 1.5 minutes
Final extension 68oC 5 minutes
Hold 4oC ∞
The gene sequences was then isolated by electrophoresis through a 1% agarose
gel and gel extraction (described in Section 2.11). The isolated genes were digested
with NotI (at 3′ of gene) in the following reaction:
Cutsmart®Buffer 5µl




Following restriction digestion, DNA was again isolated by electrophoresis
through a 1% agarose gel, before extraction as described in Section 2.11.
The double-UAS Tol2 vector was a kind gift from Masa Tada (UCL). This was
transformed into competent cells and Maxiprepped (as described in Sections 2.9 and
Ari Sudwarts 73
CHAPTER 2. GENERAL METHODOLOGY
2.13). The resultant plasmid was double-digested using EcoRV and NotI restriction
enzymes (New England Biolabs), in the following reaction:
Cutsmart®Buffer 5µl





Samples were mixed by pipetting and incubated at 37oC for 1 hour. The EcoRV
and NotI restriction enzymes were then heat-inactivated by incubation at 65oC for
20 minutes. The linearised plasmid was then isolated on a 1% agarose gel and
extracted as described in Section 2.11.
The gene sequences (blunt-ended at 5′, NotI sticky-ended at 3′ was ligated into
the linearised Tol2 vector (EcoRV blunt-ended at 3′, NotI sticky-ended at at 5′) in
the following reaction:
Reaction Buffer 2µl
Vector DNA xµl (50ng)
Gene insert xµl*
ddH2O (to 20µl)
T4 DNA Ligase 1µl
Total 20µl
*(3:1 insert:plasmid molecular ratio)
Samples were mixed by pipetting, then incubated at room temperature for 2
hours. Ligated gene-Tol2 constructs were transformed into competent cells and
Maxiprepped as described in Sections 2.9 and 2.13, respectively. Constructs were
then ethanol precipitated (as described in Section 2.15) prior to injection into
embryos.
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2.28 Generation of transposase mRNA
pCS2-TP was linearised using NotI restriction enzyme (New England Biolabs) in
the following reaction:
Cutsmart®Buffer 5µl




The reaction was mixed by pipetting and incubated at 37oC for 1 hour. The
digested plasmid was then PCR-purified, as described in Section 2.14.
Transposase mRNA was generated using a mMessage mMachine SP6
Transcription Kit (Ambion), according to the manufacturer’s instructions.




Reaction Buffer (10x) 2µl
Linear DNA template 3.2µl
Enzyme Mix 2µl
Total 20µl
The reaction was mixed by pipetting, then incubated at 37oC for 2 hours.
Following this, RNA was purified via phenol:chloroform extraction (reagents part
of the mMessenge mMachine SP6 Transcription Kit from Ambion).
115µl nuclease-free ddH2O and 15µl Ammonium Acetate Stop Solution were
added to the 20µl reaction, and mixed by pipetting. 150µl phenol:chloroform (1:1)
was added to the sample and mixed by pipetting. An additional 300µl chloroform
was added and mixed by pipetting. The aqueous phase was removed to a clean
sample tube.
RNA was precipitated using 1x volume isopropanol, mixed by pipetting, and
incubated at -20oC for 15 minutes. The sample was then centrifuged (full speed on
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a benchtop centrifuge) at 4oC for 15 minutes. The supernatant was discarded by
decanting and the RNA pellet re-suspended in 40µl ddH2O.
RNA concentration was determined as described in Section 2.3. RNA was then
aliquotted and stored at -80oC (long-term) or -20oC (short-term).
2.29 Injection calculations and methodology
Transgenic zebrafish lines were generated by combined injection of transgene-Tol2
constructs and transposase mRNA (both at 20ng/µl) in Danieau Buffer (58mM
NaCl, 0.7mM KCl, 0.4mM MgSO4, 0.6mM Ca(NO3)2, 5mM HEPES, pH 7.6) (e.g.
Kajita et al. 2010). A line expressing GAL4 in CNS neurons (driven by s1101t) was
a kind gift from Dr Tom Hawkins (UCL). The ‘pan neuronal ’ expression of GAL4
in this line was used to drive expression of the UAS-promoted transgene constructs
(generated as described in Section 2.27), as described previously (Arrenberg et al.
2010; Nevin et al. 2010).
A Picospritzer II (Parker) was used to control injection volumes, which were
calculated with a stage micrometer; a drop of mineral oil (∼5µl) was placed on the
scale of a the stage micrometer, and the Picospritzer pressure adjusted to produce
0.5nl per injection.
Adult zebrafish were ‘paired’ the evening before injection (usually 2x males
with 1x female), with a barrier separating the male and female fish. The following
morning, approximately 30 minutes after the room lights came on, the barriers
were lifted and the fish allowed to breed. Fertilised eggs were collected in a sieve
(to remove debris), aligned along an histology slide, and injected with 2x
Picospritzer injections (for a total injection volume of 1nl).
Following injections, embryos were placed in clean aquarium water and
incubated at 28oC. At approximately 3-dpf, carriers of the transgene were
identified by fluorescent expression, as described in Section 2.30.
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2.30 Identification of germ-line transgene carriers
Injected embryos were identified by expression of the mCherry at between 3- and
5-DPF. This demonstrated the insertion of the transgene into the genome. In order
to determine whether the transgene was expressed in the germ-line, these were
then crossed with the wild-type (s1101t-GAL4); those which produced fluorescent
offspring were thereby identified as expressing the transgene. The progeny of these
mCherry-expressing crosses were then reared and crossed to establish the line.
2.31 Microscopy
Imaging of Fluoro-Jade® B staining was conducted on a Leica DMRA2 fluorescent
microscope, using Velocity® 6.3 software (Perkin Elmer).
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CHAPTER 3. DEVELOPMENT OF AN AVERSIVE CLASSICAL
CONDITIONING ASSAY
3.1 Introduction
In order to facilitate lead identification (focussing on AD-related cognitive
impairment), the development of a behavioural paradigm was conducted. Due to
the high costs incurred using current rodent models and assay systems, the
intention of this development is for utility as a pre-mammalian screen in the
pharmaceutical industry. Thus, the behaviour must be robustly observed in
zebrafish, and relate to an impairment reported in clinical AD. This assay will
then be validated using neurotoxic and genetic models of neurodegeneration (see
chapters 4 and 5, respectively).
3.1.1 Neurodegeneration-related cognitive impairments
A range of behavioural impairments has been observed in AD patients. These
include cognitive deficiencies in episodic memory, visuospatial processing, choice
discrimination, reversal learning, and attention (e.g. Bäckman et al. 2001;
Freedman and Oscar-Berman 1989; Hodges and Patterson 1995; Mormino et al.
2009; Nasreddine et al. 2005; Ober et al. 1986; Prvulovic et al. 2002; Sahakian
et al. 1988). Whilst these behavioural deficits can themselves be related to specific
neuroanatomical structures and pathways, the identification and full
characterisation of pathogenic molecular dysregulations requires investigation
using genetically-manipulated animal models. Similarly, the subsequent screening
of pharmacological interventions requires the implementation of these animal
models in robust assays.
The transgenic expression of AD-related genetic mutations in rodents has been
shown to result in a range of cognitive deficits (discussed in Chapter 5). However
the measurement and assessment of these clinically-relevant behaviours in animal
models requires simplification of behavioural tasks to generate robust assays. For
example, spatial dysfunction is often assessed clinically by asking patients to draw
common objects (i.e. the clock drawing test ; see Agrell and Dehlin 1998; Brodaty
and Moore 1997; Esteban-Santillan et al. 1998; Sunderland et al. 1989). However
animal assays typically involve training, and the subsequent location and
discrimination of visuospatial stimuli (e.g. Cracchiolo et al. 2007; Huitrón-Reséndiz
et al. 2002; Nagahara et al. 2009). Whilst parallels can clearly be drawn between
certain aspects of research assays and clinical assessments, the functional
differences imply a disparity between the cognitive processes which govern these
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behaviours.
Additionally, the behavioural training in animal models of cognitive decline often
involves appetitive reward (e.g. Deacon et al. 2008; McDonald et al. 1994; McDonald
et al. 1996; Semina et al. 2015; Teather et al. 2002). This may present a problem
specific for models of AD developed around amyloid cascade hypotheses, due to
findings of lower body weight in transgenic mice expressing hAPP (Huitrón-Reséndiz
et al. 2002). Thus, the implication of reduced appetite in these models suggests a
reduction in incentive to perform in appetitive tasks. Further, findings that Aβ
expression alters olfactory circuitry suggests impairment to the sensory detection
of food reward (Cao et al. 2012). Thus it is possible that this impairment may
overshadow or accentuate cognitive deficits in transgenic amyloid animals, when
performing appetitive learning tasks.
In addition to lower body weight, it has been reported that both young and
old hAPP-expressing mice have lower core body temperatures (Huitrón-Reséndiz
et al. 2002). Interestingly, both body weight and core body temperature have been
associated with cholinergic function in the hypothalamus, which additionally receives
olfactory neuronal inputs (e.g. Grossman 1962; Henry 2007; Jo et al. 2005; Meister
2007; Myers and Yaksh 1969; Price et al. 1991a; Yamada et al. 2001). Thus it is
possible that transgenic hAPP expression causes early hypothalamic dysfunction.
Whilst the concept of hypothalamic dysfunction is an interesting area of research in
itself, it renders inferences of subtle cognitive dysfunction based on appetitive reward
assays difficult to interpret. Thus, simplistic cognitive measures (based on non-
appetitive tasks) may provide assays with higher validity than their more complex
counterparts.
However there are concerns as to the extent to which these measures actually
reflect cognitive function, with deficits not consistently reported between different
research groups (Karl et al. 2012). The superior performance of rats over mice in
water mazes has been attributed to their swimming ability (Lipp and Wolfer 1998).
Thus, conclusions drawn from these studies must take into regard the possibility
that experimental intervention may affect motor function and swim ability.
It must be noted that various non-cognitive abilities have been found to be
impaired in animal models of AD, including locomotion (see Harkany et al. 1998;
Pugh et al. 2007; Walker et al. 2011; Zheng et al. 1995), somatosensory ability
(adhesive removal / sticky-tape assay; see Sughrue et al. 2006; Xing et al. 2014;
Zhang et al. 2011), and exploration (open field assays; see Deacon et al. 2008;
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Harkany et al. 1998; Pugh et al. 2007; Semina et al. 2015). The lack of cognition
involved in these tasks reduces the time required for analysis, as no training /
conditioning is required. However, in the absence of a specific cognitive
impairment, it is difficult to associate these measures with a specific neurological
condition. For example, locomotor activity is affected in a rodent model of
schizophrenia, and has commonly been used as a measure of anxiety (Dawson
et al. 1995; Hikida et al. 2007). Adhesive removal assays have demonstrated
somatosensory impairment in rodent models of PD and cerebral ischaemia
(Goldberg et al. 2003; Komotar et al. 2007). Open field assays have also been used
as a measure of anxiety (Crawley 1985; Prut and Belzung 2003). In this regard,
the non-cognitive behavioural paradigms described above lack phenotypic
specificity to AD-related neurodegenerative pathologies.
Thus, the development of an efficacious drug-screening assay for
neurodegeneration requires assessment of a simplistic cognitive behaviour which is
conserved in zebrafish; the behaviour must be governed by well-defined structures
reported to be dysfunctional in neurodegenerative diseases, and require little
conditioning to achieve robust empirical measurement. In this regard, cued fear
conditioning appears to present the optimal candidate.
3.1.2 Neuroanatomy of classical fear conditioning
Cued fear conditioning can be divided into two sub-categories - “delay” and
“trace”. Both of these involve the pairing of a conditioned stimulus (CS) with an
unconditioned stimulus (US); however delayed fear conditioning involves the
co-termination of the CS and US, whilst trace fear conditioning involves a “trace”
period between the presentation of the two sitmuli - following CS but before US
(see Figure 3.1) (Curzon et al. 2009). Importantly, the insertion of a trace interval
results in the recruitment of additional neuroanatomical structures (see Figure
3.2).
fMRI studies have demonstrated the involvement of the amygdala in both delayed
and trace fear conditioning, in both rodents and humans (Büchel et al. 1999; Cheng
et al. 2003; Kochli et al. 2015). Further, research has implicated the lateral (lA)
and basolateral (blA) nuclei of the amygdala in fear conditioning, with the medial
(mA) nucleus playing a role in unconditioned fear responses (LeDoux et al. 1990;
Li et al. 2004; Quirk et al. 1995; Walker et al. 2005; see Fendt and Fanselow 1999).
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Figure 3.1: Delay vs Trace fear conditioning. During delay conditioning, the
US presented at the end of CS presentation, with both stimuli terminating together.
During trace conditioning, there is a ‘trace’ period between CS and US presentation,
during which no stimulus is presented
Additionally, the amygdala has been implicated in extinction of fear conditioning
(Knight et al. 2004).
However, whilst the amygdala is involved in both variations of cued fear
conditioning, hippocampal activity has been reported only in trace fear
conditioning (as well as non-cued contextual fear conditioning), in both
experimental animals and humans (Büchel et al. 1999; Clark and Squire 1998;
Marschner et al. 2008; Phillips and LeDoux 1992; Weiss et al. 1999).
Whilst the involvement of the hippocampus initially appears to be characteristic
of a distinct mode of fear conditioning, evidence suggests it is actually the result
of an increase in complexity of the conditioning (learning) task. By increasing the
complexity of delay conditioning, animal brains become reliant on the hippocampal
involvement (Beylin et al. 2001; Ivkovich and Stanton 2001). This demonstrates the
requirement for greater neuronal processing (and thus neuroanatomical involvement)
with increased complexity of cued conditioning.
Ari Sudwarts 82
CHAPTER 3. DEVELOPMENT OF AN AVERSIVE CLASSICAL
CONDITIONING ASSAY
Figure 3.2: Conservation of limbic system structures associated with
classical fear conditioning, in the human and zebrafish brain. Functions of
the amygdala and hippocampus in of the human brain (coronal and sagittal sections;
A & B, respectively) have been reported to be performed by the MP (/Dm) and
LP (/Dl) (respectively) of the zebrafish brain (coronal and sagittal sections; C & D,
respectively). (Images adapted from Buzzle.com® 2016; Mueller 2012; StudyBlue
2016)
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3.1.3 Zebrafish neuroanatomy
Zebrafish do not possess the aforementioned neuroanatomical structures that
govern fear conditioning in mammals (i.e. amygdalae and hippocampi). However,
as with other non-mammalian organisms, various pallial regions in the ray-finned
fishes (which include zebrafish and goldfish) have been associated with mammalian
cortical and subcortical structures. Of relevance to fear conditioning, the medial
(mP; termed Dm by Rupp et al.) and lateral (lP; termed Dl by Rupp et al.) pallial
divisions (see Figure 3.2) have been structurally and topographically parallelled
with the mammalian amygdalae and hippocampi, respectively (Braford Jr 1995;
Ganz et al. 2014; Mueller et al. 2011; Northcutt 2006; Rupp et al. 1996).
These neuronal structures have also been functionally associated with their
mammalian counterparts. Lesions speicific to the mP have been demonstrated to
impair avoidance learning (Portavella et al. 2004b). This behaviour is associated
with the mammalian amygdala (as elaborated on, above). Lesions specific to the
lP have been demonstrated to impair spatial learning (Portavella and Vargas 2005;
Vargas et al. 2006). This function has been associated with the hippocampus in
mammalian and bird brains, and the pallial function is conserved in reptiles and
fish (Morris et al. 1982; O’Keefe and Dostrovsky 1971; Olton et al. 1978a; Olton
et al. 1978b; Rodrıguez et al. 2002; see Burgess et al. 2002).
Interestingly, this pattern of impairment in pre-conditioning mP and lP lesions
(above) is mirrored when lesions are induced post-conditioning. Portavella and
colleagues reported that - in goldfish - whilst mP lesions (induced following
conditioning) affected the retention of both delay and trace fear conditioning, lP
lesions only affected retention of trace conditioning (Portavella et al. 2004a). Thus,
damage to these structures appears to affect retention (or recollection) of a
conditioned fear response.
To parallel this impairment of retention in fish with mammalian findings, in a
delay fear conditioning experiment in rodents, it was found that the frontal cortex
(FC) is involved in early consolidation of CS retention, whilst the parietal cortex
(PaC) is involved in both early and delayed consolidation (or possibly recollection)
(Sacchetti et al. 2003). Thus, it is possible that the teleost mP fulfills some of the
functions performed by the mammalian FC and PaC.
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3.1.4 Classical fear conditioning in relation to clinical and
experimental neurodegeneration
Evidence of impaired fear conditioning has been reported in several forms of
neurodegeneration. Here, it is necessary to review this literature, as an indication
of the potential research implications of an automated fear conditioning assay
(when employed with zebrafish models of neurodegeneration).
Aluminium neurotoxicity
The subject of Al toxicity in the CNS has been explored in relation to AD
neurodegeneration (see Bondy 2014; Bondy 2016; Doll 1993; Lidsky 2014). Whilst
the possible role of Al as a causative factor in AD is still contentious, it is well
accepted that Al does indeed induce neurotoxicity (e.g. Bondy 2014; Kumar and
Gill 2014).
Al treatment has previously been demonstrated to inhibit contextual fear
conditioning in rodents (Rizwan et al. 2016). However, as yet, there have been no
studies assessing this phenomenon in zebrafish. Thus, investigating the effect of Al
toxicity on fear conditioning (undertaken in Chapter 4) would indicate the efficacy
of zebrafish as a replacement (or pre-assessment) for rodent models.
Of neuroanatomical relevance, Al has been demonstrated to accumulate in the
amygdala, as well as various structures with efferent projections to the amygdala,
including the entorhinal cortex, substantia nigra, and hippocampus (Walton 2009).
Therefore, investigating the effects of Al toxicity on zebrafish fear conditioning
would indicate the conservation of neurotoxic mechanisms specific to these
structures. Additionally, this would provide a method of validating the assay
(developed in the current chapter) as a screen for neurodegeneration-related
impairment.
Alzheimer’s-like diseases
Impaired fear conditioning has been reported clinically in AD patients using both
delay and trace conditioning paradigms (e.g. Hamann et al. 2002; Hoefer et al.
2008; Woodruff-Pak and Papka 1996). Similarly, transgenic mice expressing mutated
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hAPP show impaired fear conditioning, which is somewhat attenuated by treatment
with a γ-secretase inhibitor (Barnes and Good 2005; Comery et al. 2005; Corcoran
et al. 2002).
Interestingly, Woodruff-Pak and Papka reported that delay fear conditioning is
in fact a more sensitive test in AD patients than trace fear conditioning (Woodruff-
Pak and Papka 1996). Thus the development of this type of assay may prove more
efficacious in relation to dementias of the Alzheimer’s type. Further, due to the lack
of hippocampal involvement in delay fear conditioning, it would provide a ‘cleaner’
assessment of amygdala (mP) functionality.
AD patients have been reported to present high levels of amygdala atrophy (Heun
et al. 1997; Lehericy et al. 1994; Poulin et al. 2011). This has also been reported in
AD patients with high CSF levels of Aβ42, and in patients expressing the late-onset
AD-related ApoE ε4 allele (Lehtovirta et al. 1995; Mattsson et al. 2014).
3.1.5 Aims
Classical aversion has previously been demonstrated in the zebrafish (Valente et al.
2012). Thus, the aim of this study is to replicate this finding, producing a scalable
optimised assay, suitable for use in screening (i.e. genetic and pharmacological).
This will be achieved by establishing the parameters which induce reproducible
aversive learning, whilst assessing the ability of zebrafish to retain a conditioned
response.
3.2 Methods
3.2.1 Equipment design and set-up
All specialist equipment was designed and constructed in collaboration with Zantiks
Ltd. (Cambridge, UK), and set up as shown in Figure 3.3.
Individual assay tanks measured 11cm x 20cm x 10cm (D x L x H). Electrodes
(stainless steel plates) were placed at adjacent ends of the tanks, to pass electric
current along the 20cm lengths of the tanks. The conductance of the aquarium
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Figure 3.3: Aversion assay setup. A LCD monitor was placed flat (face-up)
on a bench, with a transparent, infrared-emitting glass plate (Zantiks Ltd.) laid on
top. Multiple tanks were then placed on top of the plate, with stainless steel probes
at each end, connected to a bench-top power pack. An ethernet camera was hung
above the equipment, with an infrared filter covering the lens.
water used in the assay was measured and adjusted to 0.4mS/cm. The use of
an infrared-emitting transparent screen between the LCD monitor and tanks (in
combination with the infrared filter over the camera lens) allowed the subjects to
be detected and tracked over changing stimuli (presented on the LCD screen).
Stimuli used - presented in Figure 3.4 - were based on that adopted by Valente
and colleagues (Valente et al. 2012). Stimuli were presented through the bottoms
of the assay tanks. Both stimuli were presented during baseline and probe trials -
one stimulus to each half of the tanks (Figure 3.4 A&B). The whole of the tanks
were exposed to the CS and non-conditioned stimulus (non-CS) during conditioning
(Figure 3.4 C&D).
Behaviour was monitored using EthoVision XT 9 software (Noldus), and
extrapolated as time spent in area (for both CS and non-CS presenting areas) and
distance travelled in 30-second time bins.
Ari Sudwarts 87
CHAPTER 3. DEVELOPMENT OF AN AVERSIVE CLASSICAL
CONDITIONING ASSAY
Figure 3.4: Stimuli used for aversive classical conditioning. During baseline
and probe trials, both stimuli were presented - one to each side of the tanks
(counterbalanced; A & B). Preferences were recorded using EthoVision XT software.
During conditioning, CS and non-CS were presented to the whole of the tanks (C
& D).
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3.2.2 Assay design
The assay (including stimuli used) was designed based on a protocol developed by
Valente and colleagues (Valente et al. 2012). This involved four stages, conducted
in sequence, without any pause between them:
1. Habituation (30 minutes): Stimuli were presented via the LCD monitor,
using a Microsoft PowerPoint slideshow. Both stimuli were presented at the same
time - one to each half of the tank - by ‘splitting’ the slides. The side to which
each stimulus was presented was alternated every 5 minutes, allowing subjects to
habituate to the changing stimuli beneath the tanks. This presentation of both
stimuli is in-keeping with habituation protocols adopted in human fear conditioning
experiments (e.g. Hamann et al. 2002; Hoefer et al. 2008).
2. Baseline (30 minutes): The baseline trial was identical to the habituation
trial, except that the time spent in each area (i.e. swimming above each stimulus)
was recorded.
3. Conditioning (1.5 minutes): Conditioning involved the presentation
of the CS for 1.5 seconds, at the end of which the US (a 9V DC electric shock
lasting 80ms, unless stated otherwise) was delivered, the end of which coincided with
the termination of CS presentation. The non-CS was then presented (immediately
afterwards) for 8.5 seconds. This was repeated 9 times.
4. Probe (2 / 5 minutes): The probe trial involved both stimuli being
presented with a ‘split’ slide, as in habituation and baseline trials. In the voltage
range-finding and voltage titration experiments, the probe lasted 5 minutes, with
stimuli presentation switching after the first 2 minutes (see Figures 3.5 and 3.6,
below). Following the assessment of probe length (see Figure 3.7), a 2-minute probe
(in which the stimuli did not switch sides) was utilised.
3.2.3 Subjects
All animals used in this study were wild-type (Tubingen) adult zebrafish, between
three and six months post fertilisation. All animals were reared and housed as
described in Section 2.1.
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3.2.4 Data analysis
Data for time spent in area were then converted into CS-preference values (time
spent in CS-presenting area / total time subject was tracked), for each time bin,
using Micosoft® Excel® for Mac 2011.
Preference scores were then analysed using SPSS® Version 21 for Mac (IBM®).
Data were fitted to a linear mixed effects model, using preference for CS-presenting
area as the dependent variable, with trial (baseline or probe) as a fixed factor,
distance travelled as covariate, and subject ID number as a random effect. The
residuals of this model were plotted (SPSS Legacy Boxplot), and outliers removed
at 1.5x interquartile range (IQR). The linear mixed effects model was then run again,
without outlying data.
All post-hoc analyses were conducted using two-tailed t-tests, with Bonferroni
correction applied where necessary.
3.3 Assay development results
3.3.1 Voltage titration
In order to establish an US that delivered significant aversion, the voltage of electric
shock was titrated. Initially, a broad range-finding experiment was conducted to find
a ‘working range’ (see Figure 3.5). This indicated that 7V and 9V (DC) present
useful US in this assay.
Following the ‘range-finding’ experiment, the assay was repeated using the
range that appeared to produce significant CS aversion (7V, 9V and 12V). The
results of this titration experiment confirmed that 7V and 9V produced significant
aversion of the CS in the probe trial (see Figure 3.6A).. The effect sizes (Cohen’s
d) and number of subjects required for power were estimated using G*Power
software. These indicate that 9V produces the largest effect, with fewest subjects
required for power (Figure 3.6 B & C, respectively).
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Figure 3.5: Voltage range-finding. In order to determine a useful voltage, an
initial voltage range-finding experiment was conducted. This indicates that around
7V and 9V produced significant CS aversion (n=24). *, p<0.05; by two-tailed t-test.
Data plotted as mean ± SEM.
3.3.2 Probe length / extinction
Whilst the optimal voltage to use in the US had been determined (9V), the small
change in preference (approximately 0.5 in baseline trials vs approximately 0.4 in
probe trials) may be problematic in sample groups with higher variance in basal
preferences. Thus, the length of the probe trial was investigated to assess whether
higher aversion for the CS was observed during the initial 2 minutes (i.e. before the
stimuli presentation was switched). The results demonstrate that during the first
two minutes of the probe trial, significantly greater aversion of the CS was observed
than during the total 5-minute duration (see Figure 3.7). This effect was not related
to any change in distance travelled, demonstrating that the fish travelled the same
distances in each probe trial.
Subsequently, preference for the CS in the full (5-minute) probe was assessed
against time (see Figure 3.8 A). This initially suggested that CS aversion
extinguished over the course of the probe trial. However a significant difference
was found between Probe 1 (first 2 minutes) and Probe 2 (last 3 minutes) (Figure
3.8 B). Subsequent assessment of extinction over time during Probe 1 alone found
no significant effect (Figure 3.8 C).
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Figure 3.6: Voltage titration. Following the initial range-finding assessment,
a voltage titration experiment was conducted. This confirmed that 7V and 9V
produced significant US, as determined by CS aversion in the probe trial (A).
Estimates of effect sizes and n required for power indicate that 9V produces the
largest effect, with fewest subject required (B & C) (n=18). *, p<0.05; by two-
tailed t-test. Data plotted as mean ± SEM.
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Figure 3.7: Probe length. During the first two minutes of the probe - prior to
the ‘switching’ of the ‘split’ stimuli - greater CS aversion was observed than in the
total (5-minute) probe (n=27). *, p<0.05; **, p<0.01; ***, p<0.001; by two-tailed
t-test. Data plotted as mean ± SEM.
Ari Sudwarts 93
CHAPTER 3. DEVELOPMENT OF AN AVERSIVE CLASSICAL
CONDITIONING ASSAY
Figure 3.8: Extinction of conditioning. (A) Preference for the CS during the
probe trial was plotted against time, with the point at which stimuli presentation
was alternated indicated by the dashed vertical line. There was a significant
effect for time - F9,225.804=5.029, p<0.0005 - indicating that the conditioning was
extinguishing during the probe. (B) A comparison between Probe 1 (0-2 mins; prior
to alternation of stimuli presentation) and Probe 2 (2-5 mins; following alternation of
stimuli presentation) demonstrated a significant difference between these two trials
- F1,30.587=8.338, p=0.007. (C) Analysis of Probe 1 individually found no effect
for time - F3,70.239=0.327, p=0.806; (n=27). (D) No effect was found for distance
between the two probes - F1,32.07=0.11, p=0.742. Linear mixed effects model; ***,
p<0.001; by post-hoc two-tailed t-test. Data plotted as mean ± SEM.
Ari Sudwarts 94
CHAPTER 3. DEVELOPMENT OF AN AVERSIVE CLASSICAL
CONDITIONING ASSAY
Figure 3.9: Stimuli comparison. In order to confirm that neither of the stimuli
produced stronger aversive pairing, a comparison between the levels of aversion was
assessed. No significant difference was found between the two CS - F1,47=2.07,
p=0.157; (n=27). *, p<0.05; **, p<0.01; ***, p<0.001; by two-tailed t-test. Data
plotted as mean ± SEM.
3.3.3 Stimuli
Finally, in order to confirm that the CS used in the assay were unbiased, the level
of aversion produced by pairing each stimulus was compared (see Figure 3.9). No
significant difference was found between those subjects paired to the check stimulus
and grey stimulus.
3.4 Discussion
The aim of this chapter was to develop a reproducible, scalable fear conditioning
paradigm. This aim was achieved, with optimal aversion for the CS observed in the
first two minutes following 9V US, with no stimulus bias. The results presented here
demonstrate that zebrafish can be classically conditioned to avoid a CS in a reliable
manner. This is in support of previous findings (i.e. Valente et al. 2012).
The assay developed here was a simple delay fear conditioning paradigm. This
was chosen over a trace paradigm as it has been reported to be more specific to
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amygdala functioning (see Beylin et al. 2001; Büchel et al. 1999; Clark and Squire
1998; Ivkovich and Stanton 2001; Marschner et al. 2008; Phillips and LeDoux 1992;
Weiss et al. 1999). In light of findings that delay paradigms are more sensitive
measure of AD cognitive decline than trace paradigms, implementing this assay
using models of AD-related neurodegeneration appear the obvious choice for future
validation of this assay (Woodruff-Pak and Papka 1996).
Initial voltage range-finding and titration experiments demonstrated that a
9-volt US (passed between electrodes along 20cm aquarium water;
conductance=0.4mS/cm) produces the greatest aversion of CS in probe trials.
This is in-keeping with the US used previously by Valente and colleagues (Valente
et al. 2012).
Assessment of the length of probe found that greater CS-aversion was observed
during the first 2-minutes of the probe, prior to stimuli switching sides. Initially,
significant extinction was found over the duration of the total probe time. However
ad-hoc analysis of the two separate fractions of the trial - Probe 1 (0 - 2 mins); and
Probe 2 (2 - 5 minutes), with simuli switching between these two fractions - found a
significant difference between these two probe trials. As this effect was not related
to distance (with subjects moving approximately 200cm per 2-minute time bin in
each fraction of the probe), it is evident that this extinction was not an artefact of
‘freezing’ with CS presentation. Thus, the alternation of stimuli appears to have
induced extinction, with none occurring prior to this.
This suggests the possibility of retention over a longer period of time. From a
purely academic point of view, this would be an interesting follow-up study; to assess
the length of retention in comparison to other species. However as the purpose of this
assay was for use in pharmaceutical screening, the robust, time-efficient nature of the
two-minute probe trial (Probe 1 ) was deemed sufficient and no further development
was undertaken at this point. (However further investigation was undertaken in the
development of a drug discrimination assay; see Chapter 7).
No difference was found between subjects conditioned to either CS,
demonstrating the unbiased nature of conditioning to these stimuli. In this regard,
it should be mentioned that the two patterned stimuli were preferred to coloured
stimuli as zebrafish have been shown to bias certain colours (Avdesh et al. 2010).
Whilst it is possible to use unbiased colours, the possiblity of individual differences
in colour preference could increase variability of baseline recordings. Thus, the
patterned stimuli used here were based on those used previously (Valente et al.
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2012).
With regard to data analysis, it was noticed that some zebrafish displayed
freezing/darting behaviour following conditioning. This was observed to be
irrespective of independent variable control (as reported previously; see Parker
et al. 2012b). It is likely that this effect is due to variations in stress responding,
following administration of the US. However, due to the stressful nature of the
conditioning paradigm, these behaviours may be expected. In this regard, the
exclusion of fish which display these erratic patterns of locomotion is likely to
exclude true data points. However, this behaviour must be addressed in the
statistical model to account for variance caused by this stress-related behaviour on
conditioned learning. Thus, Distance (cm) was factored in to the mixed effects
model as a covariate.
With practical relevance to translational applications, the development of this
time-efficient, robust screening assay would facilitate disease research into disorders
which affect the neuroanatomical structure(s) that govern this behaviour (i.e. the
amygdala).
Due to the robust findings of impaired amygdala function and delay fear
conditioning in AD patients and models, the current assay is likely to be useful in
assessing genetic and toxicological factors in AD (and subsequently as a
pharmaceutical screen).
In summary, the aim of developing a robust, automated assay of simple cognitive
function has been achieved. However it is now necessary to validate the assay






CHAPTER 4. ALUMINIUM NEUROTOXICITY
4.1 Introduction
Whilst the development of a robust aversive classical conditioning assay has been
achieved (see Chapter 3), its utility as a screening tool for
neurodegeneration-associated cognitive decline requires further validation. In order
to achieve this, the consequences of pre-treatment with the neurotoxin Al was
investigated. In this regard, assessing molecular dysregulations will indicate
mechanisms of Al neurotoxicity, with a focus on genes related to AD. Additionally,
this will provide an indication of the utility of zebrafish in these two areas of
research (i.e. Al neurotoxicity and AD). Subsequently, behavioural assessment
using the classical fear conditioning paradigm will indicate the cognitive
consequences of Al toxicity, whilst additionally providing a validation of the assay
in neurodegeneration-related behavioural research.
Al is an extremely abundant element in Earth’s environment, and the second
most abundant metal found in urban soils (Alekseenko and Alekseenko 2014). The
World Health Organisation reported that human exposure from dietary consumption
is between 2.5-13mg per day (Habs et al. 1997). Al is included in antiperspirants
(amongst other cosmetic products), through which it has been associated with breast
cancer (Darbre 2003; Darbre 2005). Additionally, it is a common ingredient in
antacids, with GI absorbance increased by acidic dietary components (i.e. orange
juice, citric acid) (Fairweather-Tait et al. 1994; Weberg and Berstad 1986).
4.1.1 Aluminium neurotoxicity
Al is well established as a neurotoxin which enters the CNS, exerting a multifaceted
degenerative action on neurons:
Approximately 90% of Al in human uremic serum (pH 7.4) binds to transferrin,
which is the only serum protein found to bind the metal (Cabezuelo et al. 1997).
Transferrin’s ability to transport molecules (including drug compounds) across the
BBB suggests that it actively facilitates the otherwise passive diffusion of Al into
the brain (Edwardson et al. 1992; Pardridge et al. 1991; Roskams and Connor
1990; Ulbrich et al. 2009). After crossing the BBB, Al accumulates in various
neuroanatomical structures (many associated with AD; i.e. hippocampus,
entorhinal cortex, temporal cortex), including the amygdala (which is central to
fear conditioning, as discussed in Section 3.1.2; see Walton 2009; Ward et al. 2001).
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Rodent studies have shown that, within minutes of (intravenous) Al exposure,
the brain extracellular fluid : blood ratio reaches 0.2, which appears to be maintained
thereafter (see Yokel 2002). The ionic species of Al in solution varies, depending
pH, with high levels of Al(OH)3 at pH 7 (Achak et al. 2008). Al(OH)3 has been
shown to be neurotoxic in rodents, and its inclusion in vaccines has been associated
with increased neurological disorders (Petrik et al. 2007).
The mechanisms by which Al induces neuronal death have received notable
attention. In contemplating this wealth of research, there appears to be two main
cellular mechanisms of neurodegenerative signalling - mitochondrial dysfunction
and ER stress (e.g. Savory et al. 2003; see Figure 4.1). However there still remains
an ambiguity surrounding the relationships between these mechanisms.
Al has been found to interfere with the functioning of Na+/Ca2+ exchangers,
resulting in an increase in cytoplasmic Ca2+, which subsequently accumulates in
mitochondria (Szutowicz et al. 1998). Elevations in cellular Ca2+ have been
demonstrated to result in increased generation of ROS by activation of the
respiratory chain (Castilho et al. 1995; Hansson et al. 2008; see Starkov et al.
2004). This, in turn, leads to the secretion of cytochrome c from mitochondria,
which forms a complex with apoptotic protease activating factor (APAF)-1 (in the
cytoplasm) and subsequently triggers apoptosis via a caspase signalling cascade
(Ghribi et al. 2001b; Savory et al. 2003).
Additionally, Al has been demonstrated to induce ER stress (e.g. Rizvi et al.
2014). Whilst the precise mechanism by which Al induces this is undetermined, it
has been reported that Al causes downregulation of GRP78 (Rodella et al. 2008).
Under ‘normal’ conditions, GRP78 is bound to the three unfolded protein response
(UPR) proteins (PERK, IRE1, ATF6), inhibiting their action; when unfolded
proteins build up inside the ER, GRP78 dissociates from the UPR proteins and
binds these unfolded polypeptides (see Basha et al. 2012; Szegezdi et al. 2003).
Thus, under-expression of GRP78 suggests a dysregulated increase in UPR
signalling. In addition to the UPR proteins, GRP78 binds to caspase-7 and
caspase-12, inhibiting their (apoptotic) consequenses (Momoi 2004; Reddy et al.
2003). Thus the down-regulation of GRP78 suggests an increase in the activities of
these caspases. Aluminium has also been shown to increase expression of
caspase-12, triggering an increased mode of apoptosis by its subsequent activation
of caspase-9 (Morishima et al. 2002; Rizvi et al. 2014).
Al exposure has been shown to result in the translocation of both NF-κB and
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CHAPTER 4. ALUMINIUM NEUROTOXICITY
GADD153 transcription factors to the nucleus (Ghribi et al. 2001a). NF-κB has a
complex role in inflammatory signalling, the extent of which is still uncertain (see
Lawrence 2009). GADD153 has been shown to down-regulate the antiapoptotic
BCL-2, sensitising cells to ER stress (Ghribi et al. 2001b; McCullough et al. 2001).
BCL-2 exerts its antiapoptotic function by inhibiting the translocation of apoptotic
inducing factor (AIF) from mitochondria to the nucleus (Daugas et al. 2000).
Thus, the reported Al-induced mitochondrial clustering and translocation towards
the nucleus suggest a facilitation of AIF’s nuclear translocation and subsequent
apoptotic function (Dewitt et al. 2006). However, as both NF-κB and GADD153
regulation is controlled by mitochondrial ROS, it is possible their consequential
molecular dysregulations are actually secondary to mictochondrial dysfunction
(Carrière et al. 2004; Gloire et al. 2006).
Thus, regardless of the specific molecular mechanisms which apparently facilitate
it, there is confirmative evidence of Al-induced neurotoxic signalling.
4.1.2 Disputed role in Alzheimer’s-like pathologies
As alluded to previously (Section 3.1.4), Al accumulates in neuroanatomical regions
associated with AD neurodegeneration (e.g. Walton 2009). However, the potential
role of aluminium in AD aetiology is somewhat controversial.
Whilst there is clearly a large genetic component to AD, some level of
environmental interaction is clearly also involved. An early twin study revealed
that genetics alone are an insufficient predictor of AD, with only around 40%
concordance in both monozygotic and dizygotic twins (Nee et al. 1987).
Subsequent twin studies have placed the concordance at 19-21% and 5-11% for
monozygotic and dizygotic twins (respectively), with only 50% concordance in
relation to the presence of the ApoE ε4 allele (Breitner et al. 1995; Räihä et al.
1996). Thus, whilst genotype clearly has a strong implication in these diseases, it
is far from sufficient to holistically explain their pathogeneses.
Geographical studies have associated areas containing high concentrations of
Al in drinking water, with increased instances of AD (e.g. Gauthier et al. 2000;
Martyn et al. 1989; McLachlan et al. 1996). Similarly, Al exposure has been reported
to induce phenotypes associated with AD pathology, in both clinical findings and
laboratory animals.
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However, the concept of Al as a causative or triggering factor in AD remains
controversial. Dialysis encephalopathy results from insufficient removal of Al from
the blood of dialysis patients, resulting in its accumulation in grey matter of the
brain (Alfrey et al. 1976; McDermott et al. 1978). However, despite causing atrophy
and cognitive impairments, the pathology of dialysis encephalopathy patients has
been found to be distinct from that of AD patients (e.g. Shirabe et al. 2002). This
disparity relates to the distinct molecular dysregulations between Al toxicity and
AD, demonstrating that Al (at least independently) is insufficient to induce AD:
Early findings suggested that Al induces neither tau phosphorylation, nor its
subsequent formation of paired helical filaments (PHF) (despite inducing
aggregation) (Scott et al. 1993; Shea and Husain 1995). It has since been found
that Al-induced NFT do contain hyperphosphorylated tau, with its expression
found both in dialysis patients and in experimental animals (Harrington et al.
1994; Savory et al. 1995; Singer et al. 1996). However the inability of Al to induce
PHF formation remains a difficulty for advocates of Al as a factor in AD aetiology.
Additionally, a lack of direct biophysical interaction between Al accumulation
and Aβ plaques has been reported (Harrington et al. 1994; Landsberg et al. 1992).
However, it may not be necessary for this neurotoxin to interact biophysically with
amyloid. For example, an upstream dysregulation of either transcriptional control
or molecular signalling may result in amyloid aggregation. Additionally, inhibition
of proteases involved in the breakdown of amyloid peptides could induce much the
same pathology. Thus a lack of direct interaction between Al and amyloid does not
necessarily imply a lack of associated dysregulation.
Findings that Al in the brain increases with age demonstrates the accumulation of
this neurotoxin (McDermott et al. 1979). However, no difference was found between
the Al content of AD brains and age-matched controls (McDermott et al. 1979;
Shore and Wyatt 1983). This suggests that, whilst Al may not be an independent
causative factor in AD aetiology, it may be a facilitating factor in individuals with
genetic vulnerability.
Whilst the concept of Al as a causative factor in AD remains controversial, it
clearly disrupts signalling in pathways associated with AD. Thus, these molecular
mechanisms affected by Al toxicity must be evaluated in relation to known AD
signalling pathways, to assess its validity as a toxic model of neurodegeneration-
related cognitive decline.
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Molecular dysregulation
Tau is a MAP, facilitating tubulin’s formation of microtubules and stabilising them
(Weingarten et al. 1975; see Gong and Iqbal 2008). Tau is post-translationally
modified; it is phosphorylated by GSK3β or Cdk5 (when in complex with its
regulator) and dephosphorylated by phosphatases; notably PP2A (e.g. Sontag
et al. 1996; see Stoothoff and Johnson 2005; Walton 2013). Hyperphosphorylation
of tau has been associated with the formation of PHF in AD, resulting in NFTs
(Bancher et al. 1989; Grundke-Iqbal et al. 1986; Morishima-Kawashima et al.
1995).
Some amyloid cascade hypotheses have pointed to the activation
(phosphorylation) of GSK3β by Aβ (see Figure 4.2; Kremer et al. 2011; Pei et al.
2008; Terwel et al. 2008). However PP2A expression has been reported to be
decreased in AD brains, suggesting a mechanisms of impaired dephosphorylation
(rather than only hyperphosphorylation) (Vogelsberg-Ragaglia et al. 2001). In this
regard, Al has been found to impair PP2A activity (Walton 2007; Yamamoto et al.
1990). Further, there is evidence that chronic Al exposure in humans results in
AD-like brain pathologies, increased phosphorylated tau and cognitive decline
(Harrington et al. 1994; Lu et al. 2014). Thus, whilst the effects of Al exposure on
tau processing may not entirely resemble that of AD (i.e. a lack of evidence for
increased GSK3β), it appears to affect a related pathway.
In addition, there are parallels between Al exposure and AD in the form of other
molecular dysregulations. A preliminary study by Lukiw and colleagues found that
∼71% of genes highly dysregulated (≥3-fold mRNA change) in AD are also affected
by in vitro Al exposure (Lukiw et al. 2005). This includes the APP gene, which is
highly associated with AD pathologies.
A protein up-regulation of APP has been reported in vivo in rodents treated
with Al (e.g. Li et al. 2012). An extensive study by Wang and colleagues found
that the expression of several genes commonly associated with AD are affected - at
protein expression level - in Al-treated rats (Wang et al. 2014). The authors
reported increases in APP, BACE1 and subunits of γ-secretase (i.e. PS1, NCT), in
the hippocampi and cortices. Additionally, they reported decreases in some genes
of the a disintegrin and metalloproteinase (ADAM) gene family in hippocampi
(ADAM9, ADAM10, ADAM17) and cortices (ADAM10, ADAM17). These
α-secretase enzymes cleave APP within the Aβ peptide region, inhibiting the
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Figure 4.2: Effects of aluminium on the phosphorylation of tau. Tau is
phosphorylated by GSK3β (a mechanism instigated by Aβ), and dephosphorylated
by PP2A. Aluminium has been shown to decrease PP2A activity, suggesting that
its facilitation of tau phosphorylation results from inhibition of dephosphorylation.
(Yellow text on red background, neurodegenerative effect; white text on blue
background, neuroprotective effect)
production of Aβ (non-amyloidogenic pathway). This increase in substrate (APP)
and enzymes in the amyloidogenic pathway (BACE1 and γ-secretase), coupled
with inhibition of the non-amyloidogenic enzymes (ADAM), resulted in increase
cleavage of Aβ peptides (see Figure 4.3 for mechanisms of APP metabolism).
Interestingly, the authors only found an increase in cleavage of the highly-toxic
Aβ42 peptide, not the relatively untoxic Aβ40 peptide (e.g. Wang et al. 2014; see
Dahlgren et al. 2002). This suggests that Al affects the modulation of γ-secretase
binding to / cleavage of APP, likely by affecting allosteric regulation, as reported to
occur in other pharmacological interventions which affect the species of Aβ peptides
produced (e.g. Shelton et al. 2009; Takeo et al. 2014).
In addition to (and likely resulting from) the up-regulation of innate
AD-related genes, transgenic mice (expressing hAPP) exposed to high dietary Al
have been reported to display increased expression of both Aβ40 and Aβ42 (i.e.
increased transgene cleavage) (Praticò et al. 2002). This resulted in increased
plaque formation, demonstrating that Al dysregulation affects cleavage of
transgenic hAPP processing.
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Figure 4.3: APP metabolism by secretase enzymes. In relation to AD
pathologies, APP is generally regarded as being processed by one of two pathways.
In the ‘amyloidogenic pathway ’, β-secretases (e.g. BACE1) cleave at a specific site
(β site) of the protein, releasing a soluble fragment (s-APPβ) from the N-teminal.
The remaining transmembrane C-terminal fragment is subsequently cleaved by γ-
secretase in one of several neighbouring sites, releasing an Aβ peptide between 39-
42aa long. In the ‘non-amyloidogenic pathway ’, α-secretases (ADAM genes) cleave
at a specific site (α site) of the APP protein, releasing a longer soluble fragment
(s-APPα) from the N-terminal. As the α site is located within the region of the Aβ
peptide, this peptide is not released by the subsequent γ-secretase cleavage of the
transmembrane C-terminal fragment. (Image from Zhang and Saunders 2009).
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Whilst an Al-induced up-regulation of APP has been reported in vivo at a protein
level, it is unclear whether this results from modulation of gene transcription. The
only study to investigate the effects of Al on APP mRNA expression reported only
preliminary data from a microarray study, which has yet to be replicated (Lukiw
et al. 2005). Additionally, this study was conducted using primary culture, rather
than in vivo. In this regard, there are clear disparities between the effects of Al in
vivo and in vitro. For example, Al has been repeatedly demonstrated to induce cell
death (apoptosis) in vivo (e.g. Prakash and Sudhandiran 2015). However an in vitro
study found no effect of Al (up to 300µM) on cell survival in a neuroblastoma cell
culture, in the absence of a synthetic Aβ peptide (Castorina et al. 2010). Further, as
astrocytes are known to express APP, it is difficult to draw confirmative conclusions
from in vitro studies in which neurons are cultured in the absence of glia. Thus, the
effects of Al on the transcriptional regulation of APP in vivo are, as yet, unknown.
Similarly, the aforementioned finding of increased BACE1 protein expression is
unconfirmed in vivo at a transcriptional level (Wang et al. 2014). One in vitro
study reported a mRNA up-regulation of BACE1 following three hours of Al
exposure, suggesting this may be a useful period of treatment (Castorina et al.
2010). However the effect was preceded (one hour following incubation) and
succeeded (from 12 hours following incubation) by down-regulations. This delay
may indicate that the reported up-regulation might not be in direct response to
Al, but rather a result of an underlying primary dysregulation (i.e. APP
up-regulation, Ca2+ dysregulation, mitochondrial dysfunction, ER stress), which
results in an increase in BACE1 transcription. Thus, in vivo data is required to
confirm the aforementioned in vitro study.
γ-secretase is a protease complex, formed of four subunits - presenilin (either
PS1 or PS2), NCT, APH1, and PEN1 (see Newman et al. 2011; Wolfe 2008). Thus,
the reported Al-induced up-regulation of PS1 and NCT has potential implications
for the functionality of the γ-secretase complex (Wang et al. 2014).
However, γ-secretase has roles distinct from APP metabolism. For example, it
has been demonstrated to cleave other transmembrane proteins (including Notch)
and module Ca2+ signalling (e.g. De Strooper et al. 1999; Shideman et al. 2009).
Interestingly, high expression of both presenilin subunits (PS1 and PS2) has been
reported in mitochondria-associated membranes (MAM) (a membranous interface
between mitochondria and ER), as has γ-secretase activity (Area-Gomez et al. 2009).
Further, PS2 (but not PS1) has been demonstrated to facilitate mitochondrial Ca2+
influx by increasing MAM associations (Zampese et al. 2011a; Zampese et al. 2011b).
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Thus, given the aforementioned Al-induced Ca2+ dysregulation in both mitochondria
and ER (see Section 4.1.1), it seems likely that γ-secretase dysfunction plays a role
in this.
Regardless of γ-secretase’s role in Ca2+ signalling, it’s high expression in
MAMs suggests cleavage of APP in this cellular region. Indeed, high levels of Aβ
peptide production (i.e. secretase cleavage of APP) has been reported in MAMs
(Schreiner et al. 2015). In this light, the aforementioned extensive reporting of
both mitochondrial dysfunction and ER stress (in both Al toxicity and AD) may
be linked by processes of amyloid metabolism in the MAM. Further, this presents
another molecular mechanism of cellular dysfunction linking Al toxicity and AD.
However, given the likelihood of allosteric regulation, as well as the distinct
functions of the individual subunits, assessment of gene expression will likely be an
insufficient indication of γ-secretase functionality. Thus, expression of these genes
will not be assessed in the present study.
The long-term purpose of the behavioural (classical aversion) assay - developed
in Chapter 3 - is to identify neuroprotectant compounds and neuroprotective
mechanisms. A strong candidate for investigation in this area is the function of
PIN1:
PIN1 has been shown to inhibit aggregation of Aβ peptides, as well as
hyperphosphorylation of tau, and GSK3β activity (Bulbarelli et al. 2009; Kimura
et al. 2013; Lu et al. 1999; Ma et al. 2012; Pastorino et al. 2006). (Additionally,
impaired PIN1 function has been reported in AD patient brains, although no
genetic mutation was found to be associated with the disease (Maruszak et al.
2009; Sultana et al. 2006)).
There is evidence that Al induces a change to the secondary structure of PIN1,
causing α-helices to change into β-sheets (Wang et al. 2013). In this regard, as
the functionality of PIN1 was reported to be inhibited, it is possible that an up-
regulation occurs to enhance the neuroprotective mechanism. Alternatively, it is
equally likely that the neurotoxic action of Al is facilitated by a down-regulation
of PIN1. Thus, the regulation of this gene is of interest for both these modes of
neurodegeneration.
Thus, in light of the objective to identify neuroprotective mechanisms, the
assessment of PIN1 activity (following Al exposure) would provide an indication of
potential disruption to this pathway. The signalling pathway proposed for
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Figure 4.4: Aluminium dysregulates AD-related genes and disrupts
neuroprotective signalling. Aluminium exposure increases the protein expression
levels of both APP and BACE1. It has also been demonstrated to affect the
secondary structure of PIN1, converting α-helices into β-sheets. This, in turn,
disrupts the neuroprotective consequences of PIN1 signalling (i.e. inhibition of
Aβ aggregation and dephosphorylation of tau). (Yellow text on red background,
neurodegenerative effect; white text on blue background, neuroprotective effect;
ˆrg, up-regulation; 2o α > β, protein secondary structure change from α helix to β
sheet)
investigation (see Figure 4.4) involves two genes commonly associated with the
amyloidogenic pathway of AD - namely APP and BACE1 (zebrafish appb and
bace1 ). qPCR will be conducted to assess whether previous reports of Al-induced
protein up-regulations of these genes are transcriptionally modulated. It is
therefore hypothesised that mRNA expression of these two genes will be increased
following Al exposure. Additionally, the effect of Al on PIN1 transcription will be
assessed, as an indication of whether this neuroprotective pathway is affected. This
may manifest as a protective up-regulation (in response to APP and BACE1
expression), or as a degenerative down-regulation (possibly as a direct result of Al
exposure). Thus, a two-tailed hypothesis is proposed - that PIN1 expression will
be affected by Al. Together, these data are intended to provide evidence of
Al-induced molecular dysregulation, and an insight into an affect on a
neuroprotective mechanism.
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Neuroanatomical accumulation and behavioural phenotypes
Al has been reported to accumulate in various regions - both in humans and
experimental animals - with highest levels detected in the hippocampus
(McDermott et al. 1979; Yuan et al. 2012). Interestingly, the regions which
accumulated Al in rats were also found to contain higher products of lipid
peroxidation, supporting links between Al exposure and oxidative stress (Yuan
et al. 2012). Mice exposed to Al have demonstrated decreased spatial memory
function, measured by perfomance in a water maze (Kaneko et al. 2006). With
regard to human exposure, ex-workers who had been exposed to Al dust (at an Al
melting plant) over the course of their careers were found to perform poorly in a
range of cognitive tests (compared to controls) ten years after retirement (Polizzi
et al. 2002).
As the amygdala has been found to accumulate Al, it seems likely that toxicity
would result in impaired performance in the classical aversion assay (Developed
in Chapter 3) (Walton 2009). Indeed, it has also been reported that Al-treated
mice display impaired fear conditioning (Hashmi et al. 2015). Interestingly, this was
found to be ameliorated by non-steroidal anti-inflammatory drugs (NSAID), which
are also believed to protect against AD progression in arthritic patients, as well as
rodent models of AD (e.g. Heneka et al. 2005; Lim et al. 2000; Lim et al. 2001;
Myllykangas-Luosujärvi and Isomäki 1994; Rogers et al. 1993).
4.1.3 Aims
The initial aims of this investigation are to establish whether Al toxicity induces a
transcriptionally-regulated change in expression of zebrafish appb, bace1 and pin1.
This will test the hypothesis that Al exposure affects the expression of genes
associated with neurodegeneration. Additionally, an attempt will be made to
qualitatively assess whether this results in neuronal apoptosis within the zebrafish
amygdala-like structure - the Dm (mP). Finally, cognition (in relation to Dm
functionality) will be assessed using the classical aversion assay, as developed in
Chapter 3. This will test the hypothesis that Al toxicity induces impairment to
classical fear conditioning.
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4.2 Methods
4.2.1 Subjects
Wild-type (TU) adult zebrafish were bred and reared in our facility, as described
previously (e.g. Parker et al. 2012b). Fish were housed in groups of 30, in ∼28oC
water, on a 14h:10h light:dark cycle. Fish were transferred to the room where
behavioural experimentation was conducted at least 24 hours prior to
experimentation. All experiments were conducted in accordance with the Animals
(Scientific Procedures) Act, 1986, under license by the Home Office (UK).
4.2.2 Aluminium exposure
Zebrafish were individually exposed to aluminium chloride (AlCl3) for 3 hours, at
doses stated. This length of time has previously been demonstrated to be sufficient
to cause a mRNA up-regulation of both appb and bace1 in zebrafish (Nik et al.
2012).
4.2.3 qPCR
Zebrafish were sacrificed by decapitation, brain tissue dissected out and frozen
immediately on dry ice. Total RNA was extracted, DNAse-treated and reverse
transcribed, as described in Sections 2.2 and 2.4.
Standard curves were loaded on each plate from PCR samples of known fragment
concentrations, as determined using Avogadro’s constant. Fragment numbers in test
samples were determined by the qPCR machine (BioRad CFX Connect) from the
Cq values, based on the standard curves.
Regarding post-hoc testing; for appb and bace1 expression analyses, one-tailed
t-tests or one-sided Dunnett’s tests were conducted (as indicated). This is due
to the previous evidence demonstrating an AlCl3-induced up-regulation for these
genes at the protein level; (e.g. Wang et al. 2014). Thus, should down-regulations
be detected, this would be regarded as an feedback from high protein expression
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(i.e. homeostatic dysregulation caused by inhibition of proteolytic breakdown of
the relevant protein). For pin1 expression, two-tailed t-tests or two-sided Dunnett’s
tests were conducted (as indicated). This is because of the lack of previous evidence
indicating a possible direction of dysregulated expression.
4.2.4 Fluoro-Jade® B staining
Zebrafish were treated with 100µM AlCl3 for three hours, then allowed to recover
for one hour. This ‘recovery period’ was intended to replicate the habituation (30
minutes) and baseline (30 minutes) periods of the classical aversion assay, during
which they were not exposed to Al. Fish were then sacrificed by decapitation, brain
tissue was dissected out, and frozed immediately in OCT compound, on dry ice.
Brains were cut at -20oC, in 10µm sections. Slides were then stored at -20oC,
until processing.
Fluoro-Jade® B was purchased from Millipore, and slides stained as described
in Section 2.25.
4.2.5 Classical aversion assay
The classical aversion assay was conducted as developed and described in Chapter
3, using 2-minute probes.
Subjects were treated in aquarium water containing AlCl3 (at the doses stated)
for three hours. Subjects were then netted into assay tanks (which did not contain
AlCl3), and assayed immediately.
As discussed in Section 3.4, Distance travelled was factored into the mixed effects
statistical model as a covariate, to account for any variance caused by differences in
locomotion.
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Figure 4.5: Stability of housekeeping genes. qPCR data were entered into the





qPCR was undertaken to assess transcriptional regulation of gene (appb, bace1,
and pin1) expression, following acute aluminium exposure. Zebrafish were exposed
to AlCl3 for three hours, as this exposure time has previously been found to be
sufficient for Al-induced transcriptional dysregulation (Castorina et al. 2010). If not
sacrificed immediately, fish were placed in a recovery tank for the period of time
specified.
Determination of stable house-keeping gene
qPCR amplification was conducted on three housekeeping genes - β-actin, gapdh,
rpl13α (in tandem with experimental genes).
Gene stability was calculated using the ‘RefFinder ’ online tool (Lab 2016). This
tool integrates multiple algorithms which assess gene stability, assigning a stability
value based on these outputs (Xie et al. 2012). The results demonstrate that rpl13α
was most stably expressed in the experimental conditions (see Figure 4.5). Thus,
experimental genes were normalised to rpl13α in subsequent AlCl3 experiments.
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Effects of acute AlCl3 exposure (100µM) on gene expression
The expression levels of appb, bace1 and pin1 were assessed following acute exposure
to AlCl3 (100µM). Results (see Figure 4.6) found no transcriptional up-regulation
of appb or bace1 (p = 0.33 & 0.098, respectively; by one-tailed independent t-tests).
Whilst the up-regulation of pin1 failed to reach significance, the effect may be viewed
as marginally significant (p=0.06; by two-tailed independent t-test). In light of this,
power analysis was conducted (using G*Power version 3.1 software) for pin1 data.
This estimated that 24 subjects would be required in total (12 per group), indicating
that the study may have been under-powered.
Prolonged effects of AlCl3 (100µM) on gene expression
The prolonged effects of AlCl3 exposure on gene expression were determined at 30
minutes and 60 minutes post exposure (to coincide with initiation of baseline and
conditioning in the classical aversion behavioural assay). Results are presented in
Figure 4.7. No effect was found for appb expression (p=0.849). A significant up-
regulation was found for bace1 expression (p=0.006) at 60 minutes post exposure.
The ANOVA model for pin1 expression failed to reach significance (p=0.06); however
a significant up-regulation was detected post-hoc at 30 minutes post exposure, which
had attenuated by 60 minutes.
Dose-dependent effects of AlCl3 on gene expression at one hour following
treatment
In order to confirm the effects of AlCl3 on gene expression at one-hour post
exposure, dose-response effects were assessed by simple linear regression (see
Figure 4.8). The up-regulation of appb failed to reach significance (p=0.052). A
significant up-regulation was found for bace1 expression (p=0.041). No effect was
found for pin1 expression (p=0.305).
Dose-dependent effect of AlCl3 on dapk1 expression
Whilst no effect was found for pin1 expression in the previous experiments, it was
subsequently hypothesised (ad-hoc) that dapk1 expression would be affected. This
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Figure 4.9: Dose-dependent effect of AlCl3 on dapk1 expression at
one hour post exposure. A significant up-regulation was found (F1,20=5.162,
p=0.035). By simple linear regression. Data plotted as raw values (A) and mean ±
SEM (B).
is due to findings that dapk1 inhibits pin1, inhibiting its neuroprotective functions.
Thus, in light of the failure to trigger pin1 ’s neuroprotective signalling, it was
hypothesised that Al may induce neurodegenerative signalling via pin1 inhibition.
In this regard, preliminary data suggests a significant up-regulation of dapk1
(p=0.035)
4.3.2 Neurodegeneration
In order to qualitatively associate AlCl3 toxicity with neurodegeneration, Fluoro-
Jade® B staining was conducted on telencephalic sections (which include the relative
pallial divisions; see Figure 3.2) of the zebrafish brain. Zebrafish were treated with
100µM AlCl3 for three hours, then placed in a recovery tank for one hour, before
being sacrificed.
Results are presented in Figure 4.10 (larger images in Section 9.1). Some level
of degeneration was observed in the ventral pallium (Vp) and Dc in both groups
(control and treated). The Dm showed no detectable Fluoro-Jade® B staining in
the control subjects. In AlCl3-treated brains, increased staining was observed in
the Dm. However, due to the inconsistent quality of the staining, these data are
regarded as preliminary and by no means confirmative.
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Figure 4.10: Neurodegeneration following AlCl3 treatment. FluoroJade
®
B staining was conducted on 10µm sections of zebrafish telencephalon. Increased
staining is apparent in the AlCl3-treated brains (B) compared to saline-treated
brains (A). (Larger images are included in Appendices; Section 9.1.) Approximate
positions of brain sections are indicated on the right-hand side (both A & B), with
focal region indicated in the coronal (top) graphics (images from Wulliman et al.
2012).
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Figure 4.11: AlCl3 dose-response curve. Analysis by linear mixed effects model
found significant effects for ‘AlCl3 concentration’ (F3,23.379=6.673, p=0.002) and
‘trial ’ (baseline vs. probe) (F1,28.622=24.329, p<0.0005). A significant interaction
(AlCl3 concentration * trial) was also found (F3,23.623=5.3, p=0.006). Post-hoc
analyses found that, at low concentrations of AlCl3 (≤50µM), significant aversion
of the CS was observed in the probe trial. However this effect was not seen at the
highest dose (100µM) (n=29). **, p<0.01; ***, p<0.001; by two-tailed t-test with
Bonferroni correction applied. Data plotted as mean ± SEM.
4.3.3 Dose-response curve for AlCl3 on classical aversion
In order to assess whether AlCl3 toxicity induced a behavioural phenotype, the
classical aversion assay (developed in Chapter 3) was employed. The results
demonstrate a dose-dependent effect for AlCl3 (see Figure 4.11). Thus, AlCl3
significantly impaired performance (‘learning ’) in this behavioural measure of Dm
(amygdala) function.
4.4 Discussion
The aims of this chapter were to assess whether Al toxicity in zebrafish induces
a transcriptionally-regulated dysregulation of genes associated with AD pathology
(appb and bace1 ) as well as up-stream genes which affect their function (pin1 and
dapk1 ); and whether these resulted in an impairment to classical fear conditioning.
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The initial results demonstrate that acute exposure to AlCl3 has no immediate
effect on appb or bace1 expression. The up-regulation of pin1 failed to reach
significance; however post-hoc power analysis estimates suggested that this may
have been underpowered. Thus it seems plausible that a significant up-regulation
would be found with increased power. Should this be detected in future
replications, it would appear to suggest that Al may actually be a valid therapy for
AD-related neurodegeneration, as the neuroprotective gene (pin1 ) is up-regulated
in the absence of any effect on the neurodegenerative (amyloidogenic) genes (appb
and bace1 ). However, given the extensive reporting that Al accumulates in the
brain, the effects immediately following exposure may be less relevant than the
prolonged effects (e.g. Alfrey et al. 1976; McDermott et al. 1978; Walton 2009;
Ward et al. 2001).
As the classical aversion assay involves a 30-minute habituation period,
followed by a 30-minute baseline period (prior to conditioning), gene expression
was assessed after 30- and 60-minutes recovery. No effect was found for appb at
any of the time points following exposure. However, bace1 expression was found to
significantly increase at 60-minutes following exposure. Thus, whilst there is no
effect on the amyloidogenic substrate (appb), the key enzyme in cleaving the
amyloidogenic pathway (bace1 ) was found to be up-regulated. Logically, this
would be sufficient to induce an increase in Aβ peptide cleavage, although this was
not tested in the present study. Additionally, whilst the inferential statistical
model (ANOVA) failed to find a significant effect for pin1 expression, post-hoc
analyses indicate that a significant up-regulation may occur at 30 minutes
following treatment, which attenuates by 60 minutes.
In relation to the classical aversion assay, the time when conditioning starts
(60 minutes following treatment) coincides with an increase in expression of bace1,
whilst a possible up-regulation of pin1 appears to have attenuated. This suggests
that, at the onset of conditioning, there is an up-regulation of neurodegenerative
(amyloidogenic) signalling, in the absence of pin1 -facilitated neuroprotective
signalling. However, the functional effects implied by these data are unconfirmed
without assessment of enzyme activity. Whilst this level biochemical analysis is
beyond the scope of the current thesis, it would form an important future
investigation.
At face value, the lack of effect on appb appears to contradict previous studies
which have reported an up-regulation of protein expression (e.g. Li et al. 2012;
Wang et al. 2014). However, Al has been found to inhibit the proteolytic
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breakdown of Aβ peptides (Sakamoto et al. 2006). Thus, despite no transcriptional
up-regulation, it is highly plausible that there is still an increase in appb protein,
as a substrate for the up-regulated bace1 enzyme. Thus, future research in which
protein expression is compared to mRNA expression would elucidate the nature of
the regulatory mechanisms which govern this Al-induced molecular dysregulation
(amyloidogenesis). In this regard, an attempt was made to assess APP protein
expression via western blot. However the antibody used failed to consistently
probe bands of the same size, and was thus deemed unreliable to include in the
results presented here (see Appendices, Section 9.2 for examples of antibody
inconsistency).
As these data indicate a pattern of gene expression potentially leading to
increased Aβ production during conditioning (in the behavioural assay), an
investigation of the dose-response effects (of AlCl3) was undertaken. These data
indicate that increased concentration of AlCl3 significantly increased expression of
bace1 at one hour following exposure. Whilst earlier findings (in the current
study) failed to find an effect for appb mRNA expression, the dose-response curve
indicates that a subtle affect may be present; although, again, this marginally
failed to reach significance (p=0.052). Indications that any potential up-regulation
of pin1 is attenuated by 60 minutes post exposure are supported in the
dose-response investigation, in which no effect was found.
Whilst these data support the hypothesis that neurodegeneration-related
signalling mechanisms are facilitated by Al exposure, the complex
post-translational interactions between these genes still make it difficult to predict
apoptosis. Thus, the expression of a final gene - dapk1 - was assessed.
dapk1 has been found to inhibit pin1 (by phosphorylation), thus inhibiting the
neuroprotective consequences of pin1 signalling (Figure 4.12; Lee et al. 2011).
Additionally, Ca2+ activates CaN which, in turn, activates dapk1 (by
dephosphorylation) to induce apoptosis (see Nair et al. 2013). Thus, previous
findings of Al-induced increases in cellular Ca2+ suggest an increase in dapk1
activity (Szutowicz et al. 1998). Presently, dapk1 was found to be significantly
up-regulated at one-hour post AlCl3 exposure. Therefore any neuroprotective
function of any residual increase in pin1 protein expression is likely to be inhibited
(to some extent) by the increase in dapk1 expression.
Whilst not quantitative, the findings of neurodegeneration (by Fluoro-Jade® B
staining) support the utility of Al as a positive control in neurodegeneration studies.
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Figure 4.12: Effects of dapk1 signalling on pin1 neuroprotective
signalling. dapk1 phosphorylates pin1 to inactivate it. This would inhibit
the neuroprotective signalling of pin1 (inhibition of Aβ aggregation and
dephosphorylation of tau). dapk1 is activated by CaN (via dephosphorylation),
which itself is activated by Ca2+, found to accumulate in cells following Al treatment.
Further, the increased neurodegeneration was detected in the Dm. This area has
been reported to be analogous to the tetrapod mP, and the mammalian amygdala
(see Ganz et al. 2014). Therefore neurodegeneration was specifically detected in the
neuroanatomical area associated with classical fear conditioning ; an area where Al
has previously been found to accumulate in rodents (Walton 2009).
Finally, behavioural impairment was detected in the classical fear conditioning
assay. This demonstrates that the molecular dysregulation and / or
neurodegeneration in the zebrafish brain results in a quantifiable functional
impairment, supporting the use of Al-induced neurotoxicity as this model. Thus,
the utility of this behavioural assay as a screen in neurodegeneration research is
validated.
To summarise, the effects of aluminium on gene transcription support the
hypothesis that AlCl3 induces neurodegenerative signalling, in relation to a
pathway involved in AD. This is further supported by the qualitative finding of
increased neurodegeneration in the Dm, detected by Fluoro-Jade® B staining.
The subsequent finding of impaired fear conditioning allows the acceptance of the
hypothesis that acute AlCl3 exposure results in impaired cognition. This validates
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the utility of zebrafish as model for neurodegeneration-related cognitive decline,
demonstrating a conservation of mechanisms found in mammals. Additionally, the
behavioural findings validate the utility of the fear conditioning assay as a






CHAPTER 5. GENETIC MODELS OF NEURODEGENERATION
5.1 Introduction
Previous chapters of this thesis have suggested that classical fear conditioning in
zebrafish may be used to detect behavioural changes in neurotoxin-induced
neurodegeneration (see Chapters 3 and 4). The current chapter will further
validate this assay by assessing a transgenic zebrafish line of relevance to a
neurodegenerative disease.
As a tool for genetic research, zebrafish have been used extensively in gene
manipulation studies. The focus of this chapter will be the genetic basis for AD;
however it must be noted that investigations into several other neurodegenerative
diseases (as well as non-degenerative psychiatric disorders) have utilised zebrafish
as a genetic model.
5.1.1 Alzheimer’s-like pathologies
The concept that ‘Alzheimer’s disease’ is a group of distinct diseases (albeit with
similar pathologies) was argued in the General Introduction of this thesis (see Section
1.1.2). Here, a more in-depth assessment of the various mutations which may result
in AD pathologies is presented.
APP mutations
The most commonly researched gene in AD research is the APP. As discussed
previously, its sequential cleavage by BACE1 and γ-secretase results in Aβ
peptides; the 42-amino acid species of which is associated with amyloid plaque
formation (Selkoe 1999). Thus, amyloidogenesis-centred animal models have
focussed on affecting the secretases’ binding / cleavage of APP, or else Aβ peptide
aggregation.
The majority of APP mutations have been found around the binding sites of
secretase enzymes. Wiley and colleagues categorised those proximal to the β- and
α- sites (BACE1 and α-secretase binding sites, respectively) as Class I, and those
proximal to the γ site (γ-secretase binding site) as Class II (see Figure 5.1; Wiley
et al. 2005). The current thesis chapter adopts this same classification.
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Figure 5.1: Classification of APP mutations. Mutations located around the
β- and α-cleavage sites are regarded as Class I mutations. The are the Swedish
(double), Flemish, Arctic, and Iowa mutations. Mutations located around the γ-
cleavage site are regarded as Class II mutations. These are the Austrian, French,
Florida, London, and Australian mutations. (Image from Wiley et al. 2005).
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Class I - Mutations currently known are the Swedish, Flemish, Arctic, and
Iowa mutations. Additionally, Dutch and Italian mutations are at the same site as
the Arctic mutation. Despite their close proximity, the mechanisms by which these
mutations disrupt Aβ are distinct.
For example, the Swedish double-mutation has been shown to increase
production of Aβ peptides by cleavage in vesicles (formed in the Golgi apparatus,
implicating a mechanism of extracellular secretion) (Haass et al. 1995).
Behaviourally, this has been shown to result in a range of cognitive impairments,
including spatial learning and fear conditioning deficits, in transgenic rodent
models (Hanna et al. 2012; Lalonde et al. 2002).
The Flemish mutation - despite being a Class I mutation - actually increases γ-
secretase activity. It is located within the ‘APP substrate inhibitory domain’, which
is bound by γ-secretase and normally inhibits its activity; however the Flemish
mutation impairs this inhibitory mechanism (Tian et al. 2010).
Aβ peptides containing the Arctic mutation have an increased tendency to
form protofibrils (Nilsberth et al. 2001). Interestingly, this mutation has been
shown to alter the location of APP - from cell membrane (a primary site of
ADAM10 activity) to intracellular - resulting in lower availability to α-secretase
activity (Gutwein et al. 2003; Sahlin et al. 2007). The Iowa and Dutch mutations
have been shown to facilitate fibril formation of the cleaved Aβ peptide
(Van Nostrand et al. 2001). Additionally, the Arctic, Flemish, Dutch, and Italian
mutations have all been associated with reduced proteolytic breakdown (Tsubuki
et al. 2003). Thus, the location of these mutations - all of which are in the region
of α-cleavage site - indicates that this region plays a role in Aβ degradation.
Class II - Mutations proximal to the γ-cleavage site are the Austrian, French,
Florida, London, and Australian mutations. Interestingly, despite their pathogenic
effects, many of these mutations have been found to decrease γ-secretase activity
(Wiley et al. 2005). However, all of these mutations have been shown to increase
production of Aβ42 (i.e. cleavage at the 42
nd residue of the Aβ peptide) (Hock and
Lamb 2001). In this regard, the Austrian mutation has been reported to affect the
length of Aβ peptide, resulting in greater Aβ42 and fewer Aβ40 peptides cleaved
(Kumar-Singh et al. 2000).
Unclassed - In addition to these neurodegeneration-associated mutations, one
mutation has been found to protect against AD development / progression and Aβ
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plaque formation, as well as ‘normal’ age-related cognitive decline (Callaway 2012;
Jonsson et al. 2012). This ‘Icelandic’ mutation is located within the region of Class
I mutations, however it has been found to inhibit APP interaction with BACE1
(Das et al. 2016).
The above mutations at the secretase-cleavage sites in APP have been one
approach adopted by researchers generating transgenic models of AD. However
others have investigated mutations in the secretase genes themselves.
Secretase mutations
Whilst the concept of mutations to the substrate (APP) has been extensively
explored, there have also been numerous investigations into mutations of the
metabolising enzymes - the secretases.
Regarding the α-secretases, mutations in ADAM10 have been identified in LOAD
patients, which reduced α-secretase activity and increased Aβ peptides in vitro (Kim
et al. 2009).
Although BACE1 mutations have been demonstrated to affect APP metabolism,
BACE1 deletion has been shown to attenuate Aβ deposition and memory deficits in
transgenic mice expression mutated hAPP (Laird et al. 2005). However these mice
displayed synaptic dysfunction in the hippocampi, as well as hippocampal-related
cognitive and emotional deficits. Thus, in light of the interconnectivity between the
hippocampi and amygdalae, it is likely that the deletion of BACE1 would impact
fear conditioning.
The clinical evidence of BACE1 mutations is even more unclear. A population
study of Swedish patients found that no BACE1 SNP was associated with markers
of dysregulated amyloid metabolism or BACE1 activity (Sjölander et al. 2010).
However, in a Chinese population study, two polymorphisms in the BACE1 promotor
were associated with increased risk of LOAD (Wang and Jia 2010). Interestingly, a
BACE1 SNP has been associated with PD, suggesting an association between the
dysregulated pathways in these two neurodegenerative diseases (Lange et al. 2014).
Regarding the γ-secretase subunits, mutations to both PS1 and PS2 (the
proteolytic units) have been found in genealogical studies (Bruni 1998; Levy-Lahad
et al. 1995; Rogaev et al. 1995; Scheuner et al. 1996). Further, these mutations
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have been demonstrated to increase cleavage of the Aβ42 peptide in vitro and in
vivo (Citron et al. 1997; Duff et al. 1996; Holcomb et al. 1998; Jankowsky et al.
2004). However, different PS1 mutations have been shown to have differential
affects on the resultant production of Aβ40 and Aβ42 (e.g. Bentahir et al. 2006).
ApoE ε4 and late-onset Alzheimer’s diseases
ApoE is the principal transporter of cholesterol in the CNS, facilitating multiple
metabolic and signalling processes (Elshourbagy et al. 1985; Pfrieger 2003). Whilst
neuronally-produced cholesterol is sufficient for the development of neurons, the
formation of synapses requires additional ApoE-cholesterol, produced by
astrocytes (Mauch et al. 2001). This reduces the high metabolic demands
(required for cholesterol synthesis) on neurons, by allocating this to glia (see
Shobab et al. 2005).
Both neurons and astrocytes regulate cholesterol synthesis via a homeostatic
feedback mechanism, which requires the ApoE-facilitated endocytosis of cholesterol
(Leduc et al. 2010; Shobab et al. 2005). Excess cholesterol is converted (into 24-
hydroxy-cholesterol) by neurons and excreted across the BBB, thus retaining CNS
homeostatic regulation (Björkhem et al. 1997; Lund et al. 2003; see Vance et al.
2005).
However, human ApoE is polymorphic, with three known alleles - ε2, ε3 and ε4.
Expression of the ε4 allele has been extensively associated with LOAD, in a gene
dose-dependent manner (e.g. Corder et al. 1993; Strittmatter et al. 1993). In this
regard, it has been demonstrated that all alleles of ApoE are involved in Aβ
clearance from the brain (Holtzman et al. 1999). However ε2 and ε3 expression
facilitate greatest clearance, whilst the relatively insufficient ε4 clearance results in
highly diffuse plaque formation (Castellano et al. 2011). ε3 has been demonstrated
to bind Aβ40 peptides with around 20-times the affinity of ε4 (LaDu et al. 1994).
Additionally, all alleles have been demonstrated to protect against hydrogen
peroxide-induced oxidative stress, with ε2 providing highest protection and ε4
providing lowest protection (Miyata and Smith 1996).
Interestingly, knocking out the endogenous apoE gene has been shown to
reduce Aβ deposition and plaque formation (in transgenic hAPP mice), which is
reinstated by expression of the human ε3 and ε4 alleles (Holtzman et al. 2000).
This indicates the role of ApoE in generic Aβ transport, whether extracellular
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deposition or clearance.
The ε4 allele has also been associated with a range of degeneration-associated
functions (e.g. tau phosphorylation, impaired neurite outgrowth, down-regulation
of androgen receptor), which are reversed by ε3 (Mahley et al. 2006). Thus, it
appears that many neurodegenerative effects of ε4 may result from impaired
neuroprotective functions, otherwise performed by the other alleles. In addition,
the ε3 and ε4 alleles have been demonstrated to differentially modulate the
neuroanatomical transcription of PIN1 (signalling discussed in Section 4.1.2),
suggesting another mechanism by which it can affect neuroprotective signalling
(Lattanzio et al. 2014).
However, in light of the complex nature of transgenic ApoE allele expression,
particularly with regard to the complication of endogenous gene expression,
manipulation of this gene was viewed as too intricate to provide a robust
validation of the classical aversion assay.
It is extremely important to note that, whilst these mutations all appear to
result in similar pathological phenotypes (with the obvious exception of the
‘Unclassed’ APP mutation), the biochemical and cellular mechanisms by which
these dysregulations manifest are vastly distinct. Thus, by regarding them all
under the umbrella term ‘Alzheimer’s disease’, the distinct causes and mechanisms
of these dysfunctions are somewhat disregarded. For this reason, in the current
article, the term ‘Alzheimer’s-like diseases ’ has been used.
Zebrafish models of Alzheimer’s-like diseases
In assessing the amyloidogenic aspects of AD, it is necessary for the model organism
to possess orthologues of the APP gene, as well as the secretase genes which cleave
it (or else transgenically express these genes). In this regard, zebrafish possess two
APP paralogues - appa and appb (Guo et al. 2012; Musa et al. 2001; Xi et al. 2011).
They also possess orthologues of the BACE1 and presenilin genes (which code for
β- and γ- secretases, respectively) (Groth et al. 2002; Leimer et al. 1999; Nik et al.
2012; Xi et al. 2011).
A potential obstacle to investigating amyloidogenesis in laboratory animals is
the ability of their endogenous Aβ peptides to form plaques. Whilst some
non-primate mammals have been demonstrated to possess a plaque-forming APP
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gene (e.g. polar bears, dogs, cats), these do not include many commonly-used
laboratory animals, such a rodents (e.g Cummings et al. 1996; Tekirian et al.
1996). Therefore, the necessity to knock-in hAPP is common to both rodents and
zebrafish, suggesting that the AD-related molecular mechanisms may be more
similar between these species than with humans.
The popularity of amyloid cascade hypotheses has lead to production of many
mouse models transgenically expressing hAPP (as discussed above). However
zebrafish research into AD has paid more attention to tauopathies (Bai et al. 2007;
Paquet et al. 2009; Tomasiewicz et al. 2002). Whilst these models have revealed
NFT resembling AD pathology, the lack of amyloid dysregulation questions the
efficacy of these lines as models specific to AD.
However, attempt has been made to investigate the processing of hAPP in
zebrafish. Joshi and colleagues demonstrated that under-expression of appb (by
morpholino injection) results in a morphological phenotype in embryos (Joshi et al.
2009). The authors reported that the phenotype was rescued by unmutated hAPP
expression, but not hAPPSWE expression. This demonstrates a conservation of
function between the hAPP and zebrafish appb genes, which is affected by the
AD-related Swedish mutation. A subsequent study found that the phenotype is
not induced by under-expression of appa, suggeting appb functioning to be of
greater importance in early zebrafish development (Song and Pimplikar 2012).
Whilst this developmental phenotype cannot be viewed as a model for an
age-related degenerative disease, it may present a method of morphologically
assessing amyloid processing; however a greater understanding of the functional
conservation between hAPP and appb is necessary. Regardless, the phenotype
rescue of appb by hAPP demonstrates some level of conservation, justifying the
utility of zebrafish for the transgenic study of hAPP.
In this regard, a zebrafish line which transgenically expresses hAPPLON/SWE
(expressed under the pan-neuronal HuC promoter sequence) has been obtained via
a collaboration with the Gothilf laboratory (Tel Aviv University). A transgenic
mouse line expressing hAPPLON/SWE has been reported to display a range of
cognitive deficits, including fear conditioning (Faizi et al. 2012). Thus, it is
hypothesised here that zebrafish expressing this mutant transgene will also display
impaired fear conditioning. Additionally, should no behavioural phenotype be
observed, the potential for Al to increase bace1 expression (as reported in Chapter
4) may facilitate amyloidogenic processing and result in a detectable phenotype.
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Alternative hypotheses of molecular dysregulation
Whilst amyloid cascade hypotheses have dominated much of biomedical research
into AD, amyloid-centred therapies have tended to fail in clinical development
(Mangialasche et al. 2010). It is argued in this thesis that AD-related
amyloidogenesis results from an array of molecular dysregulations producing
similar pathologies (grouped as AD). Thus, the failure of many clinical trials to
genotype patients means that patients will be administered therapies for similar
cognitive impairments which result from distinct molecular dysregulations.
Thus, whilst mutations to APP and the secretases are clearly affective in some
AD pathologies, it is highly likely that dysregulated APP metabolism can result
from up-stream dysregulations. In this regard, the consequences of DAPK1-PIN1
signalling present an interesting candidate for investigation.
As discussed previously, PIN1 signalling has neuroprotective consequences in
AD research by inhibiting both Aβ aggregation and tau phosphorylation (Bulbarelli
et al. 2009; Kimura et al. 2013; Lu et al. 1999; Ma et al. 2012; Pastorino et al.
2006; see Section 4.1.2). Whilst this suggests that mutations which inhibit PIN1
may be a causal factor in AD, no PIN1 mutation has been associated with the
diseases (Maruszak et al. 2009; Sultana et al. 2006). However, PIN1 is deactivated
by DAPK1 (see Figure 4.12).
An over-activity or over-expression of dapk1 leads to increased phosphorylation
of PIN1, decreasing its neuroprotective activity (Bialik and Kimchi 2011; Lee et al.
2011). Interestingly, H2O2-induced oxidative stress has been found to result in
DAPK1 activation, suggesting a possible down-stream facilitation of
neurodegeneration in AD instances where DAPK1 is not primarily affected (Fan
et al. 2014). Of relevance to AD, intronic DAPK1 mutations have been associated
with LOAD, suggesting a possible effect from mis-expression, rather than
dysfunction (Li et al. 2006). Additionally, increased DAPK1 expression has been
reported in the hippocampi of AD patients, however no difference was found in
cortical expression (Hainsworth et al. 2010; Kim et al. 2014).
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Behavioural deficits
As mentioned previously, the transgenic expression of hAPPLON/SWE in mice resulted
in impaired fear conditioning (amongst other cognitive deficits) (Faizi et al. 2012). It
should be noted that the authors reported an effect in contextual, but not cued fear
conditioning. However, the cued assay used was a trace fear conditioning paradigm,
which involves hippocampal activity in addition to the amygdala (see Section 3.1.2).
Thus, hippocampal involvement may mask an amygdala-centred effect, or vice versa.
In this regard, in a double-transgenic mouse model (hAPP and PS1), the
impairment to fear conditioning was associated with neither increased
neurodegeneration, nor amyloid plaque formation; but rather morphological
changes in dendritic spines in the lateral amygdala (Knafo et al. 2009). In the
same mouse model, dendritic dysfunction has been associated with close proximity
to amyloid plaques in cortical and hippocampal sections (Grutzendler et al. 2007).
Dendritic dysfunction has also been associated with the single transgenic
expression of mutated hAPP (Spires et al. 2005). Similar dendritic abnormalities
have been found in brains of AD patients (Grutzendler et al. 2007; see Knobloch
and Mansuy 2008)
Thus, it is hypothesised in the present study that transgenic expression of
hAPPLON/SWE impairs delay fear conditioning.
5.1.2 Mechanisms of transgenic expression in zebrafish
Regarding mechanisms of transgenic expression, HuC promoter has been utilised
to drive transgene expression in zebrafish (e.g. Lyons et al. 2003; Sato et al. 2006;
St John and Key 2012). HuC is expressed ‘pan-neuronally’, including at early stages
of emryonic development (Kim et al. 1996; Lyons et al. 2003). Thus, by fusing a
transgene down-stream to the HuC promotor sequence, transgenic expression can
be driven across CNS neurons. This strategy was adopted by the Gothilf lab, in
their generation of the Tg(HuC:hAPPLON/SWE) line (unpublished).
Alternatively (or additionally), the GAL4/UAS system can be utilised to drive
transgene expression. GAL4 is a transcription activator found in yeast, which binds
UAS to initiate transcription (Ornitz et al. 1991; Scheer and Campos-Ortega 1999).
Several transgenic lines have been developed which express GAL4 under the control
Ari Sudwarts 134
CHAPTER 5. GENETIC MODELS OF NEURODEGENERATION
of tissue-specific promoter sequences (e.g. HuC and s1101t are neuron-specific)
(Dell et al. 2013; Kim et al. 1996; Lyons et al. 2003; Schoonheim et al. 2010).
Thus, the subsequent introduction of a transgene - cloned down-stream of UAS -
results in tissue-specific expression. Additionally, by replacing the GAL4 C-terminal
activation domain with a viral activation domain (VP16, from herpes simplex) the
activation of UAS is increased (Croston et al. 1992; Sadowski et al. 1988).
In this regard, the Et(e1b:GAL4-vp16)s1101t (developed by Baier lab, Max
Planck Institute) expresses GAL4 specifically in CNS neurons (e.g. Dell et al.
2013; Schoonheim et al. 2010). This provides an efficacious tool for generating new
CNS-expressing trangenic lines. Thus, by cloning a gene down-stream of UAS, its
expression can be driven by the neuronally-expressed GAL4.
With regard to expression vectors, plasmids containing Tol2 transposable
elements may be utilised. When co-injected with transposase mRNA, this system
facilitates insertion into genomic DNA (Suster et al. 2009). The
pBr-Tol2-UAS-MCS -mCherry (where MCS = multiple cloning site) - developed by
Masa Tada (UCL), presents a tool which would facilitate this genetic insertion.
5.1.3 Aims
The aim of this research is to assess the effects of AD-related transgene expression
on cognition (i.e. performance in the fear conditioning assay), in zebrafish. This
will be conducted using the Tg(HuC:hAPPLON/SWE) line. Additionally, new gene
manipulation lines will be developed, as tools for future research. These will utilise
the transgenic expression of the human Aβ40 peptide, as well as an over-expression
of the zebrafish dapk1 gene. Whilst these assessment of these new lines is beyond
the time-frame allowance of this thesis, their development will be important for
understanding the molecular pathways affected by the relative molecular
dysregulation.
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5.2 Methods
5.2.1 Subjects
Tg(HuC:hAPP) fish were a kind gift from Yoav Gothilf (Tel Aviv University). This
line transgenically express hAPP, with expression driven by the pan-neuronal HuC
gene. A green fluorescent marker (expressed in the pancreas) indicates the presence
of the transgene.
The imported hAPP-expressing fish were heterozygous; these were incrossed to
produce siblings of mixed genotypes (25% homozygous, 50% heterozygous, 25% wild-
type). These were then identified as carriers or non-carriers of the transgene (by
fluorescent microscopy). The non-carrier (non-fluorescent) offspring were isolated,
raised and inbred to produce the wild-type strain (termed ”hAPP-WT” in this
thesis). The carrier (fluorescent) offspring were raised; these were then outcrossed
to identify them as homozygous (100% fluorescent offspring) or heterozygous (50%
fluorescent offspring) via Mendelian genetics. The homozygous fish were isolated,
raised and inbred to produce the homozygous strain (termed ”hAPPLON/SWE” in
this thesis).
In order to develop new transgenic lines, a line which expresses GAL4 throughout
the CNS was utilised. These fish - Et(e1b:GAL4-vp16)s1101t - were a kind gift from
Tom Hawkins (UCL).
5.2.2 RT-PCR
Zebrafish were sacrificed by decapitation and brain tissue dissected out. They were
then frozen immediately on dry ice and stored at -80oC until processing.
RNA was extracted, DNAse-treated and reverse transcribed, as described in
Sections 2.2 & 2.4. The resultant cDNA was used to PCR-amplify hAPP and HuC
genes, .
PCR reactions were conducted using the following primers:
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Taq DNA polymerase 0.13µl
BSA (10mg/mL) 0.25µl
DMSO (100%) 1.25µl
Forward primer (10µM) 0.5µl
Reverse primer (10µM) 0.5µl
cDNA 2.5µl
Total 25µl
In order to increase specificity of the primers, ‘touch-down’ PCR was utilised.
Thermocycles:
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Initial denaturation 95oC 30 seconds
Denature 95oC 30 seconds
x10 cyclesAnneal 60
oC - 50oC* 1 minute
Extension 68oC 1.5 minutes
Denature 95oC 30 seconds
x35 cyclesAnneal 45
oC (hAPP) / 48oC (HuC) 1 minute
Extension 68oC 1.5 minutes
Final extension 68oC 5 minutes
Hold 4oC ∞
* Annealing temperature reduced by 1oC each cycle
5.2.3 Fluoro-Jade® B staining
Zebrafish were treated with 100µM AlCl3 for three hours, then allowed to recover
for one hour. They were then sacrificed by decapitation, brain tissue dissected out,
and frozed immediately in OCT compound, on dry ice.
Brains were cut at -20oC, in 10µm sections. Slides were then stored at -20oC,
until processing.
Fluoro-Jade® B was purchased from Millipore, and slides stained as described
in Section 2.25.
5.2.4 Classical aversion assay
Zebrafish were moved to the behaviour room at least 24 hours prior to
experimentation. The classical aversion assay was conducted as described and
developed in Chapter 3, using 2-minute probes.
As discussed in Section 3.4, Distance travelled was factored into the mixed effects
statistical model as a covariate, to account for any variance caused by differences in
locomotion.
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5.2.5 qPCR
Zebrafish were sacrificed by decapitation and brain tissue dissected out. They were
then frozen immediately on dry ice and stored at -80oC until processing.
RNA was extracted, DNAse-treated and reverse transcribed, as described in
Sections 2.2 & 2.4.
Standard curves were loaded on each plate from PCR samples of known fragment
concentrations, as determined using Avogadro’s constant. Fragment numbers in test
samples were determined by the qPCR machine (BioRad CFX Connect) from the
Cq values, based on the standard curves.
qPCR was conducted using primer sequences listed in Section 2.17, Table 2.2.
5.2.6 Cloning new transgenic zebrafish lines
Human Aβ40 was transgenically expressed in zebrafish, whilst the endogenous
zebrafish dapk1 gene was over-expressed.
Human Aβ40 sequences were a kind gift from Damian Crowther (University of
Cambridge). Zebrafish dapk1 gene was generated by PCR amplification from
cDNA (generated as described above), using dapk1 -specific forward






Phusion DNA polymerase 0.25µl
Forward primer (10µM) 1.25µl
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Thermocycles:
Initial denaturation 98oC 1.5 mins
Denature 98oC 10 seconds
x35 cyclesAnneal & extension 72oC 3.5 minutes
Final extension 72oC 10 minutes
Hold 4oC ∞
Both genes were cloned into pGEM®-T Easy (Promega) (as described in Section
2.16), transformed (as described in Section 2.9) and MiniPrep’ed (Section 2.12). They







The digested DNA was run on a 1% agarose gel, and the correct sized bands excised
and extracted, as per Section 2.11. The extracted genes were then cloned into pCS2+ at
the EcoRI site, as described in Section 2.26.
Following ligation into pCS2+ the genes were sequenced to confirm insertions in the
correct orientations. The genes were then PCR-amplified from the plasmid, using SP6
promoter (forward primer) (ATTTAGGTGACACTATAG) and M13 Reverse primer





Phusion DNA polymerase 0.5µl
SP6 (F) primer (10µM) 2.5µl
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Thermocycles:
Initial denaturation 98oC 30 secs
Denature 98oC 10 seconds
x35 cyclesAnneal 43oC 30 secsExtension 72oC 30 secs
Final extension 72oC 10 minutes
Hold 4oC ∞
The PCR products were purified as described in Section 2.14 and digested with NotI-






The gene - flanked by a blunt end (5‘) and NotI site (3‘) - was then cloned into the
expression vector - pBr-Tol2-UAS-MCS -mCherry (a kind gift from Masa Tada, UCL), at
these sites, in the following reaction:
Ligation Buffer 3µl
Vector (50ng)
Insert (3x fragment number of vector)
T4 DNA Ligase 1µl
ddH2O (to 30µl)
Total 30µl
The resultant vector DNA was used to transform competent cells (see Section 2.9),
MaxiPreped (see Section 2.13) and ethanol precipitated (see Section 2.15).
Purified plasmids (0.02ng) was then co-injected with transposase mRNA (0.02ng) (see
Section 2.28) into Et(e1b:GAL4-vp16)s1101t embryos, at the one-cell-stage (see Section
2.29 for injection volume calculations).
Gene carriers were identified by fluorescent protein expression (mCherry-FP) at ≥2-
DPF (see Section 2.30).
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Figure 5.2: Detection of hAPP expression in transgenic fish. cDNA from
Tg(HuC:hAPP;ins:eGFP) (homozygous vs wild-type) fish was amplified by PCR,
using primers specific for hAPP and HuC. The hAPP gene fragment was only
detected in the homozygous fish, demonstrating it’s transgenic expression. The
relatively similar expression of HuC (semi-quantitative) serves as a control.
5.3 Results
5.3.1 Assessing expression of hAPPLON/SWE transgene
In order to confirm the transgenic expression of hAPP, reverse-transcription PCR (RT-
PCR) was conducted on cDNA from the brains of Tg(HuC:hAPP;ins:eGFP) fish. Results
(see Figure 5.2) demonstrate that the hAPP gene was expressed in the homozygous fish,
with no expression detected in the wild-type cousins. The relatively similar levels of HuC
expression (semi-quantifiable by the strength of the bands) demonstrate that there were
no problems in sample processing (i.e. RNA extraction, reverse-transcription, PCR), and
that similar amount of cDNA were used in the PCR.
5.3.2 Effects of hAPP transgenic expression on classical
aversion learning
In order to determine whether transgenic hAPP expression impaired amygdala-related
cognitive functioning, the fish were assessed in the classical aversion assay (developed in
Chapter 3).
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Figure 5.3: Performance of 6.5-MPF transgenic hAPP zebrafish in
classical aversion learning. Transgenic hAPP-expressing fish were assayed
using a classical aversion paradigm. Both wild-type lines, but not the hAPP-
expressing line, significantly avoided the CS in the probe trials. Significant effects
were found for genotype (F(2,78.271)=5.278, p=0.007) and trial (‘baseline’ vs
‘probe’) (F(1,78.353)=58.114, p<0.0005). A significant genotype*trial interaction
was detected (F(2,78.009)=4.661, p=0.012; (n=81). Linear mixed effects model;
***, p<0.001; by two-tailed t-test with Bonferroni correction applied. Data plotted
as mean ± SEM.
6.5 months post fertilisation
The effect of transgenic hAPP expression on classical aversion learning was initially
assessed in adult zebrafish at 6.5-months post fertilisation (MPF). The results (see
Figure 5.3) demonstrate that, whilst the two wild-type strains significantly avoided the
CS in the probe trial, no significant aversion was observed in the transgenic strain.
3.5 months post fertilisation
Following confirmation that classical aversion learning is impaired in the transgenic hAPP
line, a pilot study was conducted to assess whether this impairment is also observable in
young adult fish (at 3-MPF). Results of this pilot indicated that no impairment was
present, with all genotypes significantly avoiding the CS in the probe trials (see Figure
5.4). No inferential statistics were conducted on these data, owing to the low number of
subjects used in the pilot (n=11).
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Figure 5.4: Pilot - performance of 3.5-MPF transgenic hAPP zebrafish
in classical aversion learning. Transgenic hAPP-expressing fish were assayed
using a classical aversion paradigm. All three genotypes significantly avoided the
CS in the probe trials (n=11). *, p<0.05; **, p<0.01; by two-tailed t-test with
Bonferroni correction applied. Data plotted as mean ± SEM.
Age-related effect
The above data indicates that impaired cognition in the hAPP genotype may present an
age-related effect. In order to investigate this, zebrafish were assessed at three different
ages - 3-MPF, 6.5-MPF, and 14.5-MPF. The results are presented in Figure 5.5.
At 3-MPF, all three genotypes significantly avoided the CS in the probe trials. However
from 6.5-MPF, the transgenic hAPP line failed to display this behaviour. No significant
main effect was found for age; however significant interactions were found for genotype*age
and genotype*trial*age.
5.3.3 pin1 expression
qPCR was conducted to assess whether pin1 expression was affected by the transgenic
expression of hAPP. Results are presented in Figure 5.6. No effect was detected in either
young (3-MPF) or old (14.5-MPF) fish.
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Figure 5.5: Transgenic hAPP expression induces an age-related effect
on cognition. Zebrafish - both wild-type and transgenically expressing hAPP
- were assessed for their performance in the classical aversion assay at three
ages. At 3-MPF, all three genotypes significantly avoided the CS in the probe
trials. However in older fish (6.5-MPF and 14.5-MPF) hAPP expression inhibited
learning. Significant effects were found for genotype (F(2,150.368)=8.113, p<0.0005)
and trial (F(1,148.041)=159.398, p<0.0005). No significant effect was found
for age (F(2,149.576)=2.375, p=0.096). However significant interactions were
found for genotype*age (F(4,149.525)=4.675, p=0.001) and genotype*trial*age
(F(4,147.190)=2.503), p=0.045. Pairwise comparison of the genotypes found that
hAPP was significantly different from TU (p=0.002) and hAPP-WT (p<0.0005).
No significant difference was found between TU and hAPP-WT (p=0.824) (n=155).
Linear mixed effects model; *, p<0.05; **, p<0.01; ***, p<0.001; by two-tailed
t-test with Bonferroni correction applied. Data plotted as mean ± SEM.
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Figure 5.6: Effect of transgenic hAPP expression on pin1 expression. The
expression of pin1 was assessed by qPCR in two wild-type lines (TU and hAPP-WT)
against transgenic hAPP fish, at 3.5-MPF (A) and 14.5-MPF (B). No significant
difference was detected at either age - 3.5-MPF (F(2,10)=1.618, p=0.246); and
14.5-MPF (F(2,10)=0.993, p=0.404) (n=15). By one-way ANOVA. Data plotted as
mean ± SEM.
5.3.4 Neurodegeneration
In order to assess whether transgenic expression of hAPPLON/SWE causes
neurodegeneration, Fluoro-Jade® B staining was conducted on telencephalic sections of
zebrafish brains.
Results are presented in Figure 5.7 (larger images are presented in the Appendix, see
Section 9.3). An increase in fluorescent staining indicates increased neurodegeneration in
the brains of transgenically-expressing hAPPLON/SWE fish. However, due to the
inconsistent quality of the staining, these data are regarded as preliminary and by no
means confirmative.
5.3.5 Developing new transgenic lines of AD-related
neurodegeneration
Whilst a phenotype was detected in the Tg(HuC:hAPP) line, one of the issue in AD-
related translational neurobiology has been a lack of effective models (discussed in the
Introduction; see Section 5.1.1). Additionally, given the range of molecular dysregulations
which result in Alzheimer’s-like phenotypes, it is apparent that a range of mutant models is
required to investigate the different diseases of AD (discussed in General Introduction; see
Section 1.1.2). Thus, new gene manipulation lines were generated. Whilst the assessment
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Figure 5.7: Neurodegeneration in transgenic hAPPLON/SWE line.
FluoroJade® B staining was conducted on 10µm sections of zebrafish telencephalon.
Increased staining is apparent in brains in transgenic hAPPLON/SWE-expressing brain
(B) compared to wild-type brains (A). (Larger images are included in Appendices;
Section 9.3). Approximate positions of brain sections are indicated on the right-hand
side (both A & B) (images from Wulliman et al. 2012).
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of these lines is not within the time-frame allowed for this thesis, they may provide a useful
tool for future research in this area. Two genes were chosen for manipulation - Aβ40 and
dapk1.
Embryos were injected at the one-cell stage (into the cell), then reared as per standard
protocols. At 2-DPF they were checked for fluorescent protein expression, as a marker of
transgene expression. Images of un-injected and injected embryos are presented in Figure
5.8. These demonstrate that expression of the transgenes were successfully driven by the
Et(e1b:GAL4)s1101t line.
5.4 Discussion
Assessment of the transgenic hAPPLON/SWE zebrafish line found expression of the
transgene via RT-PCR. This confirms that the full-length protein is transcribed in the
adult fish.
With regard to a behavioural phenotype, 6.5-MPF fish displayed impaired cognition
in the classical aversion assay. However, no effect was found at 3.5-MPF. In light of
this, an age-effect was investigated. The results of this analysis found that impairment
to classical aversion is present in old (≥6.5-MPF), but not young (3-MPF) fish. This is
in-keeping with rodent studies, which have also found age-related cognitive impairments
resulting from the transgenic expression of mutated hAPP (Chen et al. 1998; Kelly et al.
2003; Van Dam et al. 2003).
No significant effect was found for pin1 expression, indicating that homeostatic
regulation of amyloid toxicity does not feedback to this neuroprotection pathway.
However, this assessment of mRNA expression is not indicative of the functional activity
of pin1. Thus, further investigation is necessary to elucidate whether APP affects the
phosphorylation of pin1.
Additionally, an increase in neurodegeneration is apparent in hAPPLON/SWE fish.
However, there is evidence that neurodegeneration is not causative in cognitive deficits of
transgenic rodents (Stein and Johnson 2002). Therefore, future assessment of the
transgenic zebrafish line may wish to investigate the effect of hAPP on dendritic spines -
a morphological dysfunction previously found in hAPP-expressing mice - in the
transgenic fish, at a younger age (Irizarry et al. 1997; Stein and Johnson 2002).
In development of new genetic models of AD, two over-expression zebrafish lines have
been generated. The hAβ (trangenic over-expression) is not expected to induce
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Figure 5.8: Expression of transgenes in embryos following injection.
Zebrafish embryos were injected with expression plasmid and transposase mRNA
(0.02ng of each in Danieau Buffer) at the one-cell stage. Un-injected controls show
kaede expression, but no mCherry-FP (A & B). Injected embryos show expression
of both kaede and mCherry-FP (as a marker of transgene expression) (C & D).
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neurotoxicity or significant effects on cognition. However it may provide insight into the
effects of pharmacological interventions which aim to modulate γ-secretase activity (i.e.
which reduce Aβ42 cleavage and induce higher Aβ40 cleavage). The dapk1 (endogenous
over-expression) is an entirely new tool for investigation, as no stable gene-manipulation
lines have been developed in any experimental organism. However, previous research into
aberrant DAPK1-PIN1 signalling consequences - both in vitro and in vivo - indicate that
a dapk1 over-expression (as developed here) would result in neurodegeneration in
tandem with amyloidogenesis and tau hyperphosphorylation (e.g. Bialik and Kimchi
2011; Bulbarelli et al. 2009; Kim et al. 2014; Lee et al. 2011; Wu et al. 2011a). Thus,
whilst the analysis of these lines is beyond the time allowance of the current thesis, there
is sufficient knowledge of these genes to formulate hypotheses in future studies.
Finally, as the central theme of this thesis is a facilitation of translational neurobiology,
neuroprotective compounds must be regarded. In this regard, two extremely common
drugs have repeatedly been associated with anti-apoptotic function in the CNS - nicotine
and caffeine.
Nicotine has been shown to protect against Aβ toxicity in primary neuronal culture
(e.g. Kihara et al. 1997; Liu and Zhao 2004). Several nicotinic receptors have been
associated with facilitating this signalling, including α4β2, α7 (Kihara et al. 1998; Shaw
et al. 2002). This is particularly interesting in light of the extensive reporting that
cholinergic pathways are particularly vulnerable in early stages of AD progression (e.g.
Collerton 1986; Coyle et al. 1983; Francis et al. 1999; Terry and Buccafusco 2003).
Additionally, a periodontal study found that smokers express higher levels of PIN1 (in
gingival biopsies), suggesting that it may affect the DAPK1-PIN1 pathway investigated
in the current study (Cho et al. 2015).
Caffeine has been reported to exert neuroprotective properties - both in vitro and in
vivo, as well as reducing Aβ in hAPPSWE-expressing mice (Arendash et al. 2006; Arendash
et al. 2009; Rosso et al. 2007; Zamani et al. 1997). This mode of neuroprotection has
been associated with adenosine A2a receptor activity, which apparently facilitates this
mechanism (Dall’lgna et al. 2003; Dall’Igna et al. 2007; Rosso et al. 2007; Ribeiro et al.
2002).
Whilst these two compounds exert neuroprotection, they have both been extensively
investigated in light of their addictive properties (e.g. Benowitz 2010; Griffiths and
Mumford 1996; Pohler 2010; Stolerman and Jarvis 1995; Swanson et al. 1994).
Additionally, findings that caffeine and nicotine are often co-self-administered indicates
that they may facilitate each others reinforcing mechanisms (e.g. Swanson et al. 1994).
This suggests that the neuroprotective properties of these two compounds may facilitate
one-another. Thus, there appears to be an association between AD-related
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neuroprotective mechanisms and addictive mechanisms. In this light, it is highly
necessary to screen neuroprotective compounds for reinforcing properties - a key stage of
drug development which also incurs high ethical and economic costs.
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CHAPTER 6. ASSESSING THE UTILITY OF ZEBRAFISH CONDITIONED
PLACE PREFERENCE AS A MODEL FOR ABUSE POTENTIAL
6.1 Introduction
As mentioned earlier in this thesis, uncovering neuroprotective signalling mechanisms -
and discovering pharmacological interventions which target these mechanisms - is a key
goal in neurodegeneration research. However, the fact that these compounds target the
CNS presents many problems in relation to adverse effects on brain functioning. Notable
amongst these problems is the potential reinforcing properties of compounds; this is a
particular concern in AD treatment, as the cholinergic system - damaged early in AD
(nAChR-α7 has been reported to directly interact with Aβ peptides; see Wang et al.
2000b) and the target of most current therapies - is heavily involved in reward signalling
pathways (discussed in Section 6.1.1, below). This chapter will begin by reviewing common
‘drugs of abuse’ with reported neuroprotective properties, describing the mechanisms by
which they are understood to act. With regard to their abuse potential, these drugs will
then be assessed for their ability to induce drug-seeking behaviour in zebrafish (via a CPP
paradigm). These results will be discussed in relation to findings from studies of human
subjective experience, assessing the potential utility of zebrafish CPP to model human
drug reward and abuse potential.
6.1.1 Reward signalling
The mesocorticolimbic system is often regarded as the ‘reward pathway ’ of the mammalian
brain. This involves DAergic projections emanating from the VTA, ascending to the NAcc
(mesolimbic) and medial pre-frontal cortex (mPFC) (mesocortical), as well as descending
projections to the DRN (Figure 6.1a; see Ikemoto 2010; Peyron et al. 1995). In addition
to DAergic, GLUergic neurons - identified by in situ expression of VGluT2 mRNA - have
been found in these pathways (e.g. Yamaguchi et al. 2011).
Similarly, serotonin signalling has been heavily implicated in reward signalling, with
various 5-HT receptor subtypes expressed throughout midbrain, cortical and limbic
structures (see Hayes and Greenshaw 2011). Midbrain projection from the raphe nuclei
(i.e. the dorsal and median nuclei; DRN and MRN, respectively) - extend to the
forebrain, VTA and NAcc (see Hu 2016; Mylecharane 1995). The DRN sends efferents to
the NAcc, mPFC and VTA; the MRN projects to regions of the forbrain distinct to
those with DRN afferents (see Figure 6.1b; De Deurwaerdère et al. 1998; Van Bockstaele
et al. 1993; Vertes 1991; Vertes et al. 1999).
GABA signalling functions as the principal inhibitory mechanism of the adult brain
(Davies 2003). GABA-Rs in the VTA (both GABAA and GABAB) have been implicated
in modulating DA release in the NAcc, whilst GABAA has been shown to interface between
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DAergic and non-DAergic mechanisms in the VTA, modulating signalling between them
(Laviolette and Van Der Kooy 2001; Suaud-Chagny et al. 1992; Xi and Stein 1998).
Interestingly, GABAergic neurons have also been found to project from the VTA to the
PFC, whilst GABA (but not DA) is reportedly involved in signalling from the NAcc to
the PFC, facilitating communication between the two key structures of reward signalling
(Carr and Sesack 2000a; Carr and Sesack 2000b). Thus, whilst not fully elucidated, the
importance of this neurotransmitter in regulating mesocorticolimbic reward signalling is
evident.
Like GABA-Rs, opioid receptors are inhibitory. They are widely expressed
throughout brain structures, including the VTA, NAcc, FC, DRN, and MRN (see Ding
et al. 1996; Le Merrer et al. 2009; Xia and Haddad 1991). Opioid receptors in the DRN
are reported to modulate local serotonin release, indicating a mechanism of opioid
reward pharmacology (Tao and Auerbach 2002). However DA receptors appear to
facilitate opiate reward signalling, as D2-null mice do not display opiate-induced CPP
(Maldonado et al. 1997). This highlights the importance of DA in reward signalling -
even where the principal target of a compound is not a DA-R - as well as the complex
interactions between neurotransmitter systems required to facilitate this mechanism.
NMDA-R have also been reported throughout the reward circuitry, including the VTA,
NAcc, PFC, DRN and MRN (see Covington III et al. 2008; De Kock et al. 2006; Petralia
et al. 1994; Rodriguez et al. 2000; Takita et al. 1997; Tao and Auerbach 1996). NMDA
signalling in the VTA has been found to increase DA excretion in the NAcc (Suaud-Chagny
et al. 1992). Further, NMDA-R activity in the DRN and MRN has been shown to trigger
5-HT release locally, whilst DRN activity also increases its secretion in the NAcc (De Kock
et al. 2006; Tao and Auerbach 1996).
The mesocortical pathway has also been shown to receive activating (or at least
modulating) signals from cholinergic inputs to VTA DAergic neurons (Omelchenko and
Sesack 2006). Thus, cholinergic signalling appears to play a role in triggering reward
signalling, likely in combination with other neurotransmitter mechanisms.
The fact that NMDA and cholinergic mechanisms affect (or even instigate) reward
signalling is of particular relevance to the current thesis, as all drugs currently approved
to treat AD symptoms target cholinergic or NMDA signalling. Three drugs (donepezil,
rivastigmine and galantamine) inhibit the breakdown of ACh by AChE, prolonging its
action (Arias et al. 2005; Nordberg and Svensson 1998). The fourth drug (memantine)
antagonises NMDA receptors, inhibiting glutamate over-activity and subsequent
excitotoxicity (Erdö and Schäfer 1991; Reisberg et al. 2003; Volbracht et al. 2006).
In this light, it must be mentioned that AChE inhibition (pre-treatment, by donepezil
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- the most commonly prescribed AD drug) has been reported to actually inhibit nicotine-
induced reinforcement (measured by SA) in rodents (Kimmey et al. 2014). However,
in light of the variegated natures of cholinergic receptor complexes and their signalling
mechanisms, it is evident that other compounds affecting this neurotransmitter have the
inverse effect. For example, application of a muscarinic agonist has been shown to increase
both DA and 5-HT in the VTA, as well as increasing DA in the NAcc and FC (Gronier
et al. 2000). Indeed (although not a commonly held hypothesis), it has been proposed
that, whilst both types of AChR’s are involved in triggering VTA-driven reward signalling,
mAChR’s play a greater role than nAChR’s (Yeomans and Baptista 1997). Thus, whilst
clearly heavily involved in the modulation of reward signalling, the specific functions of
muscarinic and nicotinic receptors (in their various receptor isoforms) is still not entirely
elucidated.
Additionally, several reinforcing compounds which do not target cholinergic pathways
have been found to exert neuroprotective properties (discussed below in Section 6.1.2).
Thus, the necessity to screen CNS-acting neuroprotective drugs for their abuse potential
(reinforcing effects) is extremely important to the safety pharmacology stages of drug
development (particularly in relation to AD).
6.1.2 Neuroprotective drugs with reinforcing properties
Stimulants
Nicotine has a well characterised pharmacology. It affects cognitive functions and
emotional state via activation of nAChRs in the DAergic neurons of the mesolimbic
system and related structures, leading to activation of cells within this pathway (D’souza
and Markou 2011). Several receptor subtypes have been associated with facilitating this
mesolimbic activation, including α4, α6, α7 (Besson et al. 2012; Sanjakdar et al. 2015;
Tapper et al. 2004). With regard to rewarding behaviour, nicotine has been extensively
reported to cause drug-seeking responses, inducing SA in humans and rodents, and CPP
in both rodents and zebrafish (Donny et al. 1995; Fudala et al. 1985; Kedikian et al.
2013; Kily et al. 2008; Perkins 1999b; Rose and Corrigall 1997; Vastola et al. 2002;
Walters et al. 2006).
Nicotine has been demonstrated to trigger neuroprotective signalling against amyloid
toxicity, which is also mediated by nAChRs (requiring the α7 subunit), resulting in
decreased Aβ aggregation (Arias et al. 2005; Jonnala and Buccafusco 2001; Liu et al.
2007a; Shimohama 2009). In light of this, findings from a rodent study that nicotine
CPP is mediated by the β2, but not the α7 subunit (determined by both antagonism
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and genetic deletion), indicate that the rewarding and neuroprotective consequences of
nicotine pharmacology occur by distinct signalling mechanisms (Walters et al. 2006).
However, findings that the SA-aquired nicotine reinforcement actually requires the α7
subunit demonstrate the complexity of nicotine reward signalling, suggesting that α7 is
necessary for the active (SA), but not passive (CPP) aquisition of reward. Additionally,
nicotine has also been shown to increase PIN1 expression, potentially triggering the
downstream neuroprotective properties of this protein (Cho et al. 2015).
Caffeine is an antagonist of the adenosine receptors - A1, A2A, A2B, and A3. In
the CNS, the adenosine receptors are modulatory, with A1 facilitating inhibition and A2A
facilitating excitation. Thus, the A2A receptor mediates caffeine’s affect on arousal (Huang
et al. 2005). These two receptors exert counterbalancing tonal homeostatic functions -
antagonism of A1 has been shown to facilitate LTP; a function inhibited by A2A antagonism
(Costenla et al. 2010; Ribeiro and Sebastiao 2010).
The rewarding effects of caffeine result from an increase in DA secretion in the NAcc,
a phenomenon likely mediated by antagonism of the A1 receptor (Solinas et al. 2002). Its
reinforcing properties are well established, inducing SA in both humans and rodents, as
well as CPP in rodent paradigms (e.g. Bedingfield et al. 1998; Hughes et al. 1993; Liguori
and Hughes 1997; Nehlig 1999).
In relation to neuroprotection, caffeine has been shown to rescue ‘normal’ age-related
cognitive decline in rodents (Costa et al. 2008). It increases neuronal survival by
decreasing caspase 3 activity in a rodent model of PD; although evidence shows that
high concentrations lead to increased caspase 3-induced apoptosis (Kang et al. 2002;
Nakaso et al. 2008). Additionally, AD patients have been found to intake significantly
less caffeine than age-matched control subjects, although no causality is discernible from
those data (Maia and De Mendonça 2002; Ribeiro and Sebastiao 2010). In this regard,
antagonism of the A2A receptor subtype has been associated with neuroprotection in
several models of neurodegenerative disorders (including AD), highlighting the potential
role that excitotoxicity may play in these diseases (Gomes et al. 2011).
Alcohol
The neuropharmacology of ethanol reward is relatively ‘dirty’, exerting effects on several
receptor targets within the mesolimbic and mesocortical pathways. A commonly
researched mechanism is EtOH’s modulation of both GABAA and GABAB receptors
(Davies 2003; Grobin et al. 1998; Koob et al. 1998; Liang et al. 2006). It has been shown
to increase GABAA-regulated ionic currents, with a similar effect on another major
inhibitory receptor - glycine (Aguayo 1990; Celentano et al. 1988; Davies 2003; Lynch
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2004; MIHIC 1999; Nestoros 1980). In light of GABA’s modulation of DA signalling
(discussed above), EtOH’s activation of these receptors has an implicit role in reward
signalling. Further, findings that glycine signalling modulates GABA signalling from the
NAcc to the VTA (feedback from DAergic signalling in the other direction) demonstrate
the importance of glycine in reward mechanisms (see Harvey and Yee 2013).
In addition to these indirect increases in DA, EtOH has been found to directly stimulate
DAergic neurons in structures of the mesocorticolimbic pathways, including the VTA,
NAcc and mPFC (Brodie et al. 1990; Brodie et al. 1999; Ding et al. 2011; Gessa et al.
1985; Weiss et al. 1993; Yoshimoto et al. 1992). Interestingly, EtOH’s direct action on
the NAcc has also been shown to feed in to the VTA where it activates nAChRs, which
subsequently feed back to increase NAcc DA (Ericson et al. 2003; Ericson et al. 2008).
Despite the aforementioned increase in pre-frontal DA, EtOH has been demonstrated
to decrease signalling in the PFC (Tu et al. 2007). This effect is due to its inhibition of
ionic currents at NMDA-Rs (Davies 2003; Hoffman et al. 1989; Hoffman et al. 1990;
Lovinger et al. 1989; Nagy 2008; Weitlauf and Woodward 2008). To add to this array of
pharmacological consequences, EtOH also increases 5-HT in the NAcc, as well as
inhibitting its clearance from the brain (Daws et al. 2006; Yoshimoto et al. 1992).
Regarding drug-seeking behaviours, EtOH has been extensively reported to induce SA
and CPP in rodent studies (e.g. Bozarth 1990; Cunningham and Noble 1992; Cunningham
et al. 2000; Rassnick et al. 1992; Spanagel et al. 1995). It has also been demonstrated
to induce CPP in zebrafish, supporting the current investigation into the range of drugs
which induce CPP in this model organism (Collier et al. 2014; Kily et al. 2008).
The detrimental consequences on the CNS of excessive, chronic EtOH consumption
has received much research attention (e.g. Crews et al. 2004; Gazdzinski et al. 2005; Lieber
1991; Morris et al. 2010b). Further, there is evidence that EtOH’s effects on NMDA and
GABAA receptors causes apoptosis in the developing brain (e.g. Ikonomidou et al. 2000).
However findings that (moderate levels of) EtOH are neuroprotective has been reported
in relation to several manifestations of CNS atrophy. For example, EtOH’s activations
of GABA and HIF1α signalling have been associated with neuroprotective signalling in
rodent models of ischaemia-reperfusion and ischaemia brain injuries (Qi et al. 2009; Wang
et al. 2012). Moderate EtOH pre-exposure has been associated with decreased risk of AD
and other dementias by reducing toxicity from pro-neuroinflammatory proteins, including
Aβ (Brust 2010; Collins et al. 2010). Interestingly the protection against Aβ has been
associated with an increase in NMDA-R activity; an effect inhibited by memantine (the
NMDA-R antagonist currently prescribed to treat AD!) (Mitchell et al. 2009).
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Cannabinoids
Of the many cannabinoids currently identified, ∆9-tetrahydrocannabinol (THC) is the
most commonly researched compound, largely due to its psychoactivity. It is a partial
agonist of both CB1 and CB2, with CB1 activity found to produce the psychoactive
consequences of THC exposure (Pertwee 1988; Pertwee 2008; Sv́ıženská et al. 2008). CB1
also appears to facilitate the reinforcing effects of THC, by inducing DA release in the
VTA and PFC (Diana et al. 1998; French 1997). Non-human primates (NHP) have been
demonstrated to self-administer THC, but evidence indicates that rodents do not
(Justinova et al. 2003; Wakeford et al. 2016). The zebrafish Dc is small relative to the
rodent PFC, suggesting that THC would not be reinforcing in this model (see Section
6.1.4 for conservation of these structures). However, should the principle site of THC
reward be the mammalian VTA, it is possible that its action on the zebrafish PTN may
achieve this signalling. Thus it is necessary to directly investigate the presence of
THC-induced reward signalling in the zebrafish brain.
CB1 (activated by the endocannabinoid CB1 agonist, 2-Arachidonoyl glycerol)
triggers neuroprotective consequences via inhibition of NF-κB (Panikashvili et al. 2001;
Panikashvili et al. 2005). CB1 activity has been shown to reduce glutamate-induced
excitotoxicity (Shen and Thayer 1998). In relation to age-related neurodegeneration, AD
patients present decreased neuronal expression of CB1 (Ramı́rez et al. 2005). Both CB1
and CB2 are expressed in amyloid plaques, and co-localise with molecular markers of
(degenerative) microglial activation; microglial activation was found to be attenuated by
agonists of both cannabinoid receptors (Ramı́rez et al. 2005). THC has been shown to
inhibit AChE (the same function performed by three of the four currently-prescribed AD
treatments), reducing its potential to facilitate aggregation of Aβ (Eubanks et al. 2006).
THC has also been found to protect neurons in an in vitro model of PD, via
CB1-independent signalling (Carroll et al. 2012). It attenuates MS-associates
neuroinflammation, neurodegeneration, spasticity and tremor (Baker et al. 2000; Pertwee
2002; Pryce et al. 2003; Ungerleider et al. 1988). CB2 is reportedly up-regulated in a
rodent model of ALS (SOD1G93A), and THC treatment has been found to delay the
onset of symptoms and prolong longevity in this model (Moreno-Martet et al. 2014;
Raman et al. 2004).
Additionally, other (non-psychoactive) cannabinoids have been identified, which may
prove more socially acceptable as treatments for neurodegeneration. For example,
cannabidiol (CBD) has been found to reduce Aβ toxicity, whilst reducing a range of
neurodegenerative consequences including ROS production, caspase3 expression and
Ca2+ dysregulation (Iuvone et al. 2004). The fact that CBD is an antagonist of both
CB1 and CB2 demonstrates the complexity of cannabinoid signalling and its potential as
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a target of neuroprotective pharmacological intervention (Pertwee 2008).
Anaesthetics
Anaesthetics present a class of drug to which many people are exposed at some point
their lifetimes. Whilst exposure to general anaesthetics is somewhat specific to surgical
procedures, local anaesthetics are commonly used in dental treatment practices. However
the abuse potential of both anaesthetic subcategories has been reported.
Ketamine is commonly regarded as a general anaesthetic, although local
anaesthetic properties have been reported (Dowdy et al. 1973; Durrani et al. 1989). It is
a non-competitive NMDA-R antagonist (i.e. it reduces the maximal activity of NMDA
responses). The inhibition of this excitatory receptor results in a range of acute,
reversible cognitive impairments related to PFC functioning, including memory and
attentional deficits, psychological dissociation and psychosis (in a manner paralleling
certain characteristics of schizophrenia) (Malhotra et al. 1996; Moghaddam et al. 1997;
Verma and Moghaddam 1996).
Additionally, ketamine has been found to directly increase DA secretion in the PFC
(Verma and Moghaddam 1996). Interestingly, following repeated exposure to ketamine,
despite increases in basal DA, the acute increase in DA is attenuated (Lindefors et al.
1997). However the authors reported an increase in acute serotonin activity in the mPFC.
Similarly, it has been reported that ketamine increases 5-HT signalling in the DRN (Tso
et al. 2004). These enhancements of serotonergic mechanisms are associated with the
antidepressant and anxiolytic effects of ketamine (Gigliucci et al. 2013).
Ketamine also (weakly) agonises both µ- and κ-opioid receptors (Hirota et al. 1999).
Its stronger affinity for µ-opioid receptros may further explain the reinforicing properties
of ketamine, as this induces NAcc DA release (which is countered by κ-opioid receptors,
as discussed below in Section 6.1.2; see Hirota and Lambert 1996; Hustveit et al. 1995;
Spanagel et al. 1992). In rodent studies it has been found to be self-administered, as well
as inducing CPP (De Luca and Badiani 2011; Du et al. 2017)
Ketamine’s antagonism of NMDA-Rs has also been found to protect CNS neurons in
rodent models of ischaemia and epileptic seizures (Church et al. 1988; Fujikawa 1995).
In this regard, it is worth noting that other NMDA-R antagonists (e.g. the AD drug
memantine and the PD drug amantadine) have also been reported to be protective against
various CNS insults, including hypoxia, excitotoxicity and ischaemia (Danysz and Parsons
2003; Kornhuber et al. 1993; Miguel-Hidalgo et al. 2002; Weller et al. 1993). Additionally,
the positive effects of ketamine on the cardiovascular system has been proposed to improve
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blood-flow to the brain (Himmelseher and Durieux 2005).
PCP is also a NMDA-R antagnost, however its pharmacology is much ‘cleaner’ than
that of ketamine. Thus, the above-mentioned consequences of ketamine’s antagonism of
NMDA-Rs is true of PCP, including subsequent modulation of DAergic and serotonergic
pathways, as well as the induction of psychosis (see Kapur and Seeman 2002). In rodents
it is self-administered, and produces CPP (Marglin et al. 1989; Marquis et al. 1989).
PCP has been found to exert some neuroprotective effect on cerebral ischaemia, via
inhibition of creatine kinase release, an enzyme over-active in PD patients (Lu et al. 1992;
Takubo et al. 2003). Interestingly, under-expression of creatine kinase has been associated
with both AD and HD pathologies, exemplifying the distinct molecular dysregulations
which occur in different neurodegenerative conditions (Aksenov et al. 1997; Kim et al.
2010).
Procaine is a local anaesthetic which has been widely utilised by dental practitioners
in peripheral tissue, due to its inhibition of Na+ channels (Wagner and Ulbricht 1976).
Within the CNS, procaine modulates DA secretion in a similar manner to cocaine
(Hernandez et al. 1991). Additionally, it has also been shown to inhibit NMDA currents in
vitro, apparently acting on the CNS in a manner similar to ketamine and PCP (Nishizawa
et al. 2002). It induces SA in NHPs, however there is no evidence that it is reinforcing
in rodent models (Beardsley and Balster 1993; Ford and Balster 1977; Gong et al. 1996;
Woolverton and Balster 1979).
Procaine has also been found to protect neurons against Aβ toxicity, a function possibly
facilitated by its inhibition of glutamate excitotoxicity and mitochondrial dysfunction
(Lecanu et al. 2005). It may also protect against traumatic neuronal injury via inhibition
of HSP-70 (Tunc et al. 2002).
Antidepressants
Bupropion (weakly) inhibits re-uptake of norepinephrine and DA, and has been shown
to increase DA in the NAcc (Ascher et al. 1995). It induces rodent SA and CPP, and
is abused by humans (e.g. Baribeau and Araki 2013; Ortmann 1985; Reeves and Ladner
2013; Tella et al. 1997).
Bupropion also appears to exert neuroprotection against excitotoxicity in a manner
relevant to epileptic seizures, which the authors linked to its inhibition of glutamate
excitotoxicity (Lin et al. 2011; Lin et al. 2013). Further, it has been reported that
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bupropion induces an up-regulation of the neuroprotective SOD1, a possible mechanism
in this protective effect (Li et al. 2000). It has also been found to protect against
glaucoma, a function linked to its ”anti-TNF” properties (Stein et al. 2014).
Opiates
Opiates agonise the opioid receptors - δ, κ, µ, ζ, and nociceptive receptor. µ-opioid
receptors have been demonstrated to positively modulate DAergic secretion in the NAcc,
whilst κ-opioid receptors have the inverse effect (Spanagel et al. 1992). The
neuroprotective properties of opiates are largely believed to be facilitated by δ receptors .
However antagonism of µ-opioid receptors has also been found to induce
neuroprotection, suggesting that this receptor plays a role similar to the balance between
adenosine receptors A1 and A2A in a counterbalanced modulation of both these
phenomena (see Section 6.1.2; Liao et al. 2003).
Morphine acts by stimulating µ-opiate receptors, resulting in increased DA secretion
in the NAcc (Di Chiara and Imperato 1988). Rodent studies have demonstrated that
microinjection into the VTA increases DA in the NAcc, as well as inducing CPP (Leone
et al. 1991; Mucha and Herz 1985; Phillips and LePiane 1980). It is self-administered by
rodents, and has also been shown to induce CPP in zebrafish (Glick et al. 1991; Lau et al.
2006).
Morphine has been found to modulate ubiquitination in a neuroprotective manner,
via the production of NO (Rambhia et al. 2005). It appears to offer some protection
against Aβ neurotoxicity via NO, as well as downstream modulation of caspases -2 and
-3 (possibly by CaMKII) (Lin et al. 2004; Pak et al. 2005). Pre-exposure has also been
shown to protect against ischaemia (Zhao et al. 2006).
Fentanyl is also a µ-opioid agonist, although with greater affinity than morphine. It
is self-administered by both NHPs and rodents, and it induces rodent and zebrafish CPP
(Broadbear et al. 2004; Morgan et al. 2002; Mucha and Herz 1985; Nishida et al. 1989;
Stewart et al. 2015).
Kuzak and colleagues criticised the lack of adequate fentanyl use in an emergency
medical procedure as, despite clear indications of neuroprotective benefits, few patients
are administered this drug (Kuzak et al. 2006). Fentanyl has also be found to protect
against ischaemic damage in a rodent model (Wang 2006).
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6.1.3 Neuroprotective drugs without reinforcing properties
Additionally, two neuroprotective drugs were included in the screen as negative controls
for reward signalling.
Atomoxetine is a treatment for attention deficit hyperactivity disorder (ADHD), a
condition largely associated with PFC dysfunction (Arnsten 2006). It inhibits re-uptake of
DA, 5-HT and norepinephrine, thereby prolonging their signalling in the PFC (Bymaster
et al. 2002; Ding et al. 2014). It increases cortical cholinergic signalling, which is associated
with an increase in cognitive function (Tzavara et al. 2006). However, atomoxetine is not
considered to have significant abuse liability in humans (Jasinski et al. 2008). It does not
affect DA in the NAcc and does not induce CPP in rodents (Bymaster et al. 2002; Peña
et al. 2011; Swanson et al. 2006).
Atomoxetine has been demonstrated to improve functional recovery in rodent
traumatic brain injury (TBI) and spinal cord injury (SCI) (Hou et al. 2016; Reid and
Hamm 2008). It has been shown to be neuroprotective in rodent ischaemia (Park et al.
2015). Additionally, atomoxetine has been reported efficacious in restoring some level of
executive function in PD patients, although not proposed to be actually neuroprotective
in this disease (Marsh et al. 2009).
Naloxone is an inverse agonist of µ-opioid receptors, counteracting the effects of
opiates (Sawynok et al. 1979). It thus does not induce reward signalling. However naloxone
protects against microglial production of ROS - a detrimental consequence of Aβ signalling
- and has shown efficacy as a treatment for ischaemia in a rodent model (Chang et al.
2000; Liao et al. 2003; Liu et al. 2002). It also appears to protect DAergic neurons from
microglia and ROS, possibly having positive implications for PD treatment (Liu et al.
2000).
6.1.4 Conservation of reward in zebrafish
The parallels between mammalian and teleost reward signalling have been alluded to
above. However the extent of conservation between these species is still unclear. Indeed,
there is currently a lack of comprehensive insight into the range of pharmacological agents
which induce rewarding behaviour in zebrafish. However the conservation of certain key
neuroanatomical structures and behavioural responses is supported in the literature (see
Figure 6.2).
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Reward signalling
Many of the aforementioned regions involved in reward signalling (see Section 6.1.1, above)
are structures specific to the mammalian brain (with the exception of raphe nuclei, which
are conserved in zebrafish; see Turner et al. 2016; Yokogawa et al. 2012). However zebrafish
have similar structures, argued to be orthologous to those of the mammalian brain. For
example, the PTN has been reported to functionally represent the mammalian VTA (Klee
et al. 2012; Parker et al. 2013b; Rink and Wullimann 2001). Expression patterns in the
zebrafish Vd have been paralleled with the NAcc (Rink and Wullimann 2001). Similarly,
the Dc has been paralleled with various cortical regions, including some basic functions
performed by the mammalian PFC (Mueller et al. 2011; Parker et al. 2013b). These
zebrafish neuroanatomical structures are represented graphically in Figure 6.2.
6.1.5 Safety pharmacology
Safety pharmacology is a stage of drug development, concerned with assessing and
predicting possible adverse effects of novel compounds. One of the key elements of this is
assessing the abuse potential of these compounds.
Abuse potential is the likelihood that a substance will be misused (abused), due to
reinforcing pharmacological properties. All drugs approved for distribution in the UK,
Europe, and the US are required to be assessed for their abuse potential in order for
physicians to make more informed decisions when prescribing medication.
6.1.6 Reward-seeking behaviours
Safety pharmacology relies heavily on the observation of reward-related behaviours.
These have been developed into screening assays in the pharmaceutical industry.
Current industrial protocols utilise rodents for this purpose, assessing abuse potential via
assays of classic reward-seeking behaviours, including SA and CPP (as well as DD,
discussed in Chapter 7) (Panlilio and Goldberg 2007; Tzschentke 2007).
Self administration
SA involves the ad libitum administration of a drug, under the control of the subject itself.
Often the drug dose is decreased following an initial aquision of SA (at a higher dose).
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The number of administration responses, or total drug consumption, is then measured as
an index of reinforcement (e.g. Collins et al. 1983; Palmatier et al. 2006).
The development of a zebrafish SA assay would clearly be efficacious to industrial safety
pharmacology, however there is difficulty in controlling administration of the drug. For
example, the continuous locomotor activity of zebrafish poses problems for the insertion
and stable maintenance of a transcranial cannula. It is possible to administer BBB-
penetrating compounds via aquarium water (a method commonly utilised in zebrafish
CPP paradigms); however controlling the acute termination of drug exposure (as discrete
trials) presents a problem. Netting the fish induces acute stress, which would likely over-
shadow drug reinforcement. It may be possible to develop a ‘wash chamber ’ to treat fish
and subsequently remove drug via a rapid change of chamber water. However, again the
stress of this process will likely interfere with reward signalling.
Another possible method is to infuse food with a drug. However this presents its
own set of problems. For example, many drugs of abuse dampen appetite (e.g. cocaine,
amphetamine, nicotine). Additionally, it is almost impossible to reliably calculate the
concentration of drug consumption as this would depend on the volume of food dispensed,
the consistency of this volume between administrations, and the quantity of food actually
consumed by the fish. Further, the administration is likely to be restricted by the maximal
quantity of food the fish can consume. This would pose further problems for genetic studies
in which mutations affect growth (i.e. size) and appetite, as well as likely presenting sex
differences due to the relatively smaller size of the male zebrafish.
Conditioned Place Preference
Despite SA paradigms having higher face and predictive validity in relation to
drug-seeking behaviours, the relative simplicity of CPP has lead to its wide-spread
utilisation (in rodents) as a measure of reward signalling (Bardo and Bevins 2000;
Tzschentke 1998).
Essentially, CPP is a pavlovian association between an environmental context (i.e. the
CS) and the rewarding properties of a pharmacological agent (i.e. the US). The animal’s
preference - following conditioning - when given the choice of CS and a neutral stimulus
(non-CS) is indicative of the rewarding properties of the US (drug). Typically, the specifics
of this assay vary around the following procedural steps (e.g. Kily et al. 2008; Parker et al.
2016):
1. Measurement of baseline preferences when given the choice of two distinct stimuli
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2. Multiple conditioning sessions to the least-preferred (CS) of the two stimuli, paired
by exposure to a rewarding drug (US)
3. Probe assessment of ’conditioned preference’ for CS vs non-CS.
Several drugs abused in human society have been found to induce CPP in zebrafish.
These include amphetamine, cocaine, ethanol, morphine, and nicotine (Darland and
Dowling 2001; Kily et al. 2008; Lau et al. 2006; Ninkovic and Bally-Cuif 2006).
6.1.7 Aims
The aims of this chapter are to:
1. Validate a zebrafish CPP paradigm using a positive control (fentanyl)




Wild-type Tubingen zebrafish (Danio rerio) were bred in-house, or else aquired from
a commercial supplier (Wades Tropical Import Ltd., UK) at 4 week post fertilisation.
All fish were raised in the fish facility at Queen Mary, University of London, according
to standard protocols. Based on power analyses conducted previously on studies using
nicotine and EtOH, 20 fish were used at each drug concentration. CPP analyses were
conducted at 3-4 months post fertilisation. All experiments were conducted in accordance
with the Animals (Scientific Procedures) Act, 1986, under ethical guidelines by Queen
Mary Animal Care and Use Committee, and under license by the Home Office (UK).
6.2.2 CPP
CPP experiments were conducted as previously described (e.g. Parker et al. 2013a; Parker
et al. 2016). All experimental procedures were conducted in 20cm x 15cm x 30cm (WxHxL)
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plastic assay tanks (see Figure 6.3).
One week prior to habituation, fish were singly housed. They were then exposed to two
separate conditioning sessions (one per day, on two consecutive days). Each conditioning
session involved placing the fish in the assay tank, giving it freedom to explore the entire
tank (i.e. both stimulus-presenting ‘zones’), for 20 minutes each.
Baseline preferences were measured on the day following the second habituation
session. This was achieved by allowing the fish to explore the entire tank (as with the
habituation sessions), for 10 minutes. Video recordings (to calculate basal and probe
preferences for stimuli) were taken, and fish were tracked live using EthoVision XT 9
software (Noldus), with a ceiling-mounted camera suspended above the assay tanks. The
‘arenas’ were drawn to envelope the tanks, and divided into two ‘zones’ (corresponding
to the two stimuli presented in the tanks; see Figure 6.3). The proportion of ‘time spent
in zone’ was calculated from these data, as a direct index of stimulus preference. Fish
which displayed basal proportional preferences greater than 0.75 for either of the stimuli
were excluded from the rest of the study. This ranged between 5% and 40% fish per drug
conditioning (i.e. across all doses).
Conditioning was conducted on three consecutive days. Fish with basal preferences
below the exclusion threshold were conditioned to associate the non-preferred of the two
stimuli with drug administration. Initially, fish were placed in the tank - with a plastic
divider separating the two stimuli-presenting areas - on the side presenting the preferred
stimulus (for that particular fish). They were allowed to explore just this
stimulus-presenting area (non-CS) for 20 minutes, in the absence of drug. The barrier
was then removed and fish encouraged to relocate to the non-preferred
stimulus-presenting side, and the barrier replace (restricting the fish to exposure to this
stimulus). Immediately following this relocation the drug (or vehicle) was administered
by addition to the tank water from 50mL stock (at 50x treatment concentration). Fish
were then allowed to explore this stimulus-presenting area (CS) in the presence of the
drug (US).
Probe preferences were calculated in the same manner as baseline preferences, except
that only the latter five minutes of the 10-minute trial was analysed.
6.2.3 Locomotion
Drugs which failed to induce CPP (both those which had been hypothesised to induce it,
and the negative controls), were assessed for their effect on locomotor activity. Effect on
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Figure 6.3: CPP assay tank. All stages of CPP experimentation were conducted
in opaque rectangular tanks (20cm x 15cm x 30cm; WxHxL) containing 2.5L
aquarium water. Basal and post-conditioning (probe) preferences for each stimulus
was assessed by giving free access to the entire tank. During conditioning sessions,
a divider was inserted in the centre of the tank (indicated here by a vertical line
through centre of tank), restricting access to one of the two stimulus-presenting
arenas.
locomotion was used as a proxy measure, to indicate whether or not the drug might cross
the BBB to enter the zebrafish CNS (see Porsolt et al. 2002).
Drugs were tested at the same concentrations used in CPP assessment. Ten fish were
used per drug dose; the administration order of drug dosing was pseudo-randomised.
Drug administration was conducted using pre-treatment in drug-treated aquarium
water. Pre-treatment lasted 20 minutes. Following this exposure, fish were netted out
of the drug-treated water and placed in a large (22cm x 16cm x 27cm; WxHxL) tank,
containing un-treated aquarium water. Fish were allowed to habituate to the assay tank for
4 minutes (due to observations of stress-like behaviour upon first introduction to the assay
tank). Immediately following this, locomotion was assessed over a 16-minute period. This
was monitored via a ceiling-mounted camera suspended above the tanks, using EthoVision
XT 9 software (Noldus).
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Table 6.1: Details of drugs tested. Drugs were obtained from the stated








Cantilena et al. 2012




Tella et al. 1997







Richendrfer et al. 2012




Grant and Samson 1985
Kily et al. 2008
Fentanyl citrate Sigma F3886
0.008 - 0.303
(0.004 - 0.16)
Nishida et al. 1989




Riehl et al. 2011
Rocha et al. 1996
Morphine sulphate Sigma M8777
0.7 - 7.9
(0.5 - 6)
Lau et al. 2006




Collins et al. 1983
O’Connor et al. 2011
Nicotine hemisulphate Sigma N1019
0.5 - 10
(0.2 - 4.2)
Bencan and Levin 2008




Kyzar et al. 2012




Johanson and Aigner 1981
Woolverton and Balster 1979
∆9 tetrahydrocannabinol Sigma T2386
0.16 - 0.64
(0.05 - 0.2)
O’Connor et al. 2011
Mansbach et al. 1994
6.2.4 Drugs and doses
Dose ranges were selected based on previous research of CPP and/or SA, using zebrafish,
rodents or NHPs (see Figure 6.1). Maximum concentrations (in the assay tanks, mg/L)
did not exceed 2x the mammalian effective dose (mg/kg). All drugs were used at pH 6.95
- 7.5.
Drug were assessed for toxic effects on the fish, prior to experimentation. Beginning
with the lowest concentration, fish (n=3) were placed in individual tanks containing the
drug in 200mL aquarium water. Fish were exposed to the drug for one-hour, during which
they were monitored for signs of toxicity (difficulty swimming, exaggerated breathing,
haemorrhaging gills, internal bleeding). Fish were re-checked at regular intervals over
the six hours following exposure, as well as on the following morning. If no toxicity was
detected, the process was repeated using a higher concentration of drug, until the highest
intended dose had been assessed. If toxicity was detected before the highest dose was
assessed, the highest non-toxic concentration was used as the highest dose.
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6.2.5 CPP data analysis
Data were output from EthoVision as time spent in zone (for each of the two
stimulus-presenting zones), and the proportion of time spent in the CS-presenting zone
was calculated by dividing this time by the total time the fish was tracked. ‘Change in
preference’ was calculated by deducting each subject’s CS preference during the baseline
trial, from that of the probe trial.
Inferential statistical analyses were performed using SPSS® Version 21 for Mac
(IBM®). In order to determine the most appropriate statistical model (for the fit of
each dose-response curve), regression analyses were employed. Both linear and quadratic
regression models were performed to determine the shape of the curve (linear or ‘inverted
U’); the model which produced the highest t-ratio was adopted for subsequent analysis.
The residuals from the regression analysis were plotted (SPSS Legacy Boxplot);
outliers (1.5x IQR) were removed. These outliers were generally caused by tracking
errors; the maximum number of subjects removed from an experiment was 4% (for any
one drug, across all doses). The data were then analysed using polynomial general linear
model. Post-hoc Dunnett’s test was performed, comparing the dosed groups to the
control (vehicle) group (two-sided).
6.2.6 Locomotion data analysis
Locomotion data were extrapolated as ‘Distance moved ’ in 2-minute time bins. In order
to account for spurious data points (caused by problems with the tracking or acute
environmental factor which caused stress-like ‘freezing’ behaviour), any time bin in
which the subject moved less than 100cm was removed.
Data were then fitted to a linear mixed effects model, using distance travelled as the
dependent variable, with time and concentration as fixed effects. The residuals of this
model were plotted (SPSS Legacy Boxplot), and outliers were removed at 1.5x IQR. The
linear mixed effects model was then run again, without outlying data.
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Figure 6.4: CPP assay validation. The conditioning of zebrafish with fentanyl
(as an US) resulted in a quadratic regression. No effect was found in the linear
term (F1,129=1.698, p=0.195); however a significant preference change for the CS-
presenting arena was found in the quadratic term (F1,129=5.233, p=0.024) (n=130).
By one-way ANOVA, then one-sided Dunnett’s test; *, p<0.05. Data plotted as
mean ± SEM.
6.3 Results
6.3.1 Conditioned place preference
Initially, an experiment to validate the CPP paradigm was conducted. Fentanyl was chosen
as the US, as this opiate has previously been reported as reinforcing in humans, rodents
and zebrafish (Stewart et al. 2015; see Section 6.1.2). The analysis found that the drug
induced significant CPP in zebrafish (see Figure 6.4).
Subsequently, a range of ‘neuroprotective’ compounds with known reinforcing
properties was assessed for their ability to induce CPP in zebrafish. Of the 10 drugs
tested, six are reported here to be true positives (i.e. induce CPP in zebrafish; see Figure
6.5). Four were found to be false negatives (i.e. failed to induce significant CPP in
zebrafish; see Figure 6.6).
Additionally, two negative controls were included in the study - atomoxetine and
naloxone. These neuroprotective drugs have all been found to have no reinforcing effects
on humans. Neither of these drugs were found to induce CPP in zebrafish (see Figure
6.7). Thus, there were no false positive results.
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Figure 6.6: Neuroprotective drugs without reinforcing properties in
zebrafish. Four neuroprotective drugs - reported to exert reinforcing effects
in humans - failed to induce significant CPP in zebrafish. All of these drugs
produced linear dose-response curves which failed to reach significance. Bupropion
(F1,81=0.587, p=0.446) (n=83). Ketamine (F1,75=2.272, p=0.136) (n=76). Procaine
(F1,79=0.017, p=0.896) (n=137). THC (F1,82=1.115, p=0.294) (n=83). By one-way
ANOVA. Data plotted as mean ± SEM.
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Figure 6.7: Neuroprotective drugs with no reinforcing properties. Two
drugs which are not reinforcing in humans were included in the study as negative
controls. Neither of these induced significant CPP in zebrafish. Atomoxetine
produce a quadratic dose-response curve which failed to reach significance in
both the linear (F1,84=0.746, p=0.39) and quadratic terms (F1,84=2.566, p=0.113)
(n=88). Similarly, the quadratic dose-response curve for naloxone failed to reach
significance in both term - linear (F1,55=0.037, p=0.848); quadratic (F1,55=0.202,
p=0.655) (n=56). By linear regression. Data plotted as mean ± SEM.
6.3.2 Locomotion
For drugs which failed to induce CPP a locomotion assay was conducted, as a proxy
measure to indicate whether the drug crossed the BBB. All of these ‘false negative’ drugs
- bupropion, ketamine, procaine, and THC induced significant changes in locomotion (see
Figure 6.8).
Additionally, the negative control compounds used in the CPP assessment
(atomoxetine and naloxone) were assessed for their affects on locomotion. Both of these
compounds induced significant changes in locomotor activity (see Figure 6.9).
6.4 Discussion
The aim of this chapter was to test the hypothesis that a range of drugs known to be
reinforcing in humans would induce CPP in zebrafish. Of the ten drugs assessed which
are reinforcing in humans, six were found to induce significant conditioned changes in
zebrafish preference, demonstrating a conservation of the relative signalling mechanisms.
Both of the stimulants (caffeine and nicotine) significantly induced a change in
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Figure 6.8: Locomotion assessment of drugs which failed to induce CPP
in zebrafish. Neuroprotective drugs which exert reinforcing effects on humans,
but failed to induce zebrafish CPP, were assessed for their affects on locomotion.
Bupropion (F4,279=9.904, p<0.0005), ketamine (F4,305=3.74, p<0.0005), procaine
(F4,297=2.517, p=0.042) and THC (F4,240=11.588, p<0.0005) all induced significant
effects on distance travelled (n=50 per drug). By linear mixed effects model; *,
p<0.05; **, p<0.01; ***, p<0.001. Data plotted as mean ± SEM.
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Figure 6.9: Locomotion assessment of CPP ‘negative controls’.
Neuroprotective drugs which have no reported reinforcing affects on humans (and
were found to have no affect on zebrafish CPP, above) were assessed for their
affects on locomotor activity. Both of these drugs caused significant changes in
distance travelled. Atomoxetine (F4,231=10.642, p<0.0005). Naloxone (F4,253=9.758,
p<0.0005) (n=50 per drug). By linear mixed effects model; *, p<0.05; **, p<0.01;
***, p<0.001. Data plotted as mean ± SEM.
conditioned preference. The fact that these two compounds exert their reinforcing effects
via distinct molecular pathways indicates that both of these mechanisms may be
conserved in the zebrafish. With regard to nicotine, the fact that the α7 subunit has
been implicated in modulating reward signalling suggests that this receptor’s function
may be conserved (Besson et al. 2012; Marquis et al. 1989). This has important
implications in relation to neuroprotection, as the α7 subunit has been strongly
associated with facilitating nicotine-induced neuroprotective signalling (e.g. Arias et al.
2005; Jonnala and Buccafusco 2001; Liu et al. 2007a; Shimohama 2009). Thus, as
elucidating the specific functions of α7 is of importance to both of these neurobiological
phenomena, future investigations may wish to assess the extent that α7 signalling is
conserved in zebrafish.
Caffeine’s reinforcing effects have been associated with antagonism of the A1 receptor
subtype (Solinas et al. 2002). Thus, the current finding of conserved caffeine reward in
zebrafish implies a conservation of A1 signalling. In contrast, the neuroprotective
properties of caffeine have been associated with antagonism of A2A (Gomes et al. 2011).
The balance of neuronal excitation and inhibition - as affected by these two opposing
receptors - has important implications for both reward and neuroprotective signalling.
Therefore, the extent to which this balance is conserved in zebrafish is important to
understanding the efficacy of this organism to model aspects of these neurological
disorders. It is thus suggested that future research investigate the extent of adenosine
signalling conservation in zebrafish on a more holistic scale.
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As with the stimulants, both of the opiates (fentanyl and morphine) caused a
conditioned change in preference. The fact that both opiates used here are µ-opioid
receptor agonists strengthens the argument of conserved opioid signalling functioning in
zebrafish. Further, in light of findings that µ-opioid receptor antagonism induces
neuroprotection (in a rodent model of ischaemia), it would be of importance for future
research to investigate the conservation of this opposing action of µ-opioid (Liao et al.
2003).
Further, it has been reported that the µ-opioid receptor is necessary for nicotine-
induced reward (Walters et al. 2005). Thus, the extent to which this relationship between
nAChRs and µ-opioid receptors is conserved in zebrafish would present an interesting facet
of reward signalling in this organism.
The alcohol tested (ethanol) caused CPP. This is in-keeping with previous research
reporting this effect, supporting assertion that key reinforcing aspects of EtOH reward are
conserved in zebrafish (Collier et al. 2014; Kily et al. 2008).
The antidepressant tested (bupropion) failed to induce CPP; however locomotion
analysis indicates that it does indeed cross the BBB. Thus it appears that any effect it
has on increasing DA in the zebrafish Vd is insufficient to cause reinforcement (as occurs
in the mammalian NAcc), at the concentrations used here. Additionally, as the effect of
this drug on DA and norepinephrine is weak, it is possible that increased exposure is
necessary to induce the biochemical adaptations necessary to facilitate reward. However,
further research is needed to test this hypothesis. Thus, within the context of the assay
used here, exposure failed to induce CPP.
Similarly, no effect was found for the local anaesthetic procaine. The locomotor
analysis found a significant effect of the drug, indicating that it crosses the BBB. This
suggests that its modulation of DA is insufficient to induce reward signalling. However,
the locomotor analysis failed to find any single dose significantly different from controls.
Indeed, it appears that the significance of the model may be driven by the difference
between 183µM and 367 µM. This suggests that the effects of increasing procaine
concentration may be countered by homeostatic signalling in the zebrafish brain, with a
non-significant trend towards decreasing locomotion (up to 183µM) ameliorated at
higher concentrations. However research on a molecular level is necessary to investigate
this hypothesis. Further, it is possible that the drug does not, in fact, cross the BBB,
and that the subtle, significant effect on locomotion results from a pharmacological
action on peripheral tissues; however, again, further research is needed to investigate
this.
Conditioning with the cannabinoid THC failed to induce a significant change in
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preference. This suggests that the conservations of functioning in the zebrafish PTN and
Dc are insufficient to model this function of the mammalian VTA and PFC, in this
respect. However, as THC is not reinforcing in rodents, the lack of an effect does not
diminish the utility of zebrafish as a pre-screening refinement to the use of rodents in the
pharmaceutical industry (e.g. Wakeford et al. 2016).
Additionally, it has been reported that pre-exposure to THC (in the absence of
conditioning stimuli) leads to significant CPP in rodents (Valjent and Maldonado 2000).
The authors commented that first-time exposure in drug-näıve subjects induces a
dysphoria (often leading to conditioned place aversion), which is attenuated in
subsequent exposures. Thus, it is possible that pre-exposure in zebrafish would result in
a significant CPP; although further research is necessary to establish the existence of this
conservation. However, within the context of the assay utilised in the current research, it
must be concluded that THC fails to induce rewarding behaviour in zebrafish.
In relation to neuroprotection, it is worth mentioning that many phytocannabinoids
have prolonged activity in the body (compared with endocannabinoids, due to decreased
cellular uptake) (see Mechoulam et al. 2002). This suggests that such compounds may
enhance and prolong the neuroprotection exerted by endocannabinoid. In this regard,
the non-psychoactive phytocannabinoid CBD delays onset of ALS (Weydt et al. 2005).
As CBD is an indirect agonist of the cannabinoid receptors, this suggests that direct
receptor activation may not be required to initiate of these neuroprotective mechanisms.
Thus, future translational research into the neuroprotective consequences of cannabinoid
signalling may wish to target other (down-stream) molecules in the signalling pathways,
as an alternative to developing compounds with abuse potential.
The two general anaesthetics tested produced non-uniform results - PCP induced
CPP, whilst ketamine failed to do so. As the primary pharmacological action - namely,
antagonism of NMDA-Rs - is common to both of these compounds, it appears that the
non-specific actions of ketamine inhibit reward signalling. Alternatively, it is possible that
these secondary actions induce a mild aversive response, which counteracts the reward
signalling of NMDA-R antagonism.
It is unlikely that this would be facilitated by ketamine’s weak agonism of opioid
receptors, as its higher affinity for µ- over κ -receptors (rewarding and aversive,
respectively) suggest a facilitation of reward signalling. However it is possible that the
increase in 5-HT may be responsible for this effect. Indeed, it has been found that 5-HT
signalling in the periaqueductal grey matter facilitates aversion in rats (Nogueira and
Graeff 1995). In this regard, modulatory serotonergic projections have been reported to
extend from the DRN to the periaqueductal grey matter, a mechanism associated with
”defensive behaviour” (Stezhka and Lovick 1994; Stezhka and Lovick 1997; Vianna and
Ari Sudwarts 179
CHAPTER 6. ASSESSING THE UTILITY OF ZEBRAFISH CONDITIONED
PLACE PREFERENCE AS A MODEL FOR ABUSE POTENTIAL
Brandao 2003). Further, the close proximity of the periaqueductal grey matter to the
DRN (in the mammalian brain) suggests that this may indeed be a strong candidate
mechanism to explain the failure of ketamine to induce CPP. However, currently no
zebrafish neuroanatomical region has been reported to be orthologous to the mammalian
periaqueductal grey matter; thus, further research is required to elucidate the signalling
which drives this phenomenon.
In summary, the results presented in this chapter suggest that zebrafish may have a
utility as a model of human abuse potential for the assessment of stimulants, opiates and
alcohol. Using the current paradigm it appears that their neurological complexity may be
insufficient to model the human abuse of anaesthetics, antidepressants and cannabinoids.
However, analysis of a more comprehensive range within these drug classes is necessary to
understand the full potential of this organism as a model for human reward. Additionally,
it is possible that a refinement on the assay protocol (e.g. pre-exposure in the assessment of
cannabinoids) may lead to the induction of CPP in the false negative compounds reported
here. Thus, these data serve as an encouraging pilot study into the utility of zebrafish
CPP as a model of human abuse potential.
The current investigation was primarily focussed on assessment of behavioural
responses, as a measure of conserved reward mechanisms. This was, in part, due to the
involvement of elements of neuroprotective pathways, in reward signalling. Thus, the
implications of conserved reward-related behaviours suggests the relative neuroprotective
mechanisms may, too, be conserved. This is especially true of caffeine, nicotine, PCP,
and possibly EtOH, for which the primary reward pharmacology of the drugs are also
targets for the protective signalling; however this may have little bearing on those drugs
for which the relationship between the two facets of this dual action is unclear (namely,
morphine and fentanyl). Thus, future research may wish to establish the conservation of
these neuroprotective mechanisms, as well as elucidating any interactions with reward
signalling pathways.
In conclusion, the data reported here suggest that certain fundamnetal aspects of
mesocorticolimbic reward signalling are conserved in the zebrafish, although the extent
of this conservation appears limited. It is possible that the lack of induced rewarding
behaviour by certain compounds relates to the relative simplicity of zebrafish
neuroanatomical structures, secondary pharmacological mechanisms, or possibly
inadequacies of the assay. Despite this, there is clear evidence that zebrafish present an
efficacious tool for modelling at least some of the rewarding aspects of human drug
abuse. It is now necessary for further research to investigate a more extensive range of
compounds which induce CPP in zebrafish.
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CHAPTER 7. DEVELOPMENT OF A DRUG DISCRIMINATION ASSAY
7.1 Introduction
In addition to CPP (explored in Chapter 6) and SA assays, drug discrimination
paradigms are commonly used to assess the abuse potential of novel compounds. These
typically involve multiple training sessions in a ‘two-choice’ assay; conditioning an
animal to make one response following drug treatment, and the alternate response
following saline treatment (e.g. Colpaert 1999; Solinas et al. 2006).
An animal (commonly rodent or NHP) is administered a drug or saline, then placed
in an operant conditioning chamber presenting two levers. Following drug
administration, presses on one of the levers is reinforced with a reward (food pellet).
Following saline administration, presses on the other lever is reinforced. Thus, the
psychoactive ‘state’ produced by the drug administration is paired with one conditioned
response, whilst saline is paired with the alternative conditioned response. A novel
compound can then be administered and the animal placed in the chamber (with neither
lever administering reinforcement); the ability of a novel drug to pharmacologically
mimic the drug used in conditioning is then assessed by the animal’s response (i.e. choice
of lever presses).
However, the requirement of food reinforcement poses two potential problems. Chiefly,
the motivation to continually make responses is subject to the appetite of the animal.
This may be partly controlled for by limiting or ceasing the animal’s feeding outside
conditioning, as well as introducing variable or random interval schedules (which also
facilitates repetitive responding in probe trials, where no reinforcement is administered)
(Millenson 1963; Pietras et al. 2010; Young et al. 2009). However, drugs which dampen
appetite may result in fewer responses and thus require a greater number of conditioning
sessions to achieve sufficient ‘learning’. This is particularly pertinent to the development of
a zebrafish assay, as the quantities of food consumed are much lower than that of (larger)
mammals. The reliable control of food release in these small quantities is problematic
in generating an automated assay system. Thus, it is possible that non-appetitive (i.e.
aversive) conditioning may present a more efficacious paradigm in this model organism.
Regardless of these potential limitations, drug discrimination allows direct, highly
specific pharmacological comparison of the interoceptive cues induced by a novel
compound, with those of a drug whose effects are known (Solinas et al. 2006). Thus,
whilst not directly indicating reinforcing properties, drug discrimination assesses the
ability of a novel compound to mimic the pharmacological action of a drug with known
abuse potential (e.g. Appel et al. 1983; Kamien et al. 1993).
In addition to the ‘screening out ’ of drugs with high abuse potential, it is possible that a
Ari Sudwarts 182
CHAPTER 7. DEVELOPMENT OF A DRUG DISCRIMINATION ASSAY
researcher may intend to identify drug which mimic abused compounds. For example, the
identification of drugs with low abuse potential (e.g. methylphenidate) which ‘substitutes
for ’ (not discriminated from) a drug with high abuse potential (e.g. amphetamine) may
be utilised as a treatment for individuals with dependence on this compound (e.g. Pena
et al. 2011; Lile et al. 2006). In this regard, the establishment of methadone as a non-
discriminated substitute for heroin - whilst highly controversial - has the potential to
facilitate the attenuation of opiate dependence (e.g. Donny et al. 2005; Leri et al. 2004;
Newman et al. 2002).
Similarly, comparisons between cocaine and procaine found that, whilst both are self-
administered in isolation, when given the choice cocaine is preferred, even when procaine
was delivered at a concentration sixteen times that of cocaine (Johanson and Aigner 1981;
Woolverton and Balster 1979). Whilst procaine was less rewarding, its ability to substitute
for cocaine demonstrates some extent of pharmacological similarity.
7.1.1 Neurobiology of drug discrimination
Understanding the neurobiological structures involved in drug discrimination tasks is
somewhat complex. This may be due to the distinct mechanisms of action by which
many of the drugs which induce this behavioural phenomenon affect the brain (for a
selection relative to neuroprotective mechanisms, see Chapter 6, Section 6.1.2). As such,
it has received little research attention. However logic dictates that this involves an
interaction between the structures involved in basic learning (in fear conditioning, the
amygdalae, as well as hippocampi in more complex tasks; see Chapter 3, Section 3.1.2)
and the pharmacological targets (primary or subsidiary) of the relevant drug. Thus, the
involvement of amigdalae, hippocampi, VTA, NAcc, PFC, and raphe nuclei may all be
involved, to some extent.
With regard to the conservation of these structures in zebrafish, more extensive
descriptions have been discussed earlier in this thesis. However, in brief, the PTN
(VTA), Vd (NAcc), Dc (PFC), Dm (amygdala), Dl (hippocampus) have all been
associated with conserved functioning (of the relative mammalian structures).
Drug discrimination is essentially a ‘state-dependent learning ’ paradigm, in which
the psychoactivity caused by a drug provides the ‘state’; learning which occurs in this
state is better retreived when in the same state (Overton 1972; Overton 1984). These
psychological states - induced by drugs including antidepressants, antipsychotics,
barbiturates, benzodiazepines, opiates, and stimulants - have been found sufficient to
facilitate retrieval of conditioned responses in mammals, when learned under the
influence of these compounds (Colpaert et al. 1976; Hill et al. 1971; Petersen and
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Table 7.1: Neuroprotective drugs which are discriminated from saline.
Previous research has found that the following neuroprotective drugs induce state-
dependent learning in mammals. The drug-conditioned responses have been found
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La Garza and Johanson 1983
Silverman and Schultz 1989
∆9 THC Significant
Rhesus monkey (WIN 55,212-2)
Rat (CP-55,940, methanandamine)
Wiley et al. 1995
Burkey and Nation 1997
Ghoneim 1980). However, within drug discrimination paradigms, retrieval when the
subject is in the same state (drug vs saline) as conditioning was conducted under must
be quantifiably different from retrieval in the non-same state. In this regard, several
‘neuroprotective’ compounds have been found to induce discriminatory states.
7.1.2 Drug discrimination of neuroprotective compounds
As mentioned above, the specific mechanisms by which drug discrimination is facilitated
varies (dependent on the drug used, as well as the specificities of the paradigm). However
there is evidence that many drugs with neuroprotective properties induce this manner
of state-dependent discriminative learning in mammals. This evidence is summarised in
Table 7.1:
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However, despite this wealth of research into discriminative state-dependent learning
in mammals, zebrafish research has paid little attention to this area of investigation. The
current research intends to address this gap in the literature, investigating the phenomenon
of zebrafish drug discrimination by designing and developing an automated assay.
7.2 Aims
The aim of this chapter is to develop a drug discrimination paradigm. This will be
undertaken with the following objectives:
1. Develop a paradigm which induces an immediate (short-term) conditioned response
(aversion of the CS)
2. Develop a paradigm which induces prolonged (longer-term) aversion (i.e. the
conditioned response is retained over a longer period of time)
3. Test the hypothesis that zebrafish can discriminate between drugs which exert
different interoceptive cues on humans
4. Assess the ability of zebrafish to discriminate a range of (paired) compounds,
discriminated by mammalian model organisms
7.3 Methods
7.3.1 Subjects
Wild-type Tubingen zebrafish (Danio rerio) were bred in-house, and raised in the fish
facility at Queen Mary, University of London, according to standard protocols. All
experimentation was conducted on fish 4-6 months post fertilisation. All experiments
were conducted in accordance with the Animals (Scientific Procedures) Act, 1986, under
license by the Home Office (UK).
7.3.2 Assay set-up and design
All equipment was designed and set up as used in Chapter 3 (see Figure 3.3). In brief,
an infrared-transmitting screen was placed on top of a LCD monitor, with transparent
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‘assay’ tanks placed on top. Stimuli were presented via the LCD monitor - visible to the
subjects through the transparent tanks. Fish were monitored via a camera suspended
from the ceiling, with an infrared filter over the lens (to allow tracking of the fish without
interference from the stimuli). Zebrafish behaviour was monitored in real-time, using
EthoVision XT 9 software (Noldus).
7.3.3 ‘Passive’ classical fear conditioning
All passive classical fear conditioning experiments were conducted using a thirty minute
habituation period (both stimuli presented, alternating every five minutes). Basal
preferences were recorded for thirty minutes, immediately following habituation (unless
multiple habituation session were conducted, as in Section 7.4.1).
Conditioning sessions - when not conducted immediate following baseline recordings
- involved the presentation of a blank screen for one minute, followed by nine cycles of
conditioning (1.5 seconds CS presentation, terminating with administration of US; then
8.5 seconds of non-CS presentation) unless stated otherwise.
All probe preferences (those which did not immediately follow conditioning) were
conducted by netting fish into the assay tanks at the stated time following conditioning.
A blank screen was presented for one minute, followed by a 2-minute probe trial (both
stimuli presented, one to each half of the screen; counterbalanced).
7.3.4 ‘Escape’ fear conditioning
All escape fear conditioning experiments were conducted without an habituation period,
per se (i.e. in distinction to baseline recordings), unless stated otherwise (i.e. Section
7.4.1).
Baseline recordings were taken over 30 minutes, with both stimuli presented (‘split’
across the screen, as per Figure 3.4). Stimuli presentation was switched (i.e. which side
presented CS vs non-CS) after fifteen minutes.
Conditioning sessions involved the presentation of both stimuli (in the ‘split-screen’
fashion). Every time the fish swam into the ‘zone’ presenting the CS it was allowed two
seconds to escape. Failure to relocate to the non CS-presenting ‘zone’ resulted in the
administration of a 9V electric shock, delivered every second the fish was in the
CS-presenting zone (unless stated otherwise). Each discrete conditioning trial lasted 55
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seconds, followed by presentation of a blank screen for five seconds, unless stated
otherwise. The side to which each stimulus was presented (CS vs non-CS) was
pseudo-randomised between discrete trials. Thirty discrete (one-minute) trials were
conducted (unless stated otherwise). Immediately following conditioning, fish were
exposed to a ‘dark-out’ period (blank screen, no stimuli presented) for one minute, unless
stated otherwise. Conditioning which was not conducted immediately following baseline
recordings involved the presentation of a blank screen for one minute prior to stimuli
exposures.
Probe trials were designed to exactly mimic baseline trials. If this was not immediately
following conditioning, a one-minute habituation period (blank screen) was included prior
to stimuli exposure.
7.3.5 Data analysis
Data were extrapolated from EthoVision as time spent in ‘zone’ (for each of the two
stimulus-presenting ‘zones’). The proportion of time spent in the CS-presenting zone was
calculated by dividing the time in the CS zone by the total time for which the fish was
tracked.
Data were input into SPSS® Version 21 for Mac (IBM®). They were fitted to a linear
mixed effects model, with ‘distance’ as a covariate (as discussed in Section 3.4, to account
for any variance caused by differences in locomotion) and ‘subject ID ’ as a random factor,
using the relevant fixed factors (as reported in the results). The residuals of the model
were plotted (SPSS Legacy Boxplot), and outliers (1.5x IQR) were removed. The data
were then analysed using the same model. Where necessary, paired one-tailed t-tests were
conducted post-hoc.
7.4 Results
7.4.1 ‘Passive’ classical fear conditioning
Pilot - titration of discrete trials
Initially, an experiment was conducted to assess whether the basic classical fear
conditioning assay (as developed in Chapter 3) induces aversion 24-hours following
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Figure 7.1: Shock titration. The number of electric shocks delivered (paired with
CS exposure) was titrated to establish the most effective conditioning parameters,
when probe trials were conducted at 24 hours. A main effect was found for the
number of shocks delivered (F2,21.670=16.535, p<0.0005). No main effect was found
for trial (F1,21.562=1.953, p=0.176); however there was a significant trial * number
of shocks interaction (F2,21.317=16.827, p<0.0005). Post-hoc analyses of baselines
vs probes for each condition failed to find significant differences at any number of
shocks (by paired one-tailed t-test with Bonferroni correction applied). Data plotted
as mean ± SEM.
conditioning. As this manner of aversion was not previously investigated, a titration of
the number of discrete trials was included - 9 trials (1.5-minutes total, as used previously
in this thesis); 15 trials (2.5-minutes total); or 18 trials (3-minutes total).
Following a 30-minute habituation period, basal preferences were recorded as described
in Section 3.2.2 (also thirty minutes). Immediately following conditioning, a blank screen
was presented and trials were terminated. Fish were netted into individual housing tanks
and housed on a circulating system for 24 hours. Following this, fish were netted into the
assay tanks; a blank screen was presented for one minute, then both stimuli presented and
probe preferences recorded. No significant aversion of the CS was found (see Figure 7.1).
Increased habituation, titration of conditioning trials
As no aversion was observed in the initial pilot, it was hypothesised that increased
habituation to the assay setup and stimuli may facilitate retention. Zebrafish were
netted into the assay tanks and exposed to the two stimuli (CS and non-CS, ‘split
screen’) for two sessions of thirty minutes (one per day, on the two days preceding
baseline recordings and conditioning). The day following the second habituation session,
the assay was conducted as described in above (Section 7.4.1). ‘Time of probe’ was
included in data analysis as a between-subjects factor (0 hours as the positive control, 24
hours as the experimental group). Probes conducted immediately following conditioning
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Figure 7.2: Increased habituation. Zebrafish were exposed to the stimlui (as per
baseline trials) on two separate days prior to conditioning. (A) When probe trials
were conducted immediately following conditioning, a significant main effect was
found for number of shocks (F2,7.806=9.491, p=0.008). Pairwise comparisons found
9-shocks to be significantly different from 18-shocks (p=0.043). (B) However, when
probe trials were conducted 24 hours after conditioning, no significant main effect
was found for number of shocks (F2,11=3.509, p=0.066) *, p<0.05; **, p<0.01; (by
paired one-tailed t-test with Bonferroni correction applied). Data plotted as mean
± SEM.
recorded significant aversion of the CS, using 9 and 15 discrete trials (see Figure 7.2a).
However, at 24 hours after conditioning, no significant aversion of the CS was recorded
with any number of discrete trials used (see Figure 7.2b).
Length of recall assessment
As no aversion was observed at 24 hours following conditioning, an experiment was
conducted to assess the length of time following conditioning, for which CS aversion is
observable. Results indicate that significant aversion is only observable immediately
following conditioning, with extinction happening within thirty minutes of this (see
Figure 7.3).
7.4.2 ‘Escape’ fear conditioning
As the ‘passive’ fear conditioning assay failed to induce an observable long-term aversion
of the CS, it was decided to progress with a more ‘active’ form of conditioning. In the
following trials, zebrafish were given the choice of both stimuli (CS and non-CS) during
conditioning; every time the fish swam onto the zone presenting the CS, an electric shock
was administered (within parameters stated).
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Figure 7.3: Length of recall. Zebrafish were assessed for their aversion of
the CS at set time following conditioning. A significant effect was found for
trial (F4,41=4.693, p=0.003). Pairwise comparisons found that baseline was only
significantly different from Probe 0-hours ; ***, p<0.0005. Data plotted as mean ±
SEM.
Initial pilot trial
An initial pilot experiment was designed, consisting of three phases - baseline, conditioning
and probe.
During baseline recordings, zebrafish were exposed to both stimuli (using the ‘split
screen’, as per Figure 3.4), for 10 minutes
During conditioning sessions, again both stimuli were presented. Each time a fish
swam over the zone presenting the CS, the fish had two seconds to ‘escape’. Failure to
do so within 2 seconds resulted in the administration of a 9V electric shock, delivered
every second that the fish remained on the CS-presenting zone, until it escaped to the non
CS-presenting zone (or the discrete trial ended).
Probe trials were conducted in the same manner as baseline trials, except that a one
minute ‘dark-out’ period was included prior to presentation of stimuli.
The entire paradigm was repeated on two consecutive days. Thus, the baseline on Day
2 serves to assess whether aversion of the CS occurs at 24-hours following conditioning, as
well as providing a comparison for the probe on that day.
Initial analysis of this pilot found no effect for trial or day (see Figure 7.4a). A plot
of CS preference against time indicated that extinction may occur in the first 1.5 minutes
of the probe trial (Figures 7.4b), with a significant difference in preference between the
two days (suggesting that extinction occurs more rapidly on the second day; Figure 7.5a).
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However, subsequent analysis of these data found no significant aversion on either day
(Figure 7.5b). This demonstrates that the parameters of the paradigm are insufficient to
induce a conditioned aversion of the CS.
Manipulation of baseline (habituation) and ‘dark-out’ period
In order to establish efficacious parameters, an experiment was conducted to assessed
whether increased exposure to the stimuli (‘habituation’) during baseline monitoring
would facilitate aversion of the CS in the probe trial. Thus, the length of baseline was
manipulated in this experiment (10 vs 30 minutes). Additionally, the ‘dark-out’ period
was manipulated to assess the short-term length of aversion.
Initially a qualitative assessment was conducted. This indicated that increasing pre-
conditioning (baseline) exposure to 30 minutes faciliatated immediate CS aversion, but
that this aversion failed to be retained at 30 minutes following conditioning (see Figure
7.6). Subsequently, a quantitative experiment was conducted, empirically confirming this
finding (see Figure 7.7).
Increased number of discrete trials
Following this establishment of an escape assay which induces immediate CS aversion,
an experiment was conducted to assess whether increasing the number of discrete trials
within the 30-minute conditioning session would increase aversion. Thus, the previously
used conditioning parameters of thirty trials (30x 60-second discrete trials) was compared
to ninety trials (90x 20-second discrete trials).
The result of this analysis found that both conditioning parameters induced significant
aversion of the CS (see Figure 7.8). However no difference between the two conditions
was found. As the aversion produced by the original parameters was of higher significance
(despite this not being different from the new paradigm), the assay development proceeded
around the thirty-trial paradigm.
Manipulation of ‘dark-out ’ period
Using the parameters established thus far (30-minute baseline; 30x 60-second
conditioning trials), the ‘dark-out’ period was titrated to establish the short-term length
of retention. This analysis failed to find significant aversion past a one-minute ‘dark-out’
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Figure 7.5: Analyses using 1.5-minute probes. (A) Comparison of the
initial 1.5-minutes of probes (for each day) found a main effect was found for day
(F1,14.807=5.074, p=0.04). (B) Assessment of the full data set found no main effects;
neither for trial (F1,8.569=0.269, p=0.617) nor day (F1,9.77=4.399, p=0.063). No trial
* day interaction was found (F1,8.769=1.91, p=0.201). Data plotted as mean ± SEM.
interval (see Figure 7.9). Whilst the aversion at five minutes may have reached
significance with increased power (the baseline is lower than the other groups), it clearly
does not continue past this time interval. Thus, it was deemed insufficient for the
requirements of a drug discrimination assay.
Manipulation of US frequency
The trials conducted thus far have utilised a US administration frequency of one shock
per second. Therefore, it was hypothesised that, by increasing the frequency of shock
administration, increased aversion would be observed. However, the results of this
experiment failed to support this hypothesis. Further, the increase in US frequency
appears to trend towards a decrease in aversion (see Figure 7.10). Thus, the delivery of
one shock per second was continued for assay development.
Repeated conditioning sessions
As the objective of the current chapter is the development of a drug discrimination assay,
multiple conditioning sessions, over several days, will be required. Thus, the assay from
this point will be developed in this manner.
Initial pilot
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Figure 7.8: Increased number of discrete trials. Fish were exposed to the
either 30 trials (30x 60seconds) or 90 trials (90x 20seconds). No significant effect
was found for number of discrete trials (F1,9.322=0.338, p=0.575). No number of
discrete trials * trial interaction was found (F1,9.753=1.433, p=0.26). A significant
main effect was found for trial (F1,15.729=55.488, p<0.0005). By linear mixed effects
model, then one-tailed paired samples t-test with Bonferonni correction applied; **,
p<0.01; ***, p<0.001 Data plotted as mean ± SEM.
Figure 7.9: Titration of ‘dark-out period. The ‘dark-out ’ period between
conditioning and probe trial was titrated to investigate the length of time for which
aversion is observable. A main effect was found for trial (F1,20.681=10.619, p=0.004).
No main effect was found for the ‘dark-out ’ period (F4,18.891=1.821, p=0.167);
however a significant trial * dark-out interaction was found (F4,18.834=6.234,
p=0.002). By linear mixed effects model, then one-tailed paired samples t-test with
Bonferroni correction applied; *, p<0.05. Data plotted as mean ± SEM
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Figure 7.10: Manipulating the frequency of US delivery. During
conditioning, zebrafish were exposed to US (9V electric shock) whilst swimming
inside the ‘zone’ presenting the CS (following the two seconds escape time at the
start of each discrete trial). Shocks were delivered at a frequency of 1-, 2- or 5-shocks
per second (as labelled). No main effect was found for shock frequency (F2,47=0.219,
p=0.804). A significant main effect was found for trial (F1,47=45.255, p<0.0005).
No shock frequency * trial interaction was found (F2,47=1.389, p=0.259). By linear
mixed effects model, then one-tailed paired samples t-test with Bonferroni correction
applied; **, p<0.01; ***, p<0.001. Data plotted as mean ± SEM.
A pilot study was conducted to assess the prolonged retention of CS aversion, following







Day 2-4 (Tuesday - Thursday) Conditioning (sessions 2-4) 31 mins
Day 5 (Friday) Probe 31 mins
Results of this experiment found no significant aversion of the CS at 24 hours following
the final conditioning session (see Figure 7.11).
Repeated conditioning sessions; manipulation of habituation exposure
It was hypothesised that increasing exposure to the conditioning stimuli may facilitate
attention to them, resulting in increased aversion of the CS. Thus, prior to each
conditioning session, zebrafish were exposed to both stimuli (‘split’ across the screen, as
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Figure 7.11: Repeated conditioning sessions pilot. Zebrafish were exposed
to four conditioning sessions (one per day, on four consecutive days), then probed
one day following the final conditioning session. No significant effect was found for
trial (F1,12=0.383, p=0.548). Data plotted as mean ± SEM.
in trial sessions), for thirty minutes. As a control, a group were also exposed to a blank
(black) screen (as opposed to the stimuli), in the same manner. The results of this
experiment found no significant aversion of the CS in either group (see Figure 7.12).
Repeated conditioning sessions; voltage titration
Finally, it was hypothesised that the CS may be too strong for repeated conditioning
session (possibly due to induced stress). Thus, a voltage titration was conducted to assess
whether a lower level of electric shock would facilitate longer-term aversion. The results
of this titration experiment demonstrate that none of the voltages utilised induced an
observable delayed aversion (see Figure 7.13).
7.5 Discussion
The results presented here failed to establish a paradigm of long-term conditioned
responding - an essential precursor to the development of a drug discrimination assay.
As discussed in Chapter 3, simplistic delay fear conditioning is largely reliant on
amygdala functioning; however with increased complexity of these paradigms, the
hippocampus becomes involved (see Section 3.1.2). Thus, the establishment of a delay
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Figure 7.12: Manipulation of habituation exposure. Subjects were exposed
to either a blank screen or the conditioning stimuli during the habituation period.
No significant effects were found for trial (F1,13=0.588, p=0.457) or habituation
exposure (F1,13=4.051, p=0.065). No trial * habituation exposure interaction was
found (F1,13=0.005, p=0.946). By linear mixed effects model. Data plotted as mean
± SEM.
Figure 7.13: Voltage titration. Zebrafish were conditioned on four consecutive
days, using 2V, 5V, or 9V US. No main effects were found for trial (F1,19.539=0.074,
p=0.789) or voltage (F2,12.711=0.662, p=0.533). No trial * voltage interaction was
found (F2,12.352=1.023, p=0.388). Data plotted as mean ± SEM.
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fear conditioning assay (developed in Chapter 3, and used in all subsequent chapters)
indicated that the amygdala functioning which facilitates this manner of conditioning is
conserved in zebrafish (likely in the Dm). However, in the current chapter, the
requirement of more complex conditioning (to develop a drug discrimination assay)
failed to produce significant aversion (when measured at a more delayed time point).
Thus, it is possible that the conservation of hippocampal functioning (likely in the
zebrafish Dl) is insufficient to reproduce more complex fear conditioned behaviours. In
this regard, it would be of interest for future research to investigate trace fear
conditioning paradigms in zebrafish. Indeed, by titrating the length of the trace period,
the extent of hippocampal functional conservation may be indicated.
Prior research (in which amygdala functioning was inhibited in rats) has demonstrated
the amygdala’s involvement in the acquisition of classical fear conditioning, but not its
consolidation (Wilensky et al. 2000). Thus, the failure of the current research to observe
aversive behaviour at a delayed point in time (i.e. beyond one minute post conditioning)
suggests a lack of consolidation. In this regard, rats with hippocampal lesions acquire
conditioning, however the rate of extinction is accelerated (Winocur 1990). This supports
the argument - in light of the current findings - that amygdala functioning is conserved
in zebrafish to a much greater extent than hippocampal functioning. However the level of
zebrafish ‘hippocampcal-associated functioning’ (i.e. memory consolidation) must now be
investigated in order to predict the possibility of exploiting this function in the development
of a drug discrimination paradigm.
It must be noted that others have reported longer-term retention of fear conditioning
using simple operant paradigms. Zebrafish have been conditioned to cross a ‘hurdle’ in
response to a CS, to avoid an electric shock (e.g. Pradel et al. 1999; Xu et al. 2007). Thus
conditioned learning is assessed by a single operant response - crossing the hurdle from one
compartment to the other. It may be possible to develop this paradigm into a two-choice
assay for utility as a drug discrimination paradigm, by pairing the US to different CS (i.e.
two different coloured lights). However undertaking this investigation would involve the
construction and development of new hardware (i.e. new assay tanks with a hurdle and
a dark compartment) which was not achievable in the time-frame of the current thesis.
Thus, future research may wish to attempt this method of assay development.
Additionally, perineuronal nets (PNN; comprised of chondroitin sulphate
proteoglycans, CSPG) have been shown to play an important role in inhibiting the
extinction-induced loss of fear conditioned memory traces. In juvenile rats, prior to PNN
development (<24 days), extinction of fear conditioning actually leads to the erasure of
the fear memory (measured by a lack of ‘spontaneous recovery ’ of the conditioned
response); however, following the formation of PNNs, extinction no longer erases the
memory (e.g. Gogolla et al. 2009; Quirk et al. 2010; Wang and Fawcett 2012). This has
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been associated with the function of PNNs in stabilising synapses, inhibiting neuroplastic
changes (Wang and Fawcett 2012). In this regard, the function of CSPGs in zebrafish
appears to be inverse from that of mammals; in zebrafish they have been shown to guide
axonal regeneration, a function inhibited by CSPGs in mammals (Becker and Becker
2002; Kroehne et al. 2011). Thus, it seems logical that zebrafish PNNs may facilitate the
breakage of synapses (as a mediator of synaptic plasticity), especially in light of the
increase plasticity of the zebrafish brain (Kizil et al. 2012; Kyritsis et al. 2012). However
research into this function of PNN in zebrafish is currently lacking. Thus, it may present
an interesting area for future investigations into mechanisms of neuronal regeneration.
It is possible that the repeated administration of an aversive US results in ‘learned
helplessness’. In this regard, it may be possible to exploit the social nature of zebrafish
to avoid complications of both aversive (learned helplessness) and appetitive (satiation)
reinforcement. The presentation of conspecifics has been utilised as a US, which may
provide increased motivation to respond (e.g. Sison and Gerlai 2011). However, again,
this investigation was not achievable within the time-frame of the current thesis.
In conclusion, the apparent lack of conservation of hippocampal functioning in
zebrafish presents a problem in the development of a drug discrimination assay. However
a greater elucidation of the extent of this conservation in necessary, in order to exploit
these competencies for the development of state-dependent - and subsequently, drug
discrimination - paradigms. Designing paradigms around operant behaviours, or else
utilising a social (rewarding) US may lead to increased retention of learning, and may be





CHAPTER 8. GENERAL DISCUSSION
8.1 Thesis summary
The purpose of the research undertaken in this thesis was to evaluate the utility of zebrafish
- as a pre-mammalian model organism - in translational neurobiological research settings.
This focussed on two related neurological conditions - Alzheimer’s-like diseases and drug
reinforcement.
8.1.1 Alzheimer’s-like diseases
The establishment of a classical aversion paradigm - and its validation using aluminium
toxicity - presents an exciting tool for both pharmacological and genetic research. Indeed,
the fact that this assay is so quickly implemented (the whole cycle, which may assess
multiple fish simultaneously, takes 63.5 minutes) demonstrates its effective implementation
for screening purposes. Further, the demonstration that zebrafish function in this AD-
related behavioural paradigm, and that this learning is inhibited by neurotoxin-induced
neurodegeneration, indicate the efficacy of zebrafish in this area of research.
To further regard the utility of zebrafish, the finding that transgenic hAPPLON/SWE
expression causes an age-related decline in performance in the behavioural assay promotes
the use of zebrafish as a refinement (or at least pre-screen) to rodents. Indeed, whilst
doubts are cast over the role of amyloid in the aetiologies of AD, the data generated from
the transgenic line suggest that zebrafish may be implemented in the stead of commonly
used models of rodent amyloidopathies.
Additionally, the generation of new transgenic zebrafish was undertaken and achieved.
Whilst it was not possible to characterise these lines in the current thesis, they present
tools which may be efficacious for future investigations into Alzheimer’s-like pathologies.
8.1.2 Safety pharmacology
A range of compounds with neuroprotective properties were assessed for their abilities
to induce CPP in zebrafish. Both of the stimulants (caffeine and nicotine), both of the
opiates (fentanyl and morphine) and the alcohol (ethanol) administered caused significant
changes in stimulus preference. This demonstrates a conservation of their pharmacological
targets (and their down-stream signalling cascades) within reward pathways, in zebrafish.
Similarly, the significant effect for the general anaesthetic, PCP, demonstrates that its
pharmacological action (NMDA-R antagonism) produces a conserved effect in zebrafish.
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However, the other general anaesthetic, ketamine, failed to produce a significant effect,
despite having the same primary pharmacological action. In this regard, its lower affinity
for the receptor may demonstrate that NMDA-R-induced reward signalling is weaker in
zebrafish than in mammals.
Similarly, the failure of the antidepressant (bupropion), local anaesthetic (procaine)
and cannabinoid (THC) to induce CPP suggest a lower level of conservation in the
signalling facilitating these reward mechanisms (DA and norepinephrine re-uptake
inhibition, DA secretion and NMDA inhibition, and CB-induced DA release;
respectively).
8.1.3 State-dependent learning
The failure to establish a drug discrimination assay does not indicate an inability of
zebrafish to perform state-dependent learning tasks, as the assay development failed to
induce prolonged retention of learning. This may be due to accelerated extinction (e.g.
exposure to the stimuli causes a form of retrieval-induced forgetting). Alternatively, it may
be that memory consolidation is less efficient in zebrafish (suggesting a lower conservation
of hippocampal-related functioning).
In this regard, several different paradigms may be adopted - using either aversive and
non-aversive US - as alternatives to the one utilised here. Thus, the failure to establish an
assay in the current thesis should not be regarded as a failure of zebrafish to perform this
task. Rather, it presents one method by which they do not retain long-term conditioned
aversion. However, in light of the myriad different paradigm which can be adopted, it
was not possible to fully explore the development of a drug discrimination assay in the
time-frame of the current thesis.
8.2 Future directions
8.2.1 Neurodegeneration
The findings of impaired fear conditioning in transgenic hAPPLON/SWE fish appears to
have positive implications for industrial pharmaceutical screening of novel AD-targetting
drugs. However it is necessary for future research to attempt to rescue this phenotype via
the administration of neuroprotective compounds. Whilst this investigation was beyond
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the scope of the current research, it would provide further support to the implementation
of zebrafish as a pre-mammalian organism in industrial drug discovery.
Additionally, the generation of new gene-manipulation strains of zebrafish may
provide exciting tools for future investigations into the pathogenesis of AD. The hAβ40
transgenic line may provide insight into the downstream signalling consequences of this
peptide, in the absence of aberrant neuronal apoptosis expected from Aβ42 expression,
thus elucidating the consequences of dysregulated amyloid signalling. Perhaps more
interestingly, the dapk1-overexpressing zebrafish line may provide some insight into
AD-related dysregulations up-stream of amyloid dysregulation. Thus, the utilisation of
these generated lines may further facilitate research, both in basic and in translational
settings.
It must also be noted that there are potential implications for the fear conditioning
assay (developed herein) in the research of other neurodegenerative conditions:
Parkinson’s disease
The loss of DA-ergic neurons in the substantia nigra is the major pathological
characteristic of PD (Bernheimer et al. 1973; Hornykiewicz 1975). However the
amygdalae and hippocampi receive DA-ergic afferent signals from the substantia nigra,
suggesting secondary (non-motor) dysfunctions to these structures (Gasbarri et al. 1994;
Menegas et al. 2015; Swanson 1982).
In this regard, the presence of (PD-associated) Lewy bodies has been reported in the
amygdala of PD patients, as well as a decreased amygdala size (Braak et al. 1994; Harding
et al. 2002). Additionally, decreased DA activity in the amygdala has been associated with
depression in PD (Remy et al. 2005). This implies that patients would exhibit impairments
to behavioural / emotional responses related to amygdala functioning. Indeed, PD patients
show reduced startle responses, as well as decreased amygdala activity when perceiving
fear, which is slightly rescued by DA treatment (Bowers et al. 2006; Tessitore et al. 2002).
Rodent studies have demonstrated that the stimulation or selective destruction of DA-
ergic neurons in the substantia nigra disrupts nociceptive responses (Barceló et al. 2012;
Carey 1986; Takeda et al. 2005; Tassorelli et al. 2007; see Chudler and Dong 1995). This
suggests an impairement in US detection, and subsequently CS pairing. Further, there is
evidence that inhibition of DA-ergic neurons in the pars compacta of the substantia nigra
- which project to the central nucleus of the amygdala - results in impaired ‘surprise’
learning (Lee et al. 2008)
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Thus, the evidence of amygdala dysfunction in PD suggests an impairment to fear
conditioning. However currently there is no data (clinical or animal) to support this
hypothesis. Thus, it is proposed that future studies into non-motor aspects of PD
investigate the possibility of impaired fear conditioning. This would allow the assay
developed herein to be utilised in this area of research.
Huntington’s disease
HD is caused by a mutation in the extremely ubiquitous HTT gene which, within
neurobiology, is commonly investigated in relation to atrophy of the caudate nucleus,
putamen, cortical, striatal and basal ganglia areas (e.g. Bernheimer et al. 1973; Jernigan
et al. 1991; Kassubek et al. 2004; Roos et al. 1985; Thieben et al. 2002; Vonsattel et al.
1985; see Petrasch-Parwez et al. 2012; Burg et al. 2009). Given the crossover of these
sites with PD, the same logical justifications of impaired amaygdala functioning - and
subsequently aversive conditioning - may apply.
Indeed, a certain amount of attention has been paid to the amygdala in HD research.
fMRI studies in patients has associated decreases in amygdala volume and connectivity
with impaired recognition of emotional facial expressions (Kipps et al. 2007; Mason et al.
2015). Further, pre-symptomatic carriers of the mutated HTT gene display decreased
amygdala activity during a task that induces ‘irritability’, suggesting that a test of
amygdala function may be useful in early detection (Klöppel et al. 2010).
As with PD, there is a lack of studies that have investigated aversive conditioning in
HD patients. However transgenic mice expressing a human mutant form of HTT display
impaired fear conditioning, suggesting that implementing a mutant zebrafish model of HD
in the assay developed herein would have implications for HD lead identification (Bolivar
et al. 2003).
8.2.2 Safety pharmacology
The selection of neuroprotective drugs which induced CPP suggest that drugs developed
with these pharmacological actions may be screened for their reinforcing properties in
zebrafish, prior to mammalian (rodent) assays. In this light, a more comprehensive range
of drugs and drug classes may be investigated in the future, providing greater insight into
the conservation of reward-related pharmacological signalling consequences, as touched
upon here.
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Finally, the attempt to develop a drug discrimination assay utilising fear
conditioning paradigms suggests that this mode of conditioning is insufficient for
consolidation of learning. However the implementation of alternative paradigms (using
aversive, appetitive or social US) has previously been reported to produce learning with
longer-term retention. Thus, future investigations may wish to adopt these alternative
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Klöppel, S. et al. (2010). “Irritability in pre-clinical Huntington’s disease”. In:
Neuropsychologia 48.2, pp. 549–557.
Knafo, S. et al. (2009). “Morphological alterations to neurons of the amygdala and
impaired fear conditioning in a transgenic mouse model of Alzheimer’s disease”.
In: The Journal of pathology 219.1, pp. 41–51.
Knight, D. C. et al. (2004). “Amygdala and hippocampal activity during
acquisition and extinction of human fear conditioning”. In: Cognitive, Affective,
& Behavioral Neuroscience 4.3, pp. 317–325.
Ari Sudwarts 229
BIBLIOGRAPHY
Knobloch, M. and I. M. Mansuy (2008). “Dendritic spine loss and synaptic
alterations in Alzheimer’s disease”. In: Molecular neurobiology 37.1, pp. 73–82.
Kochli, D. E. et al. (2015). “The amygdala is critical for trace, delay, and contextual
fear conditioning”. In: Learning & Memory 22.2, pp. 92–100.
Kola, I. and J. Landis (2004). “Can the pharmaceutical industry reduce attrition
rates?” In: Nature reviews Drug discovery 3.8, pp. 711–716.
Komotar, R. J. et al. (2007). “Neurologic assessment of somatosensory dysfunction
following an experimental rodent model of cerebral ischemia”. In: Nature
protocols 2.10, pp. 2345–2347.
Koob, G. F. et al. (1998). “Neurocircuitry targets in ethanol reward and
dependence”. In: Alcoholism: Clinical and Experimental Research 22.1, pp. 3–9.
Kornhuber, J et al. (1993). “Amantadine and memantine are NMDA receptor
antagonists with neuroprotective properties.” In: Journal of neural
transmission. Supplementum 43, pp. 91–104.
Koutsilieri, E. and P. Riederer (2007). “Excitotoxicity and new antiglutamatergic
strategies in Parkinson’s disease and Alzheimer’s disease”. In: Parkinsonism &
related disorders 13, S329–S331.
Kremer, A. et al. (2011). “GSK3 and Alzheimer’s disease: facts and fiction...” In:
Frontiers in molecular neuroscience 4.
Kroehne, V. et al. (2011). “Regeneration of the adult zebrafish brain from neurogenic
radial glia-type progenitors”. In: Development 138.22, pp. 4831–4841.
Krstic, D. and I. Knuesel (2013). “Deciphering the mechanism underlying late-onset
Alzheimer disease”. In: Nature Reviews Neurology 9.1, pp. 25–34.
Kumar, V. and K. D. Gill (2014). “Oxidative stress and mitochondrial dysfunction
in aluminium neurotoxicity and its amelioration: a review”. In: Neurotoxicology
41, pp. 154–166.
Kumar-Singh, S. et al. (2000). “Nonfibrillar diffuse amyloid deposition due to a γ
42-secretase site mutation points to an essential role for N-truncated Aβ42 in
Alzheimer’s disease”. In: Human molecular genetics 9.18, pp. 2589–2598.
Kuzak, N., D. W. Harrison, and P. J. Zed (2006). “Use of lidocaine and fentanyl
premedication for neuroprotective rapid sequence intubation in the emergency
department”. In: Canadian Journal of Emergency Medicine 8.02, pp. 80–84.
Kyritsis, N. et al. (2012). “Acute inflammation initiates the regenerative response
in the adult zebrafish brain”. In: Science 338.6112, pp. 1353–1356.
Kyzar, E. J. et al. (2012). “Effects of hallucinogenic agents mescaline and
phencyclidine on zebrafish behavior and physiology”. In: Progress in
Neuro-Psychopharmacology and Biological Psychiatry 37.1, pp. 194–202.
La Garza, R. de and C. Johanson (1983). “The discriminative stimulus properties
of cocaine in the rhesus monkey”. In: Pharmacology Biochemistry and Behavior
19.1, pp. 145–148.
Lab, D. (2016). RefFinder ONLINE. url: http://fulxie.0fees.us (visited on
07/21/2016).
Lader, M. (1994). “Anxiolytic drugs: dependence, addiction and abuse”. In:
European Neuropsychopharmacology 4.2, pp. 85–91.
LaDu, M. J. et al. (1994). “Isoform-specific binding of apolipoprotein E to beta-
amyloid.” In: Journal of Biological Chemistry 269.38, pp. 23403–23406.
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9.2 Failed western blot detection of appb
Ari Sudwarts 265
CHAPTER 9. APPENDICES
Failed western blot detection of appb. Total protein extractions were run on
SDS-PAGE and blotted onto nitrocellulose. The antibody used (Abcam ab17473)
failed to produce consistent results, probing protein bands of varying sizes. Thus,




9.3 FluoroJade® staining of hAPPLON/SWE brains
Control
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100µM
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